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Proper temporal epigenetic regulation of gene expression is essential for cell fate
determination and tissue development. However, epigenetic mechanisms involved in
control of bone-specific transcriptional programs remain largely unexplored. In this
study we focused on functional characterization of two epigenetic regulators –
Bromodomain-containing Protein-4 (BRD4) and Ring Finger Protein 40 (RNF40) in
development and maintenance of osteoblast fate. BRD4 was previously shown to
control the transcription of defined subsets of genes in various cell systems. In this
study we examined the role of BRD4 in promoting lineage-specific gene expression
and show that BRD4 is essential for osteoblast differentiation. Genome-wide
analyses show that BRD4 is recruited to the transcriptional start site of
differentiation-induced genes. Unexpectedly, while promoter-proximal BRD4
occupancy correlated with gene expression, genes which displayed moderate
expression and promoter-proximal BRD4 occupancy were most highly regulated
during differentiation and sensitive to BRD4 inhibition. Therefore, we examined distal
BRD4 occupancy and uncovered a specific co-localization of BRD4 with the
transcription factors C/EBPb, TEAD1, FOSL2 and JUND at putative osteoblast-
specific enhancers. These findings reveal the intricacies of lineage specification and
provide new insight into the context-dependent functions of BRD4.
RNF40 forms with RNF20 the obligate E3 complex and mediates monoubiquitination
of lysine 120 of histone H2B (H2Bub1). Despite its global correlation with active gene
transcription, we previously demonstrated a specific role for H2Bub1 in controlling
osteoblast (OB)-specific gene expression during OB differentiation of mesenchymal
stem cells (Karpiuk et al., 2012, Mol Cell). To address the significance of H2Bub1 for
bone development in vivo, we generated OB-specific Rnf40 conditional knockout
Abstract
XVI
(KO) models. Given the crucial role of RUNX2 in osteoblast lineage commitment and
chondrocyte hypertrophy, the Rnf40Runx2-Cre knockout mice developed
achondroplastic-like phenotype with shorter bone sizes. Surprisingly, micro
computed tomography (µCT) analysis showed increased bone mineral density
(BMD) in these mice, a finding that could be associated with decreased osteoclast
function and hence osteopetrosis-like phenotype. Remarkably, the Rnf40Bglap-Cre KO
mice displayed only osteopetrotic-like phenotype with significant increase in bone
mineral density without any further alterations in bone formation and apposition rate.
This suggested the importance of H2Bub1 at the earlier stages of osteoblast
commitment. Strikingly, the number of osteoclasts was substantially reduced in these
mice suggesting the increased BMD to be associated with reduced bone resorption.
Ex vivo differentiation studies confirmed a role for Rnf40 and H2Bub1 in OB
differentiation as revealed by decreased alkaline phosphotase activity/expression,
mineralization and expression of Runx2 and Sp7 in KO OBs. Consistently, Rnf40-
deficient OBs showed significantly reduced Rankl expression and triggered less
osteoclast formation as revealed by osteoblast and osteoclast co-culture
experiments. Remarkably, the reverse effect in modulating osteoblast specific
H2Bub1 levels in Ubiquitin-Specific Protease 22 (Usp22)Runx2-Cre KO  mice  did  not
have any impact on bone in mice.  Altogether, these data indicate significance of
H2Bub1 signaling in regulating the osteoblast lineage commitment. Moreover,
H2Bub1 appears to act as defining epigenetic regulator of osteoblast-osteoclast
“communication“ in vivo which provides a basis for future studies to investigate the







Bone is the major supportive tissue of the body. It is responsible for the individual body
shape, enables body movement, provides protection for inner soft tissues and serves as
a major storage of calcium and phosphate ions. Moreover, bones “host” bone marrow -
the main source of blood cells in adults. These properties make bone a very dynamic
organ that undergoes constant remodeling to adapt to daily mechanical changes placed
upon it, which is also the key mechanism during bone fracture repair.
Four bone types can be characterized in an adult human. These include long (i.e.
phalanges, femur), short (i.e. tarsal and carpal bones), flat (i.e. cranial bones) and
irregular (vertebrae) bones (Buckwalter et al., 1995; Clarke, 2008). In a typical bone,
the bones tissue is localized around the hematopoietic bone-marrow and is surrounded
by periosteum, the connective-tissue membrane (Buck and Dumanian, 2012;
Buckwalter et al., 1995). The medullary cavity is lined by endosteum. Based on the
structural density, the bone tissue is further classified into two tissue types: compact
(cortical) and cancellous (trabecular).  Whereas the compact bone provides the
resistance to the mechanical loading to the bone, the flexible trabecular structures
enable the deformation of the bone in response to the same load. Despite the same
composition, the trabecular bone is metabolically more active and displays higher
rate of bone-turnover than the cortical bone. The ratio of cortical and trabecular tissue
within the bones depends on the bone type.  In the long bones, the cortical bone
constitutes the substantial part of the central diaphysis. The diaphysis gradually
transitions into metaphysis that is mainly made of cancellous bone. The metaphysis
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underlies the epiphyseal growth plate consisting of proliferating chondrocytes involved in
bone lengthening which in adults gets replaced by the bone tissue forming the
epiphyseal line. The polar ends of the long bones called epiphysis most commonly form
the joint surfaces and, hence, are covered by articular cartilage. The epiphysis similar to
metaphysis are represented by trabecular tissue (Figure 1).
Figure 1. Schematic representation of anatomic structures of a long bone.
Based on histological properties, bone tissue can be further classified into woven
and lamellar bone. The first is characterized by the unorganized pattern of
mineralization and fibrillary structure. Woven bone is evident in the embryonal
skeleton and gradually gets replaced by more organized lamellar bone consisting of
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densely packed collagen fibrils (Buck and Dumanian, 2012; Buckwalter et al., 1995;
Clarke, 2008).
Both trabecular and cortical bone harbor osteons which are considered the functional
units of the bone tissue. In the compact bone these are also known as Haversian
systems. Given the concentric structure consisting of lamellae surrounding the blood
vessel channels (Haversian Canal) that supply blood and nutrients to the bone cells,
these units resemble the sequential order of bone formation. The Haversian Systems
are usually oriented in parallel order to long axis of the bone. Besides the
longitudinal channels, there are also so called Volkmanns Canals with transverse
blood vessels connecting the osteons with the periosteum (Clarke, 2008).
In fact, highly vascularized outer fibrous layer of periosteum provides the substantial
part of blood supply to the bone. Importantly, the inner layer of periosteum referred
as cambium or osteogenic layer is densely populated by osteoprogenitor cells and
differentiating osteoblasts contributing to radial growth of the bones (Dwek, 2010).
Bone cells
In general, bone formation and development, the normal bone functioning and
homeostasis are controlled by coordinated play of three cell populations in the bone:
osteoblasts, osteocytes and osteoclasts (Figure 2). Additionally, the chondrocytes
are similarly considered the key players involved in endochondral ossification. While
osteoclasts rise from hematopoietic progenitor cells, the rest of above mentioned
cells involve one common progenitor cell type, i.e. the mesenchymal stem cells
(Buck and Dumanian, 2012; Buckwalter et al., 1995).
Osteoblasts are mononucleated cells involved in bone matrix synthesis, deposition
and responsible for its subsequent mineralization (Figure 2). The bone matrix
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consists mainly of the inorganic component represented by hydroxyapatite, and the
collagen rich organic component. In addition to collagen, some other non-
collagenous proteins such as sialoproteins, proteoglycans and gla-containing
proteins make up the content of the organic matrix.  The process of hydroxyapatite
formation starts within the intracellular vesicles of the osteoblasts. The presence of
calcium binding bone sialoprotein and calbindin along with some phospholipids
enable accumulation of the calcium ions within these vesicles. The phosphate
enrichment within the vesicles is regulated by the activity of type III Na/Pi
cotransporter. Once reaching the certain level of the ions, the solubility point of
CaPO4 is exceeded leading to the crystal formation. At this point, the hydroxyapatite
crystals start extending into the extracellular matrix through the penetration of
vesicular membranes. The concertation of Ca2+ ions and inorganic phosphate Pi
within the extracellular fluid is critical for the continuation of the crystal formation.
More importantly, it was shown that inorganic pyrophosphate (PPi) acts as inhibitor
of mineralization. Therefore hydrolysis of PPi by alkaline phosphatase resulting in Pi
formation is crucial in regulation of mineralization process by osteoblasts (Orimo,
2010).
Once trapped within the secreted matrix the osteoblasts become terminally
differentiated forming the osteocytes. In fact, 90 percent of all bone cells is
represented by osteocytes (Kini and Nandeesh, 2012). Osteocytes possess
filapodial processes residing within the bone matrix canaliculi allowing nutritional and
signaling exchange between the cells and blood vessels. Hence, the embedded
osteocytes form the syncytium within the bone enabling interconnection of these
cells with each other and with bone surface (Figure 2).  Given the embedded location
and high connection possibility, osteocytes display mechanosensory functions. In
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response to mechanical loading, these cells coordinate the interaction of osteoblasts
with osteoclasts by signaling molecules, and hence, control the bone homeostasis
and remodeling. Moreover, these cells through the process of osteocytic osteolysis
resulting in perilacunar remodeling can modulate their own environment (Prideaux et
al., 2016).  Osteoblasts also form the bone lining cells recognized as resting
osteoblasts within endosteum on the surface of quiescent bone.
Osteoclasts differentiate from bone marrow macrophages (Figure 2). By fusing
together they form multinucleated cells and are responsible for bone-matrix
resorption (Buck and Dumanian, 2012; Buckwalter et al., 1995; Clarke, 2008). While
macrophage colony-stimulating factor (M-CSF) signaling is required for control of
cellular proliferation and survival of osteoclasts, the differentiation and resorptive
activity of osteoclasts largely depend on receptor activator of nuclear factor kappa-B
(RANK) signaling (Kim and Kim, 2016). The cells of osteoblastic lineage by
producing activator of NF-jB ligand (RANKL) that binds to the RANK receptor on the
surface of osteoclasts induce the differentiation of the latter from progenitors and
subsequently their activation. On molecular level, the osteoclast formation and
differentiation largely depend on RANKL induced activation  of nuclear  factor kappa-
B (NF-kB), that controls the sequential expression of FBJ osteosarcoma oncogene
(c-FOS) and nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1
(NFATC1) (Yamashita et al., 2007). The resorptive activity of osteoclasts can be
further modulated by the secreted form of RANK receptor - osteoprotegerin (OPG). It
is considered as decoy receptor that by binding to the RANKL inhibits it further
interaction with RANK receptor on the surface of osteoclasts. Consistently, the
RANKL/OPG ratio in the serum or bone marrow is important determinant of normal
bone remodeling (Boyce and Xing, 2008). Upon activation signaling, osteoclasts
Introduction
6
undergo extensive cytoskeleton reorganization and attach to the bone matrix through
the actin rich podosomes. This results in formation of sealing zone that marks the
future resorption site. Once the attachment is complete, osteoclasts start resorbing
the matrix through ruffled border membrane that is actually characterized as the
resorbing organ of the osteoclasts. At this point, fusion of highly acidic intracellular
vesicles with the plasma membrane and subsequent release of the content of these
vesicles into resorption lacuna results in partitioning and dissolution of
hydroxyapatite crystals. The almost simultaneous release of cathepsin K leads to
downstream degradation of matrix proteins. In addition to cathepsin K, osteoclast-
specific tartrate resistant acid phosphatase (TRACP) is similarly involved in the
matrix degradation process (Väänänen, 2005). Moreover, several matrix
metalloproteases can contribute to the matrix resorption, however might not carry the
limiting function in this process (Delaissé et al., 2003). At the same time the products
of degradation along with calcium and phosphate ions are endocytosed back into
osteoclasts and subsequently released into the extracellular fluid through the
functional secretion domain of the osteoclasts. Presumably, after task completion
osteoclasts undergo apoptosis (Väänänen, 2005).
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Figure 2.The bone cells and bone remodeling process. Bone undergoes continues remodeling
within the discrete sites referred as Bone Remodeling Compartment (BRC). During this process upon
activation, the osteoclasts derived from hematopoietic stem cells (HSC) start the bone resorption.
Following resorption, the mononuclear macrophage-like cells of unknown origin (referred as
osteomacs) coordinate the coupling of bone resorption by the following step of bone formation. This
happens within the reversal phase. Consistently, the osteoblasts of mesenchymal origin (derived from
mesenchymal stem cells, MSC) start producing the osteoid which subsequently undergoes
mineralization. The osteoblasts imbedded in the bone matrix eventually mature and differentiate into
osteocytes, which are also involved in coupling of bone resorption to bone formation. Osteoblasts also
form the bone lining cells that cover the bone surfaces and thought to be involved in cellular
communications with osteocytes. They also make the canopy over the remodeling sites.
Bone formation
The initial steps of osteogenesis require the formation of mesenchymal cell (MSC)
condensations, location and shape of which are determined by the intricate network
of signaling molecules. Depending on the character of patterning signals, the
indicated mesenchymal condensations can directly differentiate into osteoblasts
choosing the path of intramembranous ossification, or through formation of
chondrocytes they enter the path of endochondral ossification (Hojo et al., 2015). In
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fact, the primary skeleton is entirely made of cartilage and later during the fetal
development and postnatal growth it gets replaced by the stiff bone tissue. The
matter of lineage specification choice of bipotential osteo-chondroprogenitor cells
depends on the subsequent expression of master regulators in response to signaling
molecules. The initially SRY box-containing gene 9 (SOX-9) positive mesenchymal
stem cells by subsequent co-expression of L-SOX5 and SOX-6 direct the
chondrogenic differentiation of MSCs.  The pre-cartilaginous cell condensations start
expression of adhesion molecules such as N-cadherin, tenascin-C and others to
enable the tight clustering of these cells within the nodules (Lefebvre and Bhattaram,
2010). In the next stage following the formation of condensed structures, the cells
enter the stage of rapid proliferation forming the shafts of the bones and extensively
produce extracellular matrix. Eventually, several layers of chondrocytes at different
maturation steps form the growth plate (Figure 3) that is responsible for future bone
lengthening.  Within the staggered structure the proliferating chondrocytes stop
dividing, increase in volume and become hypertrophic. Hypertrophic chondrocytes
precede the layer of terminally differentiated matrix-mineralizing chondrocytes.
Whereas all the previous forms of chondrocytes express collagen type 10a1
(COL10A1) the terminal chondrocytes start expressing more osteoblast-specific
markers including Runt-related transcription factor 2 and 3 (RUNX2 and RUNX3).
Additionally, MADS-box containing myocyte enhancer factor 2c and 2d transcription
factors (MEF2c and MEF2d) are expressed, and along with RUNX2/3 they determine
the terminal differentiation path of chondrocytes. Presumably, the terminally
differentiated chondrocytes later undergo apoptosis. Following the death of
chondrocytes a variety of cells invade the “liberated” space including the osteoblasts
that start producing bone matrix, osteoclasts that remove the cartilaginous matrix,
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stromal and hematopoietic cells that form the bone marrow (Figure 3).  A number of
factors produced by chondrocytes assist this process, such as VEGF that enables
blood vessel formation by invading endothelial cells, matrix metalloproteases that in
addition to osteoclast-specific enzymes (e.g. MMP9) resorb the matrix. Hence, the
initial steps of bone formation within the diaphysis of the fetal bones are defined as
primary ossification center. During the postnatal development secondary centers in
the epiphyses arise. Eventually, in the adulthood the two ossification centers fuse
upon the closure of the growth plate (Lefebvre and Bhattaram, 2010)
Intramembranous ossification is mainly characteristic for the formation of flat skull
bones. The earlier expression of RUNX2 with subsequent induction of osterix (OSX)
gene directs the MSCs along the osteogenic path (de Crombrugghe et al., 2001). In
this case osteoblasts produce first the unmineralized bone matrix (osteoid) in radial
direction forming the ossification center in the middle of the bones. Expression of
Colagen type1a (COL1A1) and Alkaline Phosphatase (ALPL) is important event
preceding the onset of mineralization. Eventually, the developing bones get
connected by an elastic tissue referred as sutures. Infiltrated by undifferentiated
osteoprogenitor cells, these mainly contribute to future bone growth. Within the first
two years of life, these sutures eventually disappear leading to the fusion of skull
bones.
Signaling networks in bone
Several pathways converge in the establishment, development, maintenance and
specialization of osteo- and chondrocyte-specific cell types.  Among them
noteworthy is to mention the Indian Hedgehog (Ihh), Wnt-Wingless and the
Transforming growth factor-beta (TGF-β) and bone morphogenic protein (BMP)
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signaling pathways (TGF-β/BMP pathway) (Hojo et al., 2015). The crosstalk of these
pathways coordinates the rather complex process of bone formation, development
and homeostasis in a time-, stage and cell-type-specific manner.
The Ihh signaling is important for endochondral bone development by controlling the
formation of RUNX2-expressing osteoblasts. Response to Ihh signaling is mediated
through transcription factors GLI1, GLI2 and GLI3 (Hojo et al., 2015). Ihh through
GLI1 regulates the expression of osteoblast-specific genes (Hojo et al., 2012).  It
was shown that by interacting with RUNX2, GLI2 positively affects the osteoblast
differentiation of mesenchymal stem cells (Shimoyama et al., 2007). At the same
time, Ihh signaling controls the proliferation and maturation of pre-hypertrophic
chondrocytes through regulation of Parathyroid hormone related protein (PTHrP)
expression in these cells. The PTHrP-deficient mice display inhibited proliferation
and early maturation of hypertrophic chondrocytes leading to achondroplasia-like
changes in mice (Karaplis et al., 1994). Similarly, Ihh inhibits the differentiation of
chondrocytes in endochondral bone through the transcriptional repressor GLI3
(Koziel et al., 2005). In this context, the FGF signaling exerts opposite to Ihh effects
in chondrocytes by blocking the proliferation of chondrocytes.
The role of Wnt-signaling acts mainly downstream of Ihh signaling and is
indispensable for the healthy bone formation. Activated by a variety of glycoprotein
ligands, canonical Wnt pathway mediates its signaling through the stabilization of β-
catenin, whereas one of the noncanonical Wnt signaling pathways involves calcium-
dependent regulation of cellular migration, and the noncanonical planar cell polarity
pathway through the GTPases regulates the cytoskeleton that is responsible for cell
shape (Kim et al., 2013b) . The canonical Wnt pathway is important at all the stages
of osteoblast formation and differentiation (Baron and Kneissel, 2013). Importantly,
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the Wnt-signaling activation supports the already osteoblast committed MSCs
(expressing RUNX2) to further specialize into OSX positive cells (Hu et al., 2005) by
blocking the chondrogenic potential of these cells.  Moreover, the β-catenin signaling
blocks the adipogenic commitment of MSCs (Case and Rubin, 2010). Little is known
about the relevance of noncanonical Wnt-signaling in the regulation of bone
formation. Nonetheless, noncanonical ligand Wnt7b was reported to promote
osteoblast differentiation through G protein–coupled protein kinase C δ (PKC-δ)
activation (Tu et al., 2007). Similarly, Wnt5b mediated activation of noncanonical Wnt
signaling exhibited anti-adipogenic potential by repressing the expression of PPARγ
and hence favoring the osteoblast lineage commitment of MSCs (Takada et al.,
2007)
TGF-β/BMP pathway includes a large number of extracellular signaling molecules
which have profound functions at all the steps of osteogenesis including
mesenchymal stem cell condensations, bone morphogenesis, endochondral
ossification and osteogenic differentiation (Wu et al., 2016). Binding of the ligands to
the cell surface receptors, induces the receptor phosphorylation with subsequent
cascade activation of signal transducers Mothers against decapentaplegic
homologues (SMAD). The nuclear translocated SMAD complexes were shown to
interact with osteoblast-specific transcription factors such as RUNX2 and OSX
(Rahman et al., 2015). As indicated by their name, the BMPs have attracted great
attention due to heterotopic and orthotopic bone formation ability upon
administration. In general, BMPs support the differentiation of mesenchymal stem
cells along the osteogenic and chondrogenic lineages (Liu et al., 2007; Rahman et
al., 2015). Among many BMPs, BMP-2 and BMP-7 have been extensively
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characterized given their high osteogenic potential. Moreover, recombinant forms of
these proteins are in clinical trials of bone diseases and fracture healing.
Additionally, hormonal signaling has major impact on the bone cells and in general
bone development and remodeling. Given its essential role in regulating the calcium
homeostasis, parathyroid hormone (PTH) receptor signaling exerts dual effects on
bone by stimulating bone resorption and bone formation. By promoting the
expression of RANKL and hence affecting the RANKL/OPG ratio, PTH stimulates
activation and differentiation of bone resorbing cells, i.e. osteoclasts. At the same
time, the positive effect on the osteoblasts was found to be mainly mediated through
the downregulation of WNT inhibitor sclerostin (SOST). Interestingly, the pro-
osteoclastic effects of PTH is prominent during the continuous dosage of the
hormone, whereas the intermittent administration results in bone anabolic effects
(Silva and Bilezikian, 2015).
Vitamin D receptor signaling is important regulator of normal physiological functions
of osteogenic and chondrogenic cells. Mesenchymal stem cells at the stage of
cellular condensations already express VDR. Activated by the ligand, the VDR in a
heterodimer complex with retinoic acid receptor (RXR) is involved in transcriptional
activation of some of the osteoblastic genes such as osteocalcin (BGLAP), RANKL,
osteopontin (OPN). Moreover, the physiological significance of Vitamin D is also
explained by its essential role in controlling calcium and phosphate homeostasis
(Imai et al., 2013).
Glucocorticoid receptor (GR) signaling exhibits adverse effects on bone which is also
often observed in the patients developing osteoporosis after long treatments with
glucocorticoids (GC). GRs has two isoforms which upon ligand activation translocate
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to nucleus and in homodimerized complex bind the target GR elements (GRE) to
induce direct transactivation or repression of the target genes. Moreover, GR can
indirectly regulate gene expression by associating with other transcription factors
such as activator protein-1 (AP-1), NF-κB, or signal transducer and activator of
transcription 5 (STAT5). It has been demonstrated that GC can favor the adipogenic
specialization of MSCs in cost of osteoblastic by directly inducing the expression of
adipocyte-specific master regulator peroxisome proliferator-activated receptor γ2
(PPARγ2). Interestingly, the effects of GR signaling on osteoblasts are somehow
contradictory. Many in vitro differentiation protocols for osteoblasts include
glucocorticoid per se due to ability to increase expression of some of osteoblast-
specific genes such as alkaline phosphatase (ALPL), osteopontin (OPN), osteocalcin
(BGLAP,OC) and bone sialoprotein (IBSP) (Imai et al., 2013). Moreover, some
studies have indicated the synergistic effect of GC with some of BMPs (Mikami et al.,
2010). On the other side GC treatment was shown to block the proliferation and
differentiation of osteoblasts and induce apoptosis in these cells  The osteoblast
specific deletion of GR in mice revealed that antiproliferative effect of GC is receptor
dimerization dependent whereas the inhibitory effect on differentiation dimerization
independent (Rauch et al., 2010). Monomeric GR was shown to inhibit the AP-1
mediated regulation of some cytokines that exhibit pro-osteoblastic effects. Hence,
large amount of evidence suggests that the GC induced differences on the bone
might in fact depend on the timing, dose and duration of the treatment.
Sex hormones play key role in bone growth especially during puberty accounting to
gender differences in skeleton. These differences rise because of stimulatory effect
of androgen on periosteal bone growth whereas estrogens act in opposite way
(Oury, 2012). More importantly, sex hormones have a crucial role in bone mass
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maintenance in adulthood mainly by affecting both the osteoblasts and osteoclasts.
Estrogens mainly exert inhibitory action on osteoclasts by several mechanisms. The
pro-apoptotic effect of estrogen on osteoclasts was found to be associated with
estrogen mediated decrease in the production of M-CSF, interleukin 1 and 6 (IL-1,
IL-6) known to inhibit osteoclast apoptosis. Moreover, estrogen positively affects
expression of apoptosis inducing FAS cell surface death receptor ligand (FASL) in
osteoblasts that by binding to its receptor on osteoclasts induces apoptosis in latter.
Additionally, by promoting the OPG and inhibiting the RANKL expression in
osteoblasts, estrogens contribute to decreased differentiation and activity of
osteoclasts (Oury, 2012).  Estrogen signaling has been shown to increase osteoblast
lifespan and exhibit anti-apoptotic effects on these cells through the activation of
extracellular signal-regulated kinases (ERK) signaling pathway (Kousteni et al.,
2001). Interestingly, the osteoblast-specific deletion studies on mice of estrogen
receptor alpha (ERα) have demonstrated controversial results. The early ablation of
ERα in mesenchymal cells and osteoblast precursors (ERαPRX1-Cre and ERαOSX-Cre
mouse models, respectively) resulted in low bone mineral density (BMD) in mice in
addition to reduced cortical thickness. However, the deletion of ERα in osteoblast
precursor cells (ERαCol1a1-Cre) under the control of Col1a1 did not lead to any
prominent changes in the bone.  However, the use of another mouse model for
mature osteoblasts ERαOC-Cre and ERαDmp1-Cre revealed reduction in both the cortical
and trabecular bone parameters (Khalid and Krum, 2016). Androgens have similarly
positive role in osteoblasts. By reducing the IL-6 production it was shown to inhibit
the apoptosis of osteoblasts. Moreover, by modulating the OPG expression in
osteoblasts, androgens decrease bone resorption through  attenuation of osteoclast




As the individual’s height increases the bones also grow in size both in length and
diameter. The bones grow in length primarily through longitudinal enlargement of
growth plate cartilage repeating the steps of endochondral ossification (Figure 3).
Briefly, the chondrocytes of the growth plate by subsequent differentiation and
maturation process form the columns of chondrocytes unidirectionally extending from
epiphysis to bone metaphysis. As the unmineralized cartilage extends in length and
reaches the metaphysis, special mononuclear cells referred as septoclasts or
chondroclasts start resorbing the cartilage from the metaphysial end. Concomitantly,
the invading blood vessels enable recruitment of bone cells. The remaining sites of
the cartilage (septa) serve as potential sites of bone mineralization by osteoblasts
forming this way the primary trabecular bone (primary spongiosa). Gradually, all the
cartilage material of growth plate gets replaced by subsequent steps of bone
turnover developing this way the secondary spongiosa.   By distancing away from
the growth plate, the metaphysial trabeculae get eventually resorbed, hence, not
reaching the bone diaphysis. In contrast, given the pressure of mechanical loading on
the bone, the metaphysial trabeculae on the periphery continue growing and get thicker
eventually integrating into the metaphysial cortical bone (Rauch, 2005).
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Figure 3. Model of bone growth. The bone grows in length due to proliferative activity of
chondrocytes within the epiphyseal growth plate. Chondrocytes are formed in the germinal zone, after
which they undergo proliferation and maturation. Once mature, the chondrocytes start becoming
hypertrophic and lay down extracellular matrix. Eventually, the hypertrophic chondrocytes undergo
apoptosis, and are replaced by osteoblasts brought in with the invading capillaries. The latter form
more bone and are directly involved in matrix mineralization. Hence, the longitudinal bone growth
follows the steps of endochondral ossification. The appositional growth of the bone in diameter is
controlled by the osteogenic activity of cambium (osteogenic layer) of periosteum. Consistently, the
bone is formed from outside and the old bone is resorbed from inside (endosteum) to maintain the
bone marrow cavity.
Although bone growth in length stops in early adulthood culminating in the complete
ossification of the epiphyseal growth plate and fusion of primary and secondary
ossification centers, the bone growth in width can continue throughout the life
(appositional growth) and is mainly controlled by the physiological signaling of sex
hormones. It happens through the deposition of bone matrix by the osteoblasts of the
osteogenic layer of periosteum around the diaphysis. Additionally, newly formed
chondroblasts of the perichondrium surrounding the cartilage anlage are similarly
involved in the thickening of the bone. Consistently, during the peripheral thickening of
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the bone, matrix resorption mediated from the endosteal surface of the bone is
important for the expansion of bone marrow cavity (Rauch, 2005).
Bone modelling and remodeling
Bone is a dynamic organ that undergoes constant adaptation through bone modelling
and remodeling in response to mechanical loading and physical influences.
Bone modelling accounts for changes in the bone shape and structure to optimize the
bone strength in response to biomechanical force. This is achieved through the
independent processes of bone formation and bone resorption in the stress
experiencing regions of the bone (Seeman, 2009).
Bone remodeling is a physiological process that has substantial role in bone mass
maintenance and in regulation of serum calcium levels and, hence, bone homeostasis.
By changing the structure of the bone, bone remodeling also minimizes and prevents
the possibility and accumulation of micro damage occurrence. More importantly, bone
remodeling is critical during fracture healing.  The process of bone remodeling mainly
happens on the endosteal surface of the bone, i.e. on the endocortical, trabecular and
intracortical (Haversian systems) components. It is rarely observed on the periosteal
surface (Seeman, 2009). Unlike bone modeling, bone remodeling is controlled by the
balanced coupling of bone resorption to bone formation. Loss of balance and/or
coupling of these processes serve as the basis for the most of the skeletal diseases.
Indeed, bone loss associated with increased rate of bone resorption and/or reduced rate
of bone formation is observed during osteoporosis, the most prevalent bone disease
among aged population. Hence, the bone remodeling is dependent on the tightly
synchronized activity of several cellular compartments of bone that form the “bone
multicellular unit” (BMU) (Raggatt and Partridge, 2010). BMU is usually lined up with a
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layer of so-called canopy cells, presumably the bone-lining cells that form the bone
remodeling compartment (BRC). The process of bone remodeling starts with activation
phase which involves the sensing of remodeling-initiating signal (Figure 2). Osteocytes
play a key role in this process. By producing number of anabolic factors, osteocytes
might coordinate the action of osteoblasts and osteoclast within the BRC. Moreover,
damage associated apoptosis of osteocytes serves as a chemoattractant for osteoclast
recruitment. Similarly, the PTH induced activation of osteoblasts can induce the release
of factors by the latter such as RANKL that initiate differentiation of osteoclasts (Raggatt
and Partridge, 2010). Following the signal detection and subsequent recruitment of
osteoclasts to the sites of remodeling, the osteoclast mediated resorption of the bone
matrix starts. At the end of the resorption phase, cells of yet unknown origin infiltrate the
freshly formed resorption lacunae. These cells were proposed to be the osteoblast-
specific macrophages, the so-called osteomacs, involved in the removal of collagenous
debris. However, recent findings also suggested that these could be some kind of bone
lining cells involved in the deposition of fresh collagenous matrix. In any case, the
reversal cells most likely play important role in coupling of bone resorption to bone
formation within the BRC (Raggatt and Partridge, 2010) . Moreover, osteoclasts were
similarly shown to be involved in the regulation of coupling process. Namely, the
expression of semaphorin 4D (Sema4D) by osteoclasts was shown to inhibit the bone
formation process by osteoblasts which is required for initial step of bone resorption.  In
contrast, the expression of semaphorin 3A by osteoblasts was shown to inhibit the
further action of osteoclasts. Moreover, the expression of membrane bound ephrinB2 by
osteoclasts and ephrinB4 by osteoblasts were similarly shown to regulate the coupling
of bone resorption to bone formation. The ephrinB2 binding of osteoclasts to the
ephrinB4 on the surface of osteoblasts stimulates osteoblast differentiation whereas the
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reverse case of the signaling inhibits osteoclastogenesis, suggesting ephrinB2/ephrinB4
signaling as important event in the termination of bone resorption and initiation of bone
formation.  Consistently, the bone resorption associated release of several signaling
factors such as BMPs, TGF-β or insulin growth factor-1 (IGF-1) was found to trigger the
osteoblast differentiation. Altogether, these signaling events lead to activation and
differentiation of the osteoblasts that culminate the cycle of bone remodeling by
subsequent phase of bone matrix formation (Figure 2). Osteoblasts and osteocytes then
promote the subsequent mineralization of freshly formed matrix (Sims and Martin,
2014).
Epigenetic mechanisms in bone
As previously discussed, the development of “bony” skeleton involves a series of
steps which includes lineage commitment of mesenchymal cells into
osteochondroprogenitors and hematopoietic cells into macrophages, cellular
expansion, differentiation and maturation of the specialized cells that contribute to
formation of fully functional bone structures. Each stage of cellular progression and
development is characterized by the specific, i.e. selective pattern of gene
expression that is achieved by the orchestration of transcriptional and epigenetic
regulatory networks in spatiotemporal manner. Epigenetic mechanisms contribute to
the establishment and maintenance of gene expression patterns without altering the
DNA sequence (Figure 4). The major mechanisms of epigenetic regulation include
post-translational modifications of histones and DNA that subsequently lead to the
changes in chromatin structure and accessibility to transcriptional regulators
(Minarovits et al., 2016).  In this context, protein complexes involved in histone
exchange, chromatin reorganization and nucleosome positioning broaden the
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spectra of epigenetic mechanisms affecting gene expression (Becker and Workman,
2013). Consistently, the evolution of several histone variants that affects the
nucleosome structure and dynamics per se serves as an additional mechanism of
epigenetic control. Finally, RNA interference (RNAi) pathways and long-noncoding
RNAs (lnRNA) have emerged as additional epigenetic regulators of gene expression
at post-transcriptional and pre-translational levels (Minarovits et al., 2016).
Figure 4. Epigenetic mechanisms of gene regulation. The term “epigenetics” literally means
“above genetics” and refers to the heritable changes in chromatin organization affecting the gene
expression regulation without altering the DNA code. This can be achieved by the post-translational
modifications to DNA and histones which affect the chromatin structure and dynamics and provide the
scaffold for the recruitment of other epigenetic and transcriptional regulators. Similarly, the histone
variants can positively or negatively influence the nucleosomal stability. Consistently, the accessibility
of DNA to transcriptional machinery is regulated by the activity of ATP-dependent chromatin
remodelers. Additionally, the non-coding RNAs regulate expression by involving RNAi pathways are




In a eukaryotic cell DNA is condensed into highly organized chromatin structure.
Such a chromatin structure is composed of basic repeating units, i.e. nucleosomes.
Each nucleosome consists of a core particle with linker DNA. The core particle is
made of an octamer of histone proteins H2A, H2B, H3 and H4, each present in two
copies, and 147 bp long DNA fragment wrapped in 1.7 helical turn around the
octamer. Each core particle is connected with the adjacent neighbors through the
linker DNA. This way, the nucleosomal array structure “beads on the string” is
arranged. The further condensation of nucleosomal array into 30nm fiber structure is
partially mediated by linker histones H1 and H5 (Samara et al., 2010).  Each of the
core histones possess “histone-fold” and “histone-tail” (N-terminal) domains. The
fold-domain is responsible for the interaction of histones heterodimers with each
other. The histone dimers H3-H4 make a centrally located tetramer which is covered
by the bundles of H2A-H2B heterodimer from both sides through H2B-H4
associations. The N-terminal histone tails along with histone H2A C-terminal tail
protrude from the center of histone core.   Moreover, the N-terminal tail of histone H4
was shown to contribute to chromatin condensation by building internucleosomal
interaction with the highly acidic region (“acidic patch”) of histone dimer H2A-H2B
that constitutes the binding surface for a variety of nucleosome binding proteins.
Consistently, the latter can compete out the interaction of histone H4 N-terminal tail
from this surface, thus affecting the stability and dynamics of the nucleosome as a
whole (Kalashnikova et al., 2013).  Moreover, the histone tails are subject to many
histone post-translational modifications that may impose positive or negative
functional consequences on gene expression. The pattern of the post-translational
histone modifications is regulated by the enzymatic activity of proteins that can deposit
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the specific modification - “writers”; the “erasers” that remove it, and the “readers” that
recognize it and recruit the other “writers” and “erasers” along with transcription
machinery to further influence gene expression. Histone modifications based on net
charge change to the chromatin may influence the histone-DNA and histone-histone
interactions. For a long time this was thought to be the main mechanism affecting the
transcriptional regulation of a gene. However, more evidence suggests that specific
combination and pattern of histone modifications form a distinct code (histone code)
associated with a defined chromatin state. In this case, the “decryption” of the code by
reader-domain containing proteins is the key step in the transmission of epigenetic
information to the transcription regulatory networks (Strahl and Allis, 2000).
Post-translational histone modifications
Histone tails can undergo a variety of chemical modifications including methylation,
acetylation, ubiquitination, phosphorylation, polyadenylation, ribosylation, glycosylation
and crotonylation suggesting the vast diversity of histone code. Much research has
been done on the histone methylation, acetylation and phosphorylation in context of
transcriptional regulation of gene expression.
Histone acetylation is linked to active transcription. It is catalyzed by histone
acetyltransferases (HAT, or KAT), enzymes responsible for transferring the acetyl
residues from acetyl-CoA to the lysine ε-amino groups on the N-terminal tails of
histones, mainly H3 and H4. Two main classes of HATs have been characterized so far.
These include the Gcn5-related N-acetyltransferases (GNAT) and the MYST
(Moz/Ybf2/Sas2/Tip60) families. E1A binding protein p300 and cAMP-response
element-binding protein (CREB)-binding protein (p300/CBP) proteins have been
considered as another family of HATs and play ubiquitous role as transcriptional
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coactivators. The removal of the histone acetylation is carried out by
histonedeacetylases (HDAC). In mammals, HDACs are classified into 4 groups: class I
HDACs contains the right parietal dorsal 3 (RPD3)-like enzymes; class II, the HDA1-like
enzymes; class III is represented by the sirtuins, whereas the class IV has only one
characterized member – HDAC11. The most commonly investigated histone acetylation
sites include H3 K9/14/27 and H4 K5/8/12/16 which were shown to be widespread
marks associated with both active promoters and enhancers (Gordon et al., 2015;
Verdone et al., 2005). Subsequently, the recognition of the acetylated histones is
carried out by the bromodomain containing proteins (“readers”).
Histones methylation may lead to transcription activation or repression depending on the
location, pattern and type of the methylation. Histones can be methylated on lysine and
arginine residues. Methylation of lysine can be in mono-, di- and trimethylated form.
Arginine can be either mono- or dimethylated, the latter in symmetric or assymetric form.
The methylation involves transfer of methyl groups from S-adenosyl- L-methionine
(SAM) to the ε-amino group by hitsone methyltransferases (HAT). These enzymes can
be classified into three main groups: SET(Suppressor of variegation, Enhancer of zeste,
Trithorax)-domain-containing proteins, DOT1(Disruptor of Telomeric silencing)-like
proteins and arginine N-methyltransferases (PRMT). The latter are subdivided into two
types based on asymmetric or symmetric dimethylation properties.  The removal of
methyl groups is catalyzed by demethylases (HDM) that can be grouped into two
classes: amine oxidases and jumonji C (JmjC)-domain-containing dioxygenases
(Gordon et al., 2015; Zhang and Reinberg, 2001). The recognition of methyl groups is
carried out through the chromodomains of the proteins. The widely studied histone
methylation sites include H3K4 – associated with active or poised promoters (K4me3)
and enhancers (K4me1); H3K9 associated with heterochromatin, H3K27 involved in
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gene silencing; H3K36, H3K79me2/3 – associated with actively transcribed genes and
H4K20 associated with inactive state.
Histone phosphorylation can target all four histone molecules and occurs on serine,
threonine or tyrosine residues of the latter. It is mediated by a wide range of kinases and
can be subsequently removed by histone exchange or phosphatases. Among many,
phosphorylation of histone variant H2AX on serine 139, referred as λH2AX, is of special
importance given its role in DNA damage response. It is one of first events happening
after damage induction and wide spreading of this mark serves as recruitment platform
for a variety protein complexes involved in damage repair. Phosphorylation of serine 10
and 28 residues of histone H3 by Aurora kinase B has been linked to chromatin
condensation during cellular division. In context of gene expression regulation, histone
phosphorylation is associated with active transcription. Moreover, it has been reported
that histone phosphorylation can be involved in histone cross-talk with histone
acetylation. Namely, H3S28 phosphorylation was shown to displace the Polycomb
Repressive Complex 2 (PRC2) from gene promoters leading to loss of H3K27me3 from
these promoters with subsequent acetylation of H3K27 and gene activation (Lau and
Cheung, 2011; Rossetto et al., 2012).
Among the 4 core histones, histone H2A and H2B are more abundantly subjected to
ubiquitination. Unlike acetylation or methylation, ubiquitination involves conjugation of
relatively larger, 76 amino acid long polypeptide molecule to the indicated histone tails
certainly inducing steric changes in the nucleosome. The ubiquitin (ub) conjugation is a
three step process involving ATP dependent ubiquitin activation by E1 enzyme, the
conjugation of ubiquitin by E2 enzyme with subsequent ligation of ubiquitin to the lysine
of the target protein through its C-terminal cysteine by E3 enzymes. Histone H2B and
H2A are monoubiquitinated at positions K120 and K119, respectively (H2BK120 and
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H2AK119). Polyubiquitination is also common, and was shown for histone H2A and its
variant H2A.X during DNA damage induced signaling (Minarovits et al., 2016).
H2AK119ub1 is associated with Polycomb group (PcG) protein mediated gene silencing
and is known to be catalyzed by Ring finger protein 1B (RING1B) E3 ligase of polycomb
repressive complex 1 (PRC1). In addition, two other members of PRC1 – RING1 and
B lymphoma Mo-MLV insertion region 1 homolog (BMI1) were shown to have
supportive role in facilitating the E3 ligase activity of RING1B (Cao and Yan, 2012)
Monoubiquitination of histone H2B is carried out by E3 obligate heteromeric complex
of ring finger proteins RNF20/RNF40 (Zhu et al., 2005).  Genome-wide studies have
revealed strong association of H2BK120ub1 with actively transcribed genes (Minsky
et al., 2008). It promotes chromatin decompaction (Fierz et al., 2011) and facilitates
transcriptional elongation of genes by RNA polymerase II (RNAPII) in part through
the histone H2A/H2B dimer replacement by histone chaperon complex Facilitates
Chromatin Transcription (FACT) (Pavri et al., 2006). Moreover, H2BK120ub1
appears to be involved in histone-crosstalk influencing methylation of histone H3K4
and H3K79 thereby supporting transcription activation (Kim et al., 2005).
Consistently, like any post-translational histone modification, ubiquitination can be
reversible. This is achieved by the activity of deubiquitinating enzymes (DUBs).
Whereas some DUBs preferentially target either H2AK119ub1 or H2BK120ub1, the
others exhibit less specificity and can deubiquitinate both (Cao and Yan, 2012).
Histone modifications in bone
Cellular differentiation is accompanied by quantitative and qualitative changes in
post-translational histone modifications. In general, the changes in activating histone
modifications positively correlate with gene expression changes (Su et al., 2016).
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Consistently, the same relationship was observed for some osteoblast-specific genes
during the osteogenic differentiation of mesenchymal stem cells (MSC). For instance,
Lee and colleagues identified differentiation linked increase of H3 and H4 promoter
acetylation at osteocalcin (OC) and osterix (OSX) genes associated with decreased
recruitment of HDAC1 and increased occupancy of p300 at these promoters (Lee et al.,
2006). The spontaneous differentiation of human placental MSCs was similarly
associated with increase of H3K9 and H3K14 acetylation at RUNX2 and ALPL
promoters (Li et al., 2011).
Several histone acetyltransferases have been implicated in osteoblast-specific gene
regulation, bone formation and remodeling. As previously mentioned the parathyroid
hormone is important regulator of bone formation and remodeling. One of many genes
regulated by PTH is matrix metalloprotease-13 (MMP13) expressed in osteoblasts and
chondrocytes. It is a collagenase that has specific role during endochondral ossification.
It was demonstrated that PTH induces MMP13 expression by promoting recruitment of
p300/CBP-associated factor (PCAF) and p300 to the promoter of this gene in RUNX2
dependent manner. Consistently, the promoter acetylation of MMP13 increased
consistently in response to PTH treatment. Moreover, the activity of PCAF was further
augmented by p300 meditated acetylation of this protein (Lee and Partridge, 2010).
Moreover, in the absence of PTH signaling, MMP13 is repressed through HDAC4
interacting with RUNX2 on the promoter of this gene (Shimizu et al., 2010).
Given the positive correlation of histone acetylation with osteoblast-specific gene
expression, extensive research has been conducted on HDAC inhibition as potential
approach for inducing osteogenesis in bone pathologies such as osteoporosis. The
main effects of HDACs in bone biology can be attributed to their ability to inhibit RUNX2,
the master regulator of osteoblast differentiation. They have been also found on the
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promoters of other osteoblast-specific genes as well.  Namely, this was shown for
HDAC1 (Lee et al., 2006) and also for class II HDAC4 and HDAC5 (Jeon et al., 2006) .
Moreover, some transcriptional repressors such as zinc finger protein 521 (Zfp521) by
associating with HDAC3 repress the RUNX2 promoter activity hence modulating the
stage dependent opposing role of RUNX2 in early and mature osteoblasts (Hesse et
al., 2010). Although the HDACs share structural and some functional redundancy within
their classes, they may also display some specific functions. This was particularly shown
for HDAC8 where the germline deletion of this protein in mice lead to perinatal lethality
due to skull abnormalities mainly through derepression of homeobox genes involved in
patterning (Haberland et al., 2009). Although germline deletion of HDAC1 is also
embryonically lethal, the death is caused mainly by proliferation defects (Lagger et al.,
2002).
Based on therapeutic success of HDAC inhibitors (HDI) in epilepsy, bipolar disorder,
and cancer, this class of drugs have been extensively studied by the scientific
community. Out of many HDIs a few including suberoylanilide hydroxamic acid (SAHA)
Valproate, Panobinostat, Belinostat and others have been already clinically approved.
HDI have also displayed great anabolic features on bone. Many reports by different labs
demonstrated increased osteoblast gene expression, mineralization, alkaline
phosphatase activity and enhanced Runx2 transcriptional activity in vitro in different
osteoblastic cell lines upon HDI treatments (Cho et al., 2005; Lee et al., 2009;
Schroeder et al., 2007). Interestingly, clinical investigation of the patients treated with
valproate revealed conflicting to in vitro data results associated with decreased bone
mineral density. The in vivo studies in rodents also revealed somewhat unexpected
results based on the background strain and immune system of the mice used for the
studies (Senn et al., 2010).
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Similarly, histone methylation has profound role in regulating the differentiation potential
of MSCs towards osteoblastic lineage. For instance, MSC-specific deletion of SET
domain containing histone methyltransferase (ESET, or SETDB1) for H3K9 inhibited
differentiation of MSCs both in vitro and in vivo. It was demonstrated that ESET inhibits
RUNX2 mediated transactivation which is important for osteoblast maturation. In
agreement with this finding, MSC-specific ESET knockout mice displayed detrimental
changes in trabecular bone volume and number of osteoblasts (Lawson et al., 2013).
The role of PRC2 complex, namely H3K27 methyltransferase EZH2 has been also
addressed in the context of osteoblastic differentiation. Genome-wide profiling of EZH2
binding sites in differentiating MSCs before and after osteoblastic induction revealed
that differentiation lead to global disassociation of Enhancer of zeste homolog 2 (EZH2)
from substantial amount of target genes. Namely, out of more than 4000 EZH2 bound
genes, around 30 maintained EZH2 after osteogenic differentiation. Consistently, this
was in line with reduced H3K27me3 levels at the promoters of the target genes
including RUNX2 (Wei et al., 2011). Moreover, distinct class of histone demethylases
were identified as critical regulators of osteogenic differentiation of human adipose
derived mesenchymal cells (hASC). Recent findings demonstrated that osteogenic
differentiation of these cells was associated with reduced binding of retinoblastoma
binding protein 2 (RBP2) and lysine specific demethylase 1 (LSD1 or KDM1A) , the
H3K4me demethylases at the promoter of OC and OSX genes with subsequent
increase in methylated H3K4 levels. Furthermore, mice xenograft models with Bio-Oss
collagen scaffolds seeded with demethylase depleted hASCs revealed increased
mineralization compared to scaffolds with control hASCs (Ge et al., 2011, 2014).  The
critical role of histone demethylases in osteoblast differentiation was further
strengthened by another study by Ye L. and colleagues (Ye et al., 2012b). The authors
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identified two lysine(K)-specific demethylases KDM4B and KDM6B to be upregulated
during BMP4/7 induced osteogenic differentiation of MSCs. KDM6B was shown to
regulate BMP2, BMP4 and HOX gene expression by removing H3K27me3 whereas
KDM4B promoted DLX5 (distal-less homeobox 5) expression through removal of
H3K9me3. DLX5 has profound role in osteoblastogenesis by regulating activation of
RUNX2 (Samee et al., 2008). Similarly, another H3K27me3 demethylase, i.e. KDM6A
was shown to carry the same role by positively regulating differentiation of MSCs into
osteoblasts by affecting the expression of master regulators (Hemming et al., 2014).
The mutations causing deletion within the histone H3 lysine 36 (H3K36)
trimethyltransferase gene Whsc1 (Wolf-Hirschhorn Syndrome candidate 1) leads to the
development of the syndrome with the same name. This pathology is associated with
growth and mental retardation, and most notably, it leads to skeletal abnormalities. It
was discovered later, that Whsc1 is important for interaction of RUNX2 with p300 and
facilitates this way RUNX2 dependent transcriptional regulation of target osteoblast-
specific genes such as COL1A1 (Lee et al., 2014)
Increasing body of evidence suggests that lineage-specific gene expression is mainly
regulated by the activity of tissue-specific enhancers. The combination of histone
modifications marking the enhancer regions can dictate the functional activity of the
enhancer and its accessibility to transcription factor networks involved in lineage
determination. Genome-wide profiling of a combination of histone marks, namely
H3K36me3, H4K20me1, H3K4me1, H3K4me2, H3K4me3, H3K9ac, H3K27ac, H4K5ac
and H3K9me3 in osteoblasts induced to differentiate into osteocytes revealed more
quantitative changes in these modifications correlating with gene expression changes
rather than qualitative. This suggests that most of the epigenetically active regions
priming the osteoblast-specific regulatory elements were established at much earlier
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stages of osteoblast establishment. Moreover, vitamin D induced increase in VDR/RXR
binding events in the osteocytes were mainly localized to enhancer regions enriched by
H3K4me1, H3K27ac, H3K9ac and H4K5ac (St John et al., 2014). Consistently, a
similar enrichment pattern was observed for co-bound RUNX2 and C/EBPb enhancer
sites  in mouse osteoblasts (Meyer et al., 2014a)
We previously showed that monoubiquitination of histone H2B positively affects also
differentiation of human mesenchymal stem cells into the osteoblastic lineage (Karpiuk
et al., 2012). H2Bub1 was shown to control expression of differentiation induced genes
and differentiation of MSCs was largely impaired if cells were depleted for RNF40 or
RNF20.
BET proteins
As briefly mentioned before, the histone acetylation marks are recognized by reader
proteins via bromodomains. In humans, there are approximately 46 bromodomain
harboring proteins which are categorized into eight families based on structure and
sequence homology. The discovery of small-molecule inhibitors of Bromodomain
and Extra-Terminal (BET) family proteins with high anti-tumorigenic potential made a
breakthrough in the field of “epigenetic chemotherapy” of a variety of cancer
subtypes and, as such, made a strong basis for extensive research in the field of
BET proteins biology. The BET family includes bromodomain containing protein 2
(BRD2), BRD3, BRD4 and testis-specific BRDT. These proteins are characterized by
two N-terminal bromodomain modules (BD1, BD2), one conserved extraterminal
domain (ET), and additionally BRD4 and BRDT possess a C-terminal P-TEFb
interaction domain (PID) (Figure 5). The modular structure of BET proteins facilitates
multiple interaction possibilities for these proteins stimulating the transcriptional
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activation. The binding of bromodomains to diacetylated lysine sequences,
preferentially to H3 K9/K14 and H4 K5/8/12/16 enables tethering of the BETs to the
active chromatin (Filippakopoulos et al., 2012) through its bromodomains (Figure 5).
Moreover, the bromodomains of BRD4 can bind with acetylated non-histone
proteins. For instance, the second bromodomain (BD2) of BRD4 was shown to
actively bind the triacetylated cyclin T1 whereas the PID of BRD4 accounted for
disassociation of HEXIM from P-TEFb this way leading to its release (Schröder et al.,
2012). The latter are known to facilitate activation of RNA Polymerase II and hence
the transcriptional elongation of downstream genes. The interaction of BRD4 with
diacetylated TWIST was similarly shown to be dependent on BD2 (Shi et al., 2014).
Moreover, both bromodomains exhibit binding ability towards acetylated v-rel avian
reticuloendotheliosis viral oncogene homolog A (RelA) protein and hence are
required for NF-kB activity (Huang et al., 2009). Furthermore, based on the ability of
erythroid transcription factor GATA-1 to bind the BET proteins and subsequent
identification of BRD3 BD1 to be responsible for this interaction, it was suggested
that the same would be true for BRD4 (Lamonica et al., 2011; Stonestrom et al.,
2015). A recent finding also discovered the BD1 dependent interaction of ERG with
BRD4 (Blee et al., 2016). However, the function of BETs in transcriptional regulation
is not only acetylation dependent. In fact, BRD4 was shown to interact with a number
of transcription factors in an acetylation-independent manner (Roe et al., 2015).
Consistently, proteomic analysis revealed the ability of ET domain of BRD4 to
interact with some chromatin remodelers like nuclear-receptor binding SET domain
protein 3 (NSD3), Chromodomain Helicase DNA Binding Protein 4 (CHD4) and
Jumonji Domain Containing pretin 6 (JMJD6)  (Liu et al., 2013; Rahman et al., 2011).
Interestingly, BRD4 was also shown to interact with p53 which was dependent on the
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phosphorylation events within the NPS (N-terminal cluster of phosphorylation sites)
that controlled the conformational switch between phosphorylation dependent
interaction domain (PDID) and basic residue enriched interaction (BID) (Figure 5).
Namely, in the absence of phosphorylation, p53 binds the BID whereas the PDID
masks the BD2 from binding to acetylated chromatin. Upon phosphorylation, the
PDID interacts with BID this way unmasking the BD2 and facilitating recruitment of
BRD4-p53 complex to the chromatin (Wu et al., 2013).  The function of SEED
(Ser/Glu/Asp-rich region) domain remains unknown, however the earlier studies on
BRD2 suggested that it may be involved in the interaction with transcriptional
regulators of cell cycle E2F1 and E2F2 (Denis et al., 2000).
The role of BRD4 in transcriptional regulation was further supported by the genome-
wide analysis which revealed association of BRD4 with non-coding eRNA production
from enhancers (Di Micco et al., 2014; Kanno et al., 2014; Liu et al., 2013; Nagarajan
et al., 2014; Zhang et al., 2012). Further studies also suggested role of BRD4 in
maintaining the chromatin organization (Wang et al., 2012). Similar functions were
also shown for BRDT during male germ cell differentiation (Gaucher et al., 2012).
Given their crucial role in transcriptional regulation of gene expression, BET proteins
were also shown to promote oncogene induced aberrant gene expression in various
human malignancies. In this context, the BET inhibition was shown to induce anti-
tumorigenic effects in a variety of MYC driven cancers, such as in hematological
malignancies (Coudé et al., 2015; Filippakopoulos et al., 2010; Mertz et al., 2011), in
brain tumors medulloblastoma (Venkataraman et al., 2014) and glioblastoma
(Rajagopalan et al., 2014), in lung adenocarcinoma (Tsai et al., 2015), castration
resistant prostate cancer (Asangani et al., 2014), estrogen positive breast cancer
















BRD4 inhibition potently inhibited MYC driven osteosarcoma (Lamoureux et al.,
2014). Moreover, the BET inhibitor JQ1 was shown to block the differentiation of
both osteoblasts and osteoclasts by directly targeting the transcriptional networks
involved in lineage determination (Lamoureux et al., 2014; Park-Min et al., 2014).
Namely, BETi blocked the expression of RUNX2 in osteoblasts and RANKL
mediated MYC-NFAT axis involved in osteoclast differentiation and activation.
Figure 5. Structure and interaction partners of BRD4 protein. BRD4 protein has several functional
domains which are BD1 (bromodomain I); BD2 (bromodomain 2); PDID (phosphorylation dependent
interaction domain) including NPS (N-terminal cluster of phosphorylation sites); BID (basic residue
enriched interaction); ET (extra-terminal domain); SEED (Ser/Glu/Asp-rich region); PID (P-TEFb
interacting domain within its C-terminal domain (CTD)).
DNA methylation
In general, DNA methylation is a reversible process associated with gene repression.
It is carried out by DNA methyltransferases (DNMT) and occurs on the fifth carbon of
cytosine bases (5mC). DNA methylation is most commonly observed on the
palindromic dinucleotide repeats within the CpG islands (CGI). Almost 70% of
human gene promoters were identified to be CGI rich. In particular, these include
most of the housekeeping genes and some tissue-specifc genes (Larsen et al.,
1992; Zhu et al., 2008). During the replication, the DNA methylation pattern of
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parental strands is passed on to the newly formed daughter strands by the DNMT1
enzyme. After replication, de novo methylation sites are established by DNMT3A and
DNMT3B enzymes. Despite its inheritable nature, DNA methylation was at the same
time shown to be a very dynamic feature rapidly changing in many biological
settings. The dynamic cycle of DNA methylation involves cytosine methylation,
oxidation of methyl group by the family of Ten-eleven Translocation (TET)
dioxygenases with subsequent formation of 5-hydroxymethylcytosine (5hmC), and
restoration of unmethylated cytosines by either replication-dependent dilution or DNA
glycosylase-initiated base excision repair by TDG (thymine-DNA glyosylase) (Wu
and Zhang, 2014). Methylated DNA can be recognized by methyl-CpG binding
proteins (MBP) that by recruiting histone modifying enzymes lead to formation of
chromatin repressive signatures associated with gene inactivation. The group of zink
finger-CxxC domain (ZF-CxxC domain) containing proteins was, in contrast, shown
to maintain the unmethylated DNA structure within the CpG islands by recruiting the
H3K4 methyltransferases and DNA demethylases (Minarovits et al., 2016).
Consistently, given its broad function in regulating gene expression, DNA
methylation has profound functions in bone development. In fact, differentiation of
MSCs into osteoblasts is accompanied by the promoter methylation events at
stemness genes (Dansranjavin et al., 2009). Active promoter DNA demethylation
was consistently observed on DLX5, RUNX2, BGLAP, and OSX genes upon
osteogenic induction of hASCs (Zhang et al., 2011a).  The expression of SOST was
also shown to be dependent on promoter methylation which decreased during
transition of osteoblasts to osteocytes (Delgado-Calle et al., 2012a). Consistently,
CpG island methylation was associated with decreased expression of RANKL and
OPG genes in patients with osteoarthritis and osteoporosis (Delgado-Calle et al.,
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2012b). The reduced expression of RANKL in response to vitamin D treatment in
mouse stromal cells ST2 was in part associated with recruitment of methyl-CpG-
binding protein 2 (MeCP2)  to the methylated CpG island which then blocked the
bindindg of TATA binding protein (TBP) required for gene activation (Kitazawa and
Kitazawa, 2007).
Epigenetic contributions of non-coding RNAs
Increasing body of evidence suggests key regulatory functions of non-coding RNAs
(ncRNAs) in gene expression regulation. The ncRNAs are classified into two
categories based on their size. The small RNAs stand out as integral players of RNA
interference pathway and are mainly involved in gene silencing due to RNA
degradation and translational repression. Moreover, some of them can incorporate
function of histone and DNA methyltransferases to achieve gene silencing on
chromatin level.  The long ncRNAs (lnRNA) can affect gene expression by acting as
tethers and scaffolds for chromatin modifying enzymes, contributing to changes in
chromatin structure (Holoch and Moazed, 2015). In addition, the discovery of
enhancer RNAs revealed additional functions of lnRNAs in controlling gene
expression by assisting enhancer-promoter looping, choromatin accessibility at
defined regions,  RNAPII transcriptional elongation by releasing the negative
elongation factor (NELF) and activating positive transcription elongation factor (P-
TEFb) (Hsieh et al., 2014; Li et al., 2013; Mousavi et al., 2013; Schaukowitch et al.,
2014; Zhao et al., 2016)
Based on the action and formation mode, the small RNAs are further grouped into
three categories: micro RNAs (miRNA), short interfering RNAs (siRNA) and Piwi-
interacting RNAs (piRNA). Among these the miRNAs are the most widely studied
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class of non-coding RNAs. miRNA are initially produced as single stranded RNA
(ssRNA), referred as pri-miRNA molecules via transcription of miRNA coding genes
or during splicing events from introns. They can be produced in sense and antisense
orientiation. The ssRNA in turn forms imperfect double-stranded structure through
hairpin-looping. The pri-miRNA is recognized b Microprocessor complex consisting
of “Pasha” and “Drosha” proteins that contribute to liberation of the hairpins from
initial pri-miRNA through the RNAse III activity of the “Drosha” protein. This results in
formation of precursor miRNA (pre-miRNA). These then are transported to the
cytoplasm by the shuttler proteins where they are subjected to endonuclease
processing by Dicer enzyme. This results in formation of miRNA duplex molecule
one strand of which is integrated to the RNA-induced silencing complex (RISC),
which then binds to a specific target mRNA to induce its cleavage. miRNA can also
induce translational repression with subsequent degradation due to deadenylation of
the pol(A) tail of target mRNA (Eulalio et al., 2009; Holoch and Moazed, 2015;
Jeltsch, 2011).
miRNAs were shown to play crucial role at every stage of bone formation,
development and remodeling. Since mesenchymal stem cells have the multilineage
potential to differentiate into adipocytes, osteoblasts, chondrocyte and myoblasts, it
is of great importance to decipher the molecular mechanisms that would act some
kind of “switches” modulating the lineage determination of MSCs into favored
direction. As such, targeting specific transcription factors, i.e. master regulators
involved in one lineage can be in fact used to modulate the differentiation choice of
MCSs.  At least, 19 miRNAs were discovered to target 3’-UTR region of RUNX2 in
different cells of mesenchymal origin. In contrast, miR-27a and 27-b by inhibiting
PPARγ were shown to promote osteoblastogenesis (Hassan et al., 2015; Vrtačnik et
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al., 2014). The anabolic effect of miRNAs in bone was further demonstrated on the
example of potentiating effects of miRNAs on Wnt signaling. Namely, miR-29a, miR-
218 and miR-335-5p were shown to target and hence downregulate the expression
of Wnt inhibitors (Hassan et al., 2012; Vrtačnik et al., 2014). A recent study in
humans discovered association of high miR-214 with reduced bone formation rate in
aged patients with osteoporosis. This was most likely due to direct inhibition of ATF4,
the transcription regulator of osteoblastogenesis, by miR-214 (Wang et al., 2013).
Furthermore, as in many other cellular systems, miRNAs were reported to impose
positive or negative effects on osteoclastogenesis. For instance, miR-21 by targeting
programmed cell death 4 (PDCD4) resulted in derepression of c-FOS required for
differentiation of osteoclasts and in enhanced expression of miR-21 itself (Sugatani
et al., 2011). At the same time,  estrogen induced apoptosis of the osteoclasts was in
part shown to be achieved by downregulating the expression of miR-21 that targets
the FasL, the known inducer of apoptosis in osteoclasts (Sugatani and Hruska,
2013). These findings altogether suggest that the use of miRNA antisense inhibitors
could be considered as a potential strategy to modulate bone remodeling during
bone diseases.
Moreover, the recent advances in high-throughput sequencing techniques resulted in
identification of vast number of long non-coding RNAs controlling general and tissue-
specific cellular events during normal and diseased states.  However, up to now very
little is known about the lnRNA and their function in bone. 116 lnRNAs were found to
be differentially regulated in BMP-2 induced mesenchymal stem cells differentiating
into osteoblasts (Zuo et al., 2013). In human fetal osteoblasts (hFOBs) lncRNA-
ANCR (anti-differentiation ncRNA) was shown to be downregulated during
differentiation. Moreover, the authors discovered association of ANCR with EZH2 as
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mechanistic basis to promote RUNX2 promoter H3K27 trimethylation (Zhu and Xu,
2013).
ATP-dependent chromatin remodelers, histone variants and
histone chaperones
The level of chromatin compaction and nucleosome dynamics has a direct
consequence on the transcriptional activity of the genes. ATP-dependent chromatin
remodeler complexes (CRC) by using ATP-hydrolysis alter DNA-histone interactions
hence controlling the accessibility of DNA to transcriptional regulators. Currently, the
CRCs are classified into 4 groups: switching defective/sucrose nonfermenting
(SWI/SNF) family; imitation switch (ISWI) family; chromodomain, helicase, DNA
binding (CHD) family and inositol requiring 80 (INO80) family. All of these CRCs
share some common features associated with their structure, namely the conserved
ATPase domain that is required for remodeling through destabilization of DNA-
histone connections; domains that recognize specific histone modifications;
domains/proteins responsible for interaction with transcription factors and other
chromatin remodelers; and proteins/domain that regulate the ATPase activity.
Several mechanisms were suggested explaining the remodeling function of the
CRCs. The currently accepted model is the “loop recapture” model which speaks for
formation of a DNA loop structure on the surface of the core octamer which would
propagate in wave-like manner over the surface of core octamer. Additionally, the
ISWI group of CRCs can achieve chromatin remodeling in a different way. They bind
the nucleosome in two copies and  facilitate bidirectional sliding of DNA over the
nucleosome (Clapier and Cairns, 2009; Hargreaves and Crabtree, 2011).
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The components of SWI/SNF complex were shown to have crucial role in bone
development as well. For instance, the expression of Brahma Related Gene 1
(BRG1) is dependent on BMP2 induced RUNX2 expression. Moreover, BRG1 can
control the BGLAP expression by being directly recruited to its promoter by
CCAAT/Enhancer Binding Protein beta (C/EBPb) transcription factor. Furthermore,
OSX can utilize activity of BRG1 to facilitate target gene expression (Chen et al.,
2015).  The CHARGE syndrome in humans (combination coloboma of the eye, heart
defects, atresia of the nasal choanae, retardation of growth and/or development,
genital and/or urinary abnormalities, and ear abnormalities and deafness) is caused
by the mutations in CHD7 chromatin remodeler. Consistently, these patients also
show craniofacial abnormalities. Moreover, it was previously shown that CHD7
favors osteogenic differentiation of MSCs over adipogenic by facilitating Wnt5
induced inactivation of PPARγ (Takada et al., 2007).
The transcriptional activity can be further affected by the composition of core
octamer and hence the activity of histone chaperones involved in nucleosome
assembly and incorporation of different histone variants. Genome-wide studies have
revealed positive correlation of histone variant H2A.Z with active enhancers
(Brunelle et al., 2015). Interestingly, another report, however, suggested an inhibitory
function of H2A.Z on transcriptional regulation due to enhanced chromatin
compaction. Here authors also displayed histone H3.3 to be associated with active
enhancer (Chen et al., 2013). Multiple histone chaperones have been identified to be
involved in replication independent incorporation of histone variants into
nucleosomes and/or nucleosome assembly/reassembly. For instance, histone cell
cycle regulator (HIRA) is known as classical histone chaperone involved in assembly
of H3.3-H4. The FACT complex was shown to mediate the nucleosomal H2A-H2B to
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H2A.X–H2B exchange. Moreover, the FACT also facilitates H2A-H2B exchange in
H2BK120-dependent manner (Pavri et al., 2006). The incorporation of H2A.Z was
shown to be dependent on the chromatin remodeler complex SWI/SNF subunit p400
whereas recent finding discovered histone chaperone Acidic (Leucine-Rich) Nuclear
Phosphoprotein 32 Family, Member E (ANP32E) to be responsible for removal of
H2A.Z during DNA double-strand breaks (Gursoy-Yuzugullu et al., 2015; Xu et al.,
2012).
Up to now very little is known about the histone variants and chaperones during
osteogenesis. Interestingly, the differentiation of mouse myoblastic cells C2C12 into
osteoblasts was shown to be dependent on histone chaperone activity of HIRA and
Anti-Silencing Function 1A (ASF1A)  and hence on histone H3.3 variant (Song et al.,
2012). Moreover, a recent discovery from our group revealed the positive function of
FACT subunit structure-specific recognition protein-1 (SSRP1) in promoting
osteogenic differentiation. It was demonstrated that SSRP1 regulates expression of
Wnt signaling target genes by specifically affecting the β-catenin transclocation to
nucleus (Hossan et al., 2016). However, the “histone chaperone” activity of SSRP1
has been not examined yet in the context of osteoblastic gene expression regulation.
Epigenetic priming and pioneer transcription factors
The differential pattern of gene expression defining specific cellular phenotype is
established and maintained by the state of the chromatin architecture. Consistently,
the chromatin remodeling plays a major role in controlling the accessibility of lineage
“compatible” genes to the transcriptional machinery through dynamic regulation of
chromatin compaction and decompaction. Since chromatin regulators per se do not
have DNA sequence binding specificity, the recruitment of these factors to the
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“required” genomic sites is regulated by the activity of DNA sequence-specific
transcription factors (TF). In fact, transcription factors play the key role in the defining
the future of cell fate reprogramming. They do so by directly binding their target
sequences within the promoter, enhancer and other regulatory DNA elements. Given
their broad properties in transcriptional control, these factors can be categorized in
two groups of general and tissue/lineage-specific TFs (TTF). Moreover, the
repertoire of enhancers co-bound by several TFs establish the cell identity-specific
activation of target genes. More importantly, the epigenetic marking of enhancers
seems to happen prior the activation of promoter-coupled events (Drouin, 2014) .
The TFs require the accessibility of target DNA sequence to be able to bind it. This
suggests that initial epigenetic priming of the TF binding regions may set up the
permissive environment for lineage-specific transcription factors. Such an event of
epigenetic pre-patterning has been established in embryonic stem (ES) cells. For
instance, the cis-element within the immunoglobulin lambda-like polypeptide 1
(Igll1)–pre-B lymphocyte gene 1 (VpreB1) locus was initially marked by histone H3ac
and H3K4me2 in undifferentiated ES cells. Upon differentiation into pre-B
lymphocytes, this region expanded and became localized by TFs that resulted in
subsequent activation of Igll1 and VpreB1 genes (Szutorisz et al., 2005). Similarly, in
undifferentiated ventral foregut endoderm cells with bipotential choice to either
differentiate into hepatoblasts or pancreas cells, the histone modification
H3K9/K14ac and H3K27me3 seemed to play important role in decision making.
Namely, in undifferentiated state the H3K9/K14ac and H3K27me3 was preferentially
enriched at the pancreas-specific pancreatic and duodenal homeobox 1 (Pdx1)
elements whereas the liver-specific regulatory elements were substantially devoid of
this marks. The differentiation into hepatoblasts was consistently associated with
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increase in H3K9/K14 ac at these elements whereas the pancreatic elements
remained silent because of H3K27me3 (Xu et al., 2011).
The recent advances in genome-wide studies further revealed that epigenetic
marking of enhancers with specific histone variants such as H2A.Z or H3.3 can
similarly serve the purpose of chromatin pre-patterning for downstream activation of
enhancers and target genes (Zaret and Carroll, 2011).
Given the fact that epigenetic priming and transcription factors might be important in
the establishment of lineage specifying regulatory origins, it still remains unclear how
these TFs, chromatin regulators and histone modifications get localized to specific
genomic sites in the silent chromatin. This all suggested existence of some
additional mechanisms that would control the exposure of DNA for the regulatory
circuits. Indeed, based on earlier ChIP and in vivo footprinting studies, a specific
subtype of transcription factors was discovered that in historic terms of view appear
to be first in accessing the silent condensed chromatin and initiate downstream
events of transcriptional activation (Cirillo et al., 2002; Zaret and Carroll, 2011).
These “pioneer” transcription factors (PTF) were shown to possess the intrinsic
ability to engage their target sequences on the nucleosomes within the compact
chromatin. Later studies revealed two modes of action for PTFs. In an active mode,
given their intrinsic ability to bind DNA and histones, binding of PTF can affect the
nucleosome positioning and disrupt internucleosomal interactions which ultimately
lead to chromatin unfolding. In passive mode, the primary PTF binding to regulatory
regions primes these sites for further binding of other TFs thus resulting in
subsequent acceleration of transcriptional response (Zaret and Carroll, 2011). The
first PTFs identified were Forkhead Box A1 (FOXA) and GATA-sequence binding
TF-4 (GATA-4) involved in albumin 1 (ALB1) enhancer activation in liver precursor
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endodermal cells (Cirillo et al., 2002). Interestingly, GATA-4 was shown to precede
binding of estrogen receptor α (ERα) to osteoblast-specific enhancers of RUNX2,
ALPL and FASL during estrogen stimulation of osteosarcoma cell lines U2OS
(Miranda-Carboni et al., 2011).
The PTFs also play important role in mesenchymal stem cells. As such, the
cooperative binding of CCAAT-enhancer-binding proteins (C/EBP) β and -δ,
glucocorticoid receptor (GR), retinoid X receptor (RXR), signal transducer and
activator of transcription 5 (Stat5a) within few hours of adipocyte differentiation of
MSCs coincided with extensive changes in chromatin landscape. Moreover, most of
this TF “hotspots” localized in the vicinity of PPARγ binding sites, priming these sites
for subsequent binding of PPARγ at relatively later stages of adipocyte
differentiation. Notably, among these TFs, C/EBPb was identified as key player
binding to these “hotspots” already before the differentiation induction (Siersbæk et
al., 2011). Given the important function of GR, RXR and C/EBP factors in
osteogenesis (Gutierrez et al., 2002; Imai et al., 2013; Meyer et al., 2014a; Mikami et
al., 2010), it is more likely that these TFs would also display “pioneer” functions
during lineage commitment of OBs. In fact, most of RUNX2 binding sites in
differentiating mouse osteoblasts were co-bound by C/EBPb. Most of these sites
were localized to regions epigenetically marked to be enhancers. Moreover, upon
vitamin D stimulation, the VDR/RxR binding also coincided with most of the RUNX2
and C/EBPb binding sites.  Consistently, RUNX2 and C/EBPb binding in these cells




Epigenetic mechanisms are key regulatory elements during formation, establishment
and maintenance of tissue-specific gene expression patterns. Acquirement of a
specific cell state is always accompanied by extensive remodeling of epigenome and
transitions between the states, and hence, cellular plasticity depends on the versatile
interaction of several layers of epigenetic hierarchy. Consistently, the deregulation of
these mechanisms contributes to the initiation, progression and maintenance of
aberrant gene expression. Fortunately, the reversibility of epigenetic processes has
laid the basis for the emergence of the new field of epigenetic therapy. Currently,
epigenetic therapy is rapidly progressing especially in the field of cancer treatment
and several epigenetic inhibitors have already entered clinical trials. The recent
advances in sequencing techniques and substantial amount of sequenced data
greatly enhanced our understanding of epigenetic mechanisms controlling gene
expression. However, despite the growing field of cancer epigenetics, much less has
been undertaken in the field of bone biology.
In the current study we sought to deepen our understanding of epigenetic
mechanisms contributing to the normal process of osteoblast differentiation.  Based
on our previous observations, the differentiation of human mesenchymal stem cells
(MSC) to the osteoblastic lineage was dependent on the global levels of histone H2B
monoubiquitination at lysine 120 (H2Bub1) (Karpiuk et al., 2012).  Moreover, we
established the CDK9-WAC-RNF20/RNF40 axis to equally contribute to the
regulation of global H2Bub1 levels and hence the differentiation of MSCs into
osteoblasts (Figure 6). Cyclin-dependent kinsase 9 (CDK9) is a component of
Positive transcription elongation factor b (P-TEFb) which in addition contains one of
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three cyclin T molecules. P-TEFb activity is stringently regulated by the inhibitory
complex consisting of the  7SK  small  nuclear  ribonucleoprotein  complex, La
Related  Protein-7  (LARP7)  and  Hexamethylene  bisacetamide  Inducible  protein
(HEXIM). In this complex 7SK snRNA mediates the interaction of P-TEFb with
HEXIM which in turn blocks the kinase activity of CDK9. LARP7 was shown to
associate with 7SK snRNA and control its stability (He et al., 2008; Li et al., 2005).
Upon activation and disassociation from the inactive complex, P-TEFb stimulates
RNA Polymerase II (RNAPII) mediated transcriptional elongation. During
transcriptional activation, RNAPII is paused shortly after transcription initiation by
negative transcription elongation factors (NELF) in complex with 5,6-dichloro-1-β-d-
ribofuranosylbenzimidazole (DRB) - sensitivity inducing factor (DSIF). This event is
considered as promoter proximal pausing of RNAPII which is also required for
efficient generation of full length mRNA transcripts. During P-TEFb mediated
activation NELF-E and DSIF subunit suppressor of Ty 5 homolog (SUPTH5) are
subjected to phosphorylation which leads to release of NELF from the RNA
molecule. At the same time, P-TEFb also phosphorylates the Ser2 residues within
the RNAPII C-terminal heptapeptide repeats YSPTSPS leading to pause release of
RNAPII (Yamaguchi et al., 1999, 2013). Moreover, CDK9-mediated phosphorylation
of  the ubiquitin-conjugating enzyme E2A (UBE2A) leads to its activation and, hence,
contributes to downstream monoubiquitination of histone H2B as well (Pirngruber et
al., 2009; Shchebet et al., 2012).  The coupling of histone H2B monoubiquitination to
transcriptional elongation was further supported by the ability of WW domain
containing adaptor with coiled-coil (WAC) to directly associate the RNF20/RNF40
complex to Ser2 phosphorylated RNAPII (Zhang and Yu, 2011). Consistently, loss of







genes in MSCs most likely through global decrease in H2Bub1 levels (Karpiuk et al.,
2012).
The association of P-TEFb with the inhibitory complex also suggested a requirement
for activator proteins to mediate its release once required. As such, the BET protein
BRD4 was shown to associate with the active pool of P-TEFb and mediate its
recruitment to acetylated chromatin (Jang et al., 2005; Patel et al., 2013; Schröder et
al., 2012; Yang et al., 2005). Given its role in P-TEFb activation, we hypothesized
that BRD4 may similarly regulate the expression of osteogenic genes through
directly acting upstream of CDK9-WAC-RNF20/40 axis (Figure 6). We therefore
decided to elucidate its function during osteoblastogenesis. In line with this, we also
intended to analyze the epigenetic landscape associated with differentiation induced
changes in gene expression. Moreover, given its role as a epigenetic reader, we
further sought to decipher the transcription factors that could potentially utilize BRD4
to regulate the osteoblast-specific gene expression.
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Figure 6. The model of BRD4-CDK9-WAC-RNF20/40 axis in regulation of osteoblast-specific
gene expression. Shortly after transcription initiation, RNAPII is paused at the promoter. Given the
lineage-specific signal induction, BRD4 mediates the release of P-TEFB (CDK9) from inactive
complex. CDK9 phosphorylates then the paused RNAPII at Ser2 residues of C-terminal tail. The
Ser2P is recognized by adaptor protein WAC that links RNF20/40 to activated RNAPII on the
chromatin. The subsequent monoubiquitination of H2B by this E3 ligase complex further stimulates
transcriptional elongation by RNAPII, for example by facilitating the histone H2A-H2B exchange by
FACT, hence easing the passage of RNAPII through “bulky” nucleosomes.
Furthermore, based on the function of RNF20/RNF40 induced H2B
monoubiquitination in controlling the osteogenic differentiation we decided to
determine its function during normal bone development in mice as well. Proceeding
from our in vitro experience, we hypothesized that mice with conditional loss of
H2Bub1 would not develop functionally normal bones. Moreover, we assumed that
through modulation of H2Bub1 levels in mice, namely through the osteoblast-specific
deletion of the H2Bub1-specific DUB - ubiquitin-specific protein 22 (USP22), we
could achieve increased bone formation. This would imply an anabolic potential of
USP22 inhibitors and as such, offer a new strategy for epigenetic therapy of bone






-150 °C Freezer (MDF-C2156VAN) Panasonic, Kadoma, Japan
-20 °C Freezer Liebherr GmbH, Biberach
-80 °C Freezer “Hera freeze” Thermo Fisher Scientific, Waltham, USA
2100 Bioanalyzer Agilent Technology, Santa Clara, USA
Agarose gel chamber Harnischmacher Labortechnik, Kassel
Balance Sartorius AG, Göttingen
Bandelin Sonoplus Sonicator Bandelin electr. GmbH & Co. KG, Berlin
Biological Safety Cabinet “Safe 2020”   Thermo Fisher Scientific, Waltham, USA
Bioruptor ®  Plus sonication device    Diagenode SA, Liège, Belgium
Bioruptor ®  Pico sonication device    Diagenode SA, Liège, Belgium
Centrifuge (Megafuge 1.OR) Thermo Fisher Scientific, Waltham, USA
Centrifuge 4 °C (5417R) Eppendorf AG, Hamburg
Centrifuge 4 °C (Fesco 21) Thermo Fisher Scientific, Waltham, USA
Counting chamber (Neubauer) Brand GmbH & Co. KG, Wertheim
DynaMag TM  2 LifeTechnology, Carlsbad, USA
DynaMag TM  96 Side LifeTechnology, Carlsbad, USA
Eclipse TS100 Nikon, Tokio, Japan
Electrophoresis & Electrotransfer Unit    GE Healthcare Europe GmbH, München
Gel iX Imager Intas Science Imaging GmbH, Göttingen
HERAcell 150i CO 2  Incubator Thermo Fisher Scientific, Waltham, USA
Imager Western Blot Bio-Rad Laboratories, Hercules, USA
Inverse Microscope “Axiovert 40 CFL”   Carl Zeiss MicroImaging GmbH, Göttingen
Isotemp ®  water bath Thermo Fisher Scientific, Waltham, USA
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Magnet stirrer “MR3001” Heidolph GmbH & Co. KG, Schwabach
Microcentrifuge C1413-VWR230 VWR, Radnor, USA
Microscope Axio Scope.A1 Carl Zeiss MicroImaging GmbH, Göttingen
equipped with an AxioCam MRc
Microscope Axiovert 100 Carl Zeiss MicroImaging GmbH, Göttingen
Microwave Clatronic International GmbH, Kempen
Mini Trans-Blot TM  Cell Bio-Rad Laboratories, Hercules, USA
Mini-PROTEAN Tetra Cell Bio-Rad Laboratories, Hercules, USA
Mr. Frosty ®  Cryo Freezing Container    Thermo Fisher Scientific, Waltham, USA
Nano Drop ®  ND-1000 Peqlab Biotechnology GmbH, Erlangen
Optical Reaction Module CFX96 TM     Bio-Rad Laboratories, Hercules, USA
pH meter inoLab ® WTW GmbH, Weilheim
Pipette Aid ®  portable XP Drummond Scientific Co., Broomall, USA
Pipettes “Research” Series Eppendorf AG, Hamburg
PowerLyzerTM 24 MO BIO Lab., QIAGEN, USA
(Bead-Based Homogenizer)
Power supply Power Pack P25T Biometra GmbH, Göttingen
PowerPac TM  Basic Power Supply    Bio-Rad Laboratories, Hercules, USA
PowerPac TM  HC Power Supply Bio-Rad Laboratories, Hercules, USA
Qubit ®  2.0 Fluorometer Invitrogen GmbH, Karlsruhe
Refrigerator Liebherr GmbH, Biberach
Scanner Epson V700 Photo Seiko Epson, Suwa, Japan
Shaker “Rocky” Schütt Labortechnik GmbH, Göttingen
Test tube rotator Schütt Labortechnik GmbH, Göttingen
Thermal Cycler T100 TM Bio-Rad Laboratories, Hercules, USA
Thermo mixer C Eppendorf AG, Wessling-Berzdorf




96-well Multiplate ®  PCR plate, white Bio-Rad Laboratories, Hercules, USA
Bioruptor Microtubes (0.1, 0.65, 1.5 ml) Diagenode SA, Liège, Belgium
CA-Membrane 0.2 and 0.45µm filters  TH. Geyer, Wesertal
Cell scraper (16 cm, 25 cm) Sarstedt AG & Co., Nümbrecht
Cellstar 6- ,12-well cell culture plates  Greiner Bio-One GmbH, Frickenhausen
Cellstar PP-tube 15 and 50 ml Greiner Bio-One GmbH, Frickenhausen
Cellstar tissue culture dish 100×20 mm  Greiner Bio-One GmbH, Frickenhausen
Cellstar tissue culture dish 145×20 mm  Greiner Bio-One GmbH, Frickenhausen
Cryo Tube Vial (1.8 ml) Thermo Fisher Scientific, Waltham, USA
Disposable Safety Scalpel FEATHER Safety Razor Co., Osaka Japan
DNA loBinding Tube 1.5 and 0.5 ml   Eppendorf AG, Wessling-Berzdorf
Fine-ject 27Gx3/4 (Nr 20) Needles Henke-Sass Wolf, Tuttlingen
Gel blotting paper (Whatman paper)    Sartorius AG, Göttingen
HybondTM-PVDF Transfer Membrane   GE Healthcare Europe GmbH, München
Injekt-F 1ml single-up syringe B.Braun Melsungen, Melsungen
Lysing Matrix Tubes with beads MP Biomedicals, Eschwege
Microtube 1.5 ml and 2 ml Sarstedt AG & Co., Nümbrecht
Parafilm ®  “M” Pechiney Plastic Packaging, Chicago, USA
PCR-Strips Biozyme, St. Joseph, USA
Pipette filter tips Sarstedt AG & Co., Nümbrecht
Pipette tips Greiner Bio-One GmbH, Frickenhausen
Soft-Ject® Syringes 10 and 20ml Henke-Sass Wolf, Tuttlingen
Chemicals and Reagents
α,α-Trehalose (+) AppliChem GmbH, Darmstadt
Agarose Carl Roth GmbH & Co. KG, Karlsruhe
Agencourt ®  AMPure ®  XP Beads      Beckman Coulter Inc. Brea USA
Albumin Fraction V SERVA, Heidelberg
(Protease and Fatty Acid free)
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Alizarin Red S Sigma-Aldrich Co., St. Louis, USA
Ammonium persulfate Carl Roth GmbH & Co. KG, Karlsruhe
Ammonium sulfate Carl Roth GmbH & Co. KG, Karlsruhe
Antibiotic-Antimycotic LifeTechnology, Carlsbad, USA
Aprotinin Carl Roth GmbH & Co. KG, Karlsruhe
Ascorbic acid Sigma-Aldrich Co., St. Louis, USA
BET inhibitor (+)JQ1 provided by Stefan Knapp from
(C23H25ClN4O2S) Goethe-University Frankfurt am Main
Bromophenol blue Sigma-Aldrich Co., St. Louis, USA
Calcein Sigma-Aldrich Co., St. Louis, USA
Calcitriol (1α,25-dihydroxy Vit D3)      Biomol GmbH, Hamburg
Calcium Chloride Carl Roth GmbH & Co. KG, Karlsruhe
Chloroform Carl Roth GmbH & Co. KG, Karlsruhe
Dexamethasone Sigma-Aldrich Co, St. Louis, USA
Diethylpyrocarbonate  dihydrate Carl Roth GmbH & Co. KG, Karlsruhe
Dimethyl sulfoxide            AppliChem GmbH, Darmstadt
di-Sodium hydrogen phosphate Carl Roth GmbH & Co. KG, Karlsruhe
Dithiothreitol            Carl Roth GmbH & Co. KG, Karlsruhe
DMEM LifeTechnology, Carlsbad, USA
DMEM/F12 LifeTechnology, Carlsbad, USA
dNTP Bundle Jena Bioscience, Jena
Ethanol absolute Th. Geyer GmbH & Co. KG, Renningen
Ethidium bromide Carl Roth GmbH & Co. KG, Karlsruhe
Ethylenediaminetetraacetic acid Carl Roth GmbH & Co. KG, Karlsruhe
Fetal Bovine Serum Thermo Scientific HyClone, Logan,USA
Formaldehyde Sigma-Aldrich Co., St. Louis, USA
Formamide Carl Roth GmbH & Co. KG, Karlsruhe
Glycerol Carl Roth GmbH & Co. KG, Karlsruhe
Glycine Carl Roth GmbH & Co. KG, Karlsruhe
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HD Green Plus DNA Stain INTAS, Science Imaging, Göttingen
Hydrochloric acid            Carl Roth GmbH & Co. KG, Karlsruhe
Immobilon TM  Western HRP substrate  Merck Millipore KGaA, Darmstadt
Iodoacetamide Sigma-Aldrich Co, St. Louis, USA
Isopropanol Carl Roth GmbH & Co. KG, Karlsruhe
L-Ascorbic acid Sigma-Aldrich Co, St. Louis, USA
Lithium Chloride Sigma-Aldrich Co, St. Louis, USA
Leupeptin Carl Roth GmbH & Co. KG, Karlsruhe
Linear Acrylamide Ambion, USA
Magnesium chloride Carl Roth GmbH & Co. KG, Karlsruhe
MEM α powder LifeTechnologies AG, Carlsbad, US
Methanol Carl Roth GmbH & Co. KG, Karlsruhe
Monopotassium phosphate Carl Roth GmbH & Co. KG, Karlsruhe
MOPS Carl Roth GmbH & Co. KG, Karlsruhe
3-(N-Morpholino)-propansulfonic acid
sodium salt
N,N-Dimethylformamide Sigma-Aldrich Co., St. Louis, USA
N-ethylmaleimide Sigma-Aldrich Co., St. Louis, USA
Nonidept TM  P40 Sigma-Aldrich Co., St. Louis, USA
Opti-MEM LifeTechnology, Carlsbad, USA
Paraformaldehyde Carl Roth GmbH & Co. KG, Karlsruhe
PBS tablets LifeTechnology, Carlsbad, USA
Pefabloc SC Carl Roth GmbH & Co. KG, Karlsruhe
Penicillin-Streptomycin solution Sigma-Aldrich Co., St. Louis, USA
Polybrene Sigma-Aldrich, St. Louis, USA
Potassium acetate Carl Roth GmbH & Co. KG, Karlsruhe
Potassium chloride AppliChem GmbH, Darmstadt
Potassium dihydrogen phosphate Carl Roth GmbH & Co. KG, Karlsruhe
Propidium iodide solution Sigma-Aldrich Co., St. Louis, USA
Protein A Sepharose TM CL-4B GE Healthcare, Uppsala, Sweden
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QIAzol® Lysis Reagent Qiagen, Maryland, USA
RNAiMAX LifeTechnology, Carlsbad, USA
Roti ® -Phenol Carl Roth GmbH & Co. KG, Karlsruhe
Rotiphorese ®  Gel 30 Carl Roth GmbH & Co. KG, Karlsruhe
Rotipuran ®  Chloroform Carl Roth GmbH & Co. KG, Karlsruhe
Rotipuran ®  Isoamylalcohol Carl Roth GmbH & Co. KG, Karlsruhe
Sepharose TM  CL-4B GE Healthcare, Uppsala, Sweden
Skim milk powder Carl Roth GmbH & Co. KG, Karlsruhe
Sodium acetate Carl Roth GmbH & Co. KG, Karlsruhe
Sodium azide Sigma-Aldrich Co., St. Louis, USA
Sodium chloride Carl Roth GmbH & Co. KG, Karlsruhe
Sodium deoxycholate AppliChem GmbH, Darmstadt
Sodium dodecylsulfate  (SDS) Carl Roth GmbH & Co. KG, Karlsruhe
Sodium hydrogen carbonate Carl Roth GmbH & Co. KG, Karlsruhe
Sodium hydroxide Carl Roth GmbH & Co. KG, Karlsruhe
ß-Glycerolphosphate Sigma-Aldrich Co., St. Louis, USA
SYBR Green Roche Diagnostics GmbH, Mannheim
TEMED Carl Roth GmbH & Co. KG, Karlsruhe
Tris Carl Roth GmbH & Co. KG, Karlsruhe
Triton X-100 AppliChem GmbH, Darmstadt
Trypsin-EDTA LifeTechnology, Carlsbad, USA
Tween-20 AppliChem GmbH, Darmstadt
Kits and reagents
Alkaline phosphatase leukocyte kit Sigma-Aldrich Co., St. Louis, USA
Agilent High Sensitivity DNA Kit Agilent Technology, Santa Clara, USA
HOT FIREPol® DNA Polymerase Set  Solis BioDyne, Estonia
Lipofectamine TM  RNAiMAX LifeTechnology, Carlsbad, USA




MicroPlex Library Preparation TM Diagenode SA, Liège, Belgium
Qubit dsDNA HS Assay LifeTechnology, Carlsbad, USA
Immobilon Western Chemiluminiscent Millipore, Billerica, USA
HRP substrate
SuperSignal ®  West Femto Maximum  Thermo Fisher Scientific, Waltham, USA
Enzymes
Colleganase A Roche Diagnostics, Mannheim
Dispase Gibco, Life Technologies, USA
Proteinase K LifeTechnology, Carlsbad, USA
Reverse Transcriptase (M-MuLV)       New England Biolabs, FFM
RNase A Qiagen GmbH, Hilden
RNase inhibitor New England Biolabs, FFM
Taq DNA Polymerase Primetech, Minsk, Belarus
Molecular weight standards
Gene RulerTM  DNA-Ladder Fermentas GmbH, St. Leon-Rot





T. Spelsberg, Mayo Clinic, USA
 (Harris et al., 1995)
IDG-SW3 Mouse
Malayannan Subramaniam and John R.
Hawse, Mayo Clinic, USA  (Woo et al.,
2011)
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Primers were designed using the NCBI primer designing tool
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and ordered from Sigma-Aldrich
Co., St. Louis, USA .
∑ ChIP Primers
TARGET SEQUENCE (5’‡3’) REFERENCE
chr10:4705151-
4705651 F TGAGTAAACACTTAACAGGGCGT This Study
chr10:4705151-
4705651 R CATCCACGTGTTCTGCATGATT This Study
chr12:46886451-
46886951 F GCAGAAGAGTTCAGCCTCACC This Study
chr12:46886451-
46886951 R CATTCAAATACAGTGAACCCAGACC This Study
chr3: 16101551-
16102051 F ACTCATCTTCAGGAATGGGCA This Study
chr3: 16101551-
16102051 R TGTTTGTGTCAACCACCAAAGG This Study
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COL1A1 TSS F CACGTCTCGTTTTAAGCCGC This Study
COL1A1 TSS R GCCAAGAGGAAGGCCAAGTC This Study
HNRNPK +BRD4 site F TCCACGAGGTCCCTAGTTCC (Nagarajan etal., 2015)
HNRNPK +BRD4 site R GCCATTTCCCTGAGCGTGTA (Nagarajan etal., 2015)
OLIG2 +H3K27me3
Site GTCACCAACGCTCCCTGAAAT This Study
OLIG2 +H3K27me3
Site TTGCATGAGAGCAGAGGGGA This Study








CDKN1A TSS GGGGCGGTTGTATATCAGG (Pirngruber etal., 2009)
CDKN1A TSS GGCTCCACAAGGAACTGACTTC (Gomes et al.,2006)
RPLP0_TSS R CTTCGCGACCCTACTTAAAGG (Nagarajan etal., 2015)
RPLP0_TSS F CAATCAGAAACCGCGGATAG (Nagarajan etal., 2015)
SOST +H3K27me3 Site
F GAGTGCCTGGAACCTGTTTCT This Study
SOST +H3K27me3 Site
R CACCGGACACTCTATGCTGG This Study
TFF1+6KB F CAGGCTTCTCCCTTGATGAAT (Pirngruber andJohnsen, 2010)
TFF1+6KB R ACACCCACCTTCCACAACAC (Pirngruber andJohnsen, 2010)
∑ Gene Expression Primers
TARGET SEQUENCE (5’‡3’) REFERENCE
ALPL F TGGGCCAAGGACGCTGGGAA (Karpiuk et al.,
2012)
ALPL R AAGGCCTCAGGGGGCATCTCG (Karpiuk et al.,
2012)
BGLAP F ATGAGAGCCCTCACACTCCT This Study
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BGLAP R GCTTGGACACAAAGGCTGCAC This Study
BMP1 F GTTCTGAGAAGCCCGAGGTC This Study
BMP1 R AGAGCTGGCCTCTTTTCTGAG This Study
BRD4 F GCCGTCCACACTGCGTGAGC (Nagarajan et
al., 2014)
BRD4 R TCCCGGGGTGCCCCTTCTTT (Nagarajan et
al., 2014)
CDH11 F CCCTCAAGGGCCCCAGAAAT This Study
CDH11 R CGTCCCCAGTTAGCTTCTTCT This Study
DCN F GGGATAGGCCCAGAAGTTCC This Study
DCN R GATGGCATTGACAGCGGAAG This Study
ELN F TCCCGGGAGTTGGCATTTC S.Baumgart,
WG Johnsen
ELN R ACTGGGCGGCTTTGGC S.Baumgart,
WG Johnsen
RPLP0 GATTGGCTACCCAACTGTTG (Fritah et al.,
2005)
RPLP0 CAGGGGCAGCAGCCACAAA (Fritah et al.,
2005)
RUNX2 TCGGAGAGGTACCAGATGGG This Study
RUNX2 CATTCCGGAGCTCAGCAGAA This Study
TGFBR2 F CATGAGCAACTGCAGCATCAC This Study
TGFBR2 R CTTTCTCCATACAGCCACACAGA This Study
THBS2 F CCAGGGAGCTGAGATCAACG This Study
THBS2 R CCACCAATGAGCTCCCAGAG This Study
TNFRSF11B F GCGCTCGTGTTTCTGGACATC This Study
TNFRSF11B R CACACGGTCTTCCACTTTGC This Study
mAlpl F  GGGCAATGAGGTCACATCCA S.Baumgart,
WG Johnsen
mAlpl R  GTGGTTACCCGAGTGGTAG S.Baumgart,
WG Johnsen
mBglap F CCTGAGTCTGACAAAGCCTTCA This Study
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mBglap R GCCGGAGTCTGTTCACTACCTT This Study
mDmp1 F TGCTCTCCCAGTTGCCAGAT (Gingery et al.,
2014)
mDmp1 R AATCACCCGTCCTCTCTTCAGA (Gingery et al.,
2014)
mGapdh F CACTTGAAGGGTGGAGCCAA W. Xie, WG
Johnsen
mGapdh R GGTCATGAGCCCTTCCACAA W. Xie, WG
Johnsen
mMepe F TGCTGCCCTCCTCAGAAATATC (Gingery et al.,
2014)
mMepe R GTTCGGCCCCAGTCACTAGA (Gingery et al.,
2014)
mRnf40 (exon3) F GCCACACTCCTCATCGTCAA W. Xie, WG
Johnsen
mRnf40(exon4) R  CTGGGAGAGGAGTCCCATCA W. Xie, WG
Johnsen
mRunx2 F  ATCCCATCCATCCACTCCA S.Baumgart,
WG Johnsen
mRunx2 R  GCCAGAGGCAGAAGTCAGAG S.Baumgart,
WG Johnsen
mSp7 F  GCAAAGGCCTGAGAGGAGTT S.Baumgart,
WG Johnsen
mSp7 R  GGGCTCTCTCTGTTCCCCTA S.Baumgart,
WG Johnsen
∑ Genotyping Primers
Target Sequence (5’‡3’) Reference Product
Size
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The primary antibody dilutions were prepared in 5% skim milk in TBS-T and
supplemented with 0.01% sodium azide.
Target Protein ChIP WB Clone Source Cat. Nr
BRD4 1:1000 Abcam ab128874
BRD4 (N-term) 3µl Wu et al., 2006
CEBP/β 1.5µg C-19 Santa Cruz sc-150
FOSL2 1.5µg Q-20 Santa Cruz sc-604
H2B 1:10000 Abcam ab1790
H2Bub1 1µl D11 Cell Signalling 5546
H2Bub1 1:10 7B4 Prenzel et al., 2011
H3K27ac 1µg 1:1000 Diagenode C15410196
H3K27me3 1µg Diagenode C15410195
HSC70 1:20000 B-6 Santa Cruz sc 7298
IgG 1µg Abcam ab37415
JUND 1.5µg 329 Santa Cruz sc-74
RNA
Polymerase II
1.2µg 1:1000 N-20 Santa Cruz sc-899
RNF40 1:500 S-12 Santa Cruz sc-132079
STAT3 1.5µg C-20 Santa Cruz sc-482
TEAD1 1.5µg 31/TEF-1 BD Biosciences 610922
Secondary Antibodies
Name WB Source Cat. Nr.
goat anti-mouse (IgG)-
HRP
1:10000 Santa Cruz sc-2004
goat anti-rabbit (IgG)-
HRP
1:10000 Santa Cruz sc-2005
donkey anti-goat (IgG)-
HRP




Alizarin Red staining solution:  2% Alizarin Red in DI H2O, pH 4.1-4.3 adjusted
with HCl
Blocking solution: 1× PBS-T, 5% (w/v) milk
Calcein Solution: 0.4% (w/v) calcein, 0.4% sodium hydrogen carbonate prepared in
PBS, filtered before injections.
DEPC water: 0.1% (v/v) DEPC in DI H2O
Formaldehyde (FA) gel buffer (10x): 200mM 3-[N-morpholino]propanesulfonic
acid(MOPS) (free acid), 50mM sodium acetate, 10mM EDTA, pH 7 prepared in
RNAse free water.
FA gel running buffer: 10% (v/v) 10xFA gel buffer, 0.74% Formaldehyde, prepared
in RNAse free water.
Gomes Lysis Buffer: 150 mM NaCl, 1% (v/v) NP-40, 0.5% (w/v) sodium
deoxycholate, 50 mM Tris-HCl (pH 8), 20 mM EDTA, 20 mM NaF, ± 0.1-0.5% (w/v)
SDS
Gomes Wash Buffer: 100 mM Tris-HCl (pH 8.5), 500 mM LiCl, 1% (v/v) NP-40, 1%
(w/v) sodium deoxycholate, 20 mM EDTA, 20 mM NaF
Inhibitor cocktail (1×): 1 mM Pefabloc, 1 ng/μl Aprotinin/Leupeptin, 10 mM BGP, 1
mM N-ethylmaleimide, 10 µM iodoacetamide
Lämmli buffer (6×): 0.35 M Tris (pH 6.8), 30% (v/v) glycerol, 10% (w/v) SDS, 9.3%
(w/v) DTT, 0.02% (w/v) bromphenol blue
Nelson Lysis Buffer: 150 mM NaCl, 20 mM EDTA (pH 8), 50 mM Tris (pH 7.5),
0.5% (v/v) NP-40, 1% (v/v) Triton X-100, 20 mM NaF.
PBS (1×): 137 mM NaCl, 2.68 mM KCl, 4.29 mM Na2HPO4×2H2O, 1.47 mM
KH2PO4, pH 7.4
PBS-T: PBS with 0.1% (v/v) Tween-20
PBS for cell culture: 1 PBS tablet per 500 ml ddH2O
PFA (4%): 4% paraformaldehyde powder prepared in PBS
qRT-PCR mix: 75 mM Tris-HCl (pH 8.8), 20 mM (NH4)2SO4, 0.01% Tween-20, 3
mM MgCl2, 200 μM dNTPs, 0.5 U/reaction Taq DNA Polymerase, 0.25% Triton X-
100, 1:80,000 SYBR Green I, 300 mM Trehalose
RIPA buffer: 1× PBS, 1% (v/v) NP-40, 0.5% (w/v) sodium deoxychelate, 0.1% (w/v)
SDS
RNA loading dye (5x):0.16% brophenol blue solution, 4mM EDTA, 2.7%
formaldehyde, 20% (v/v) glycerol, 30.84% (v/v) formamide,40% (v/v) FA gel buffer
(10x), prepared in RNAse free water.
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SDS separating gel (X%): X%(v/v) acrylamide, 375mM Tris-HCl (pH 8.8), 0.1%
(w/v) SDS, 0.1% (w/v) APS, 0.04% (v/v) TEMED
SDS stacking gel: 5% (v/v) acrylamide, 125.5 mM Tris-HCl (pH 6.8), 0.1% (w/v)
SDS, 0.1% (w/v) APS, 0.1% (v/v) TEMED
TAE buffer (50×): 2 M Tris, 1 M Acetic acid, 0.1 M EDTA
TBS: 150 mM NaCl, 2.68 mM KCl, 4.29 mM Na2HPO4×2H2O, 1.47 mM KH2PO4,
(pH 7.4)
TBS-T: TBS with 0.1% (v/v) Tween-20
TE buffer: 10 mM Tris-HCl, 1 mM EDTA, pH to 8.0
Transfer buffer: 10% (v/v) 10× Western salts, 1% (v/v) Methanol
Tris-glycine electrophoresis buffer: 25 mM Tris, 200 mM Glycine, 0.1% (w/v) SDS
Weinmann buffer: 50mM Tris-HCl (pH 8), 10mM EDTA and 1 % SDS
Western salts (10x): 1.92 M Glycine, 250 mM Tris-HCl (pH 8.3), 0.02% (w/v) SDS
Media:
αMEM culture medium: phenol red, L-glutamine, supplemented with 10% FBS, 1%
Penicillin-Streptomycin solution (100 U/ml penicillin, 100 μg/ml streptomycin).
DMEM-F12 cell culture medium: phenol red-free, high-glucose, supplemented with
10% FBS, 1% Penicillin-Streptomycin solution (100 U/ml penicillin, 100 μg/ml
streptomycin)






These mice harbor Cre-recombinase under the control
of Bglap promoter





In these mice the fused Cre-recombinase with mutated
form of estrogen receptor (ERT2) was inserted into
ubiquitously expressed Gt(ROSA)26Sor Locus. The
fused Cre gets translocated to the nucleous upon 4-
hydroxytamoxifen treatment.




The exon 3 and 4 of Rnf40 gene are floxed with LoxP
sequences in these mice.
(Source: This Study, WG Johnsen)
Runx2-cre: These mice express Cre-recombinase under the
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Tg(Runx2-icre)1Jtuc control of second Runx2 promoter




In this mouse line, the Usp22 gene exon2 is flanked
from both sites with LoxP sequences.
http://www.mousephenotype.org/martsearch_ikmc_proj
ect/martsearch/ikmc_project/35107
High-throughput sequencing data used in the study
Dataset Type Database Accession
Number
Source
hFOB DIF_BRD4 ChIP-Seq GEO GSE82297 This Study
hFOB DIF_H2Bub1 ChIP-Seq GEO GSE82297 This Study
hFOB DIF_H3K27ac ChIP-Seq GEO GSE82297 This Study
hFOB
DIF_H3K27me3
ChIP-Seq GEO GSE82297 This Study
hFOB DIF_INPUT ChIP-Seq GEO GSE82297 This Study
hFOB DIF_RNAPII ChIP-Seq GEO GSE82297 This Study
hFOB
DIF+JQ1_H2Bub1
ChIP-Seq GEO GSE82297 This Study
hFOB
DIF+JQ1_H3K27ac
ChIP-Seq GEO GSE82297 This Study
hFOB
DIF+JQ1_H3K27me3
ChIP-Seq GEO GSE82297 This Study
hFOB
DIF+JQ1_INPUT
ChIP-Seq GEO GSE82297 This Study
hFOB UND_BRD4 ChIP-Seq GEO GSE82297 This Study
hFOB UND_H2Bub1 ChIP-Seq GEO GSE82297 This Study
hFOB
UND_H3K27ac
ChIP-Seq GEO GSE82297 This Study
hFOB
UND_H3K27me3
ChIP-Seq GEO GSE82297 This Study
hFOB UND_INPUT ChIP-Seq GEO GSE82297 This Study
hFOB UND_RNAPII ChIP-Seq GEO GSE82297 This Study
L3.6 BRD4 ChIP-Seq GEO GSE82297 V. K. Mishra, WG
Johnsen
L3.6 INPUT ChIP-Seq GEO GSE82297 V.K. Mishra, WG
Johnsen
MCF10A BRD4 ChIP-Seq GEO GSE72931 Sankari Nagarajan
et al., 2016
MCF10A INPUT ChIP-Seq GEO GSE65886 Sankari Nagarajan
et al., 2015
MCF7+E2 BRD4 ChIP-Seq GEO GSE55923 Sankari Nagarajan
et al., 2014
MCF7+E2 INPUT ChIP-Seq GEO GSE55923 Sankari Nagarajan
et al., 2014




NHOST H3K27me3 ChIP-Seq GEO GSE29611 ENCODE (Bradley
Bernstein Lab)
NHOST H3K4me1 ChIP-Seq GEO GSE29611 ENCODE (Bradley
Bernstein Lab)
NHOST H3K4me3 ChIP-Seq GEO GSE29611 ENCODE (Bradley
Bernstein Lab)












GEO GSE82297 This Study
hFOB DIF_JQ1 mRNA-
Seq










GEO GSE82297 This Study
hFOB DIF_siCNTR mRNA-
Seq
GEO GSE82297 This Study
hFOB UND_DMSO mRNA-
Seq
GEO GSE82297 This Study
hFOB UND_siCNTR mRNA-
Seq















Name Version Developer, Source












(Liu et al., 2011)
(Shin et al., 2009)
(Zhang et al., 2008)
(Liu et al., 2011)

















EpiCSeg (Mammana and Chung, 2015)
GREAT 3.0.0 (McLean et al., 2010)
GSEA (Mootha et al., 2003;
Subramanian et al., 2005)
HTSeq 0.6.0 (Anders et al., 2015)




2 (Robinson et al., 2011;







(Ye et al., 2012a)
ReMap (Griffon et al., 2015)
REVIGO (Supek et al., 2011)
RSAT (Medina-Rivera et al., 2015;
Thomas-Chollier et al., 2011,
2012)
Samtools 0.1.19 (Li, 2011; Li et al., 2009)
Statistical software R








R Development Core Team
(2008). http://www.R-
project.org
(Love et al., 2014)
(Ross-Innes et al., 2012; Stark
R and Brown G, 2011)
(Wickham, 2009)
(Warnes et al., 2015)
(Young et al., 2010)
(Chen and Boutros, 2011)











(Blankenberg et al., 2010;






(Li et al., 2009)





Immortalized cell lines and treatments
Human fetal osteoblast (hFOB 1.19) cells were maintained in 5% CO2/atmosphere
incubator in phenol red-free high-glucose Dulbecco’s modified Eagle’s media
(DMEM/F12) supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin (P/S). Cells were pretreated with JQ1 (250nM) 1 hour before
the induction of differentiation and then the inhibitor or equal volume of DMSO was
added with every media change (every second day). For induction of differentiation,
after reaching the confluency cells were treated with differentiation cocktail: 10 mM
β-glycerophosphate, 0.2 mM ascorbate, 10 nM calcitriol and 100 nM dexamethasone
and shifted to 39⁰C incubator.  Cells were differentiated for 5 days. For
undifferentiated time point, cells were harvested prior differentiation induction and
temperature change.
The experiments with IDG-SW3 osteocytes cells were performed by John R. Hawse
and Malayannan Subramaniam from Department of Biochemistry and Molecular
Biology in Mayo Clinic, USA. In brief, cells were maintained at 34⁰C in collagen
coated plates. For the experiment, cells were plated onto 12 well plates at 50%
density and allowed to grow for additional 3-4 days to reach confluency. At this point
the differentiation was induced and cells were transferred to 37’C incubator as
described in (Woo et al., 2011). The JQ1 (250nM) treatment was also started. For
Day 0 harvest, the cells were kept in differentiation media and treated with DMSO for
24 hours at 37’C. For long term treatment, differentiation media was replaced every
third day with fresh treatments of DMSO and JQ1 (250nM). The cells were harvested
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following 14 and 26 days of treatment for RNA or subjected to stainings. The
harvested RNA was sent to us.
∑ siRNA Transfections
For transient knockdown of genes cells were transfected with small interfering RNA
(siRNA) using the Lipofectamine® RNAiMAX reagent according to the
manufacturers’ protocol. Namely, 15-20 pmol of siRNA were mixed with 5 μl
RNAiMAX reagent in 500 μl of optiMEM (counted for a well of 6-well plates) and
incubated for 20 min at room temperature. Meanwhile, the cells were trypsinized,
counted and in amount of 220000-250000 cells in 1.5 ml of complete media without
antibiotics were seeded into plates. Following the incubation, the transfection mix
was added to the cells. The media was replaced to normal media after 6-12 hours
post-transfection. If required, the differentiation was induced 24 hours following the
transfection. The transfections were repeated after 72 hours following the forward
transfection protocol recommended by the manufacturer.
∑ Alkaline phosphatase staining
The alkaline phosphatase staining was performed using the Alkaline phosphatase
leukocyte kit (Sigma) following manufacturer’s instructions. Namely, after PBS wash
cells were fixed for 30 s with Citrate fixing solution containing (for 98 ml): 65 ml
acetone, 25 ml Citrate solution (Sigma-Aldrich Co., St. Louis, USA), 8 ml 37%
formaldehyde. Following fixation, cells were washed with DI H2O for 40 s and
incubated for 15 min with fresh diazonium salt solution.  For preparation of
diazonium salt solution 1 ml of FRV-Alkaline solution was mixed with 1 ml of sodium
nitrate solution and incubated for 2 min, which was then added to 45 ml of DI H2O
along with 1 ml of Naphtol AS-BI Alkaline solution. After 15 min, the staining solution
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was removed and the wells are washed 2-3 x with DI H2O and dried. Pictures of the
stained cells were taken under Microscope Axio Scope.A1equipped with an
AxioCam MRc using 2.5x magnification or the whole plates were scanned.
∑ Alizarin Red staining
After the PBS wash, the cells were fixed for 15 min with 4.2 % Formaldehyde in
PBS.  Following fixation, the cells were washed twice with DI water and stained with
Alizarin Red staining solution for 15 min.  Subsequently, the dye solution was
removed and the wells were washed trice with DI H2O. For visualization, the plates
were scanned.
Primary Cells
∑ Isolation of long bone cells
The mouse long bone primary osteoblasts were isolated from Rnf40Rosa-CreERT2
mutant mice (with “floxed” Rnf40 gene on both alleles) at age of 6 weeks. Following
the sacrification, the femora and tibia from the mouse, partially freed from skin and
underlying muscles were placed into PBS with 5% P/S. The lower extremities in PBS
were then transferred to the cell culture hood. The muscles and periosteum were
removed and carefully scraped off. The bones then were transferred into dishes with
fresh PBS with 5% P/S. The bone epiphyses were cut off and the bone-marrow was
flushed off with PBS by using 27G needles on the 1ml syringe. The clean bones
were cut into smaller pieces and distributed into 3 eppendorf tubes (per mouse) with
collagenase solution (α-MEM + 2mg/ml Collagenase A).  The tubes with the bone
pieces were incubated for 2 hours on shaking (1000rpm) thermal mixer set to 37⁰C.
In-between, the tubes were once vigorously shaked by hand. Following the 2 hours
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incubation, the digestion solution was removed and the bone pieces were washed 3
times with complete α-MEM (+10% FBS, 1% P/S) medium. The bone pieces were
then transferred into culture dishes with complete medium where they were minced
by scalpel into finer pieces. The media with bone pieces was then transferred into
6cm cell culture dishes which were placed into 37⁰C incubator. Within the first three
days the plates were not moved allowing the cells to grow out the bone pieces.
∑ Isolation of primary calvarial osteoblasts
The 1-3 days old pups of Rnf40Rosa-CreERT2 mice were placed into cell culture hood
where the heads of these animals were cut off with sharp scissors. The heads were
shortly dipped into 70% ethanol and immediately transferred into dishes with PBS (+
1%  P/S).  At  the  same  time  the  tail  tips  were  cut  for  subsequent  genotyping.  By
holding the head with forceps, the skin was carefully peeled off (without damaging
the calvaria). The exposed calvaria was cut (in shape of beetle head) and
subsequently cleared off from soft tissues including the parts of side and hind
calvaria. The calvaria was then placed into tubes with α-MEM digestion solution
containing 2mg/ml Dispase and 1mg/ml Collagenase A. The calvaria were digested
for 10 min on the thermal shaker (1000 rpm) set to 37⁰C and after first incubation the
digestion solution was discarded. The calvaria were subjected to 4 rounds of
digestion in the same conditions (1000 rpm, 37⁰C, 10 min) every time with fresh α-
MEM digestion solution. After each round, the digestion solution was accumulated in
15ml falcons additionally containing 2 ml of the complete α-MEM media (10% FBS,
1% P/S)  and stored on ice until the completion of 4th round. After the last round, the
accumulated digestion solution was centrifuged for 3-5 min at 300g to obtain the cell
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pellet.  The pellet was resuspended in complete α-MEM media and the cells were
transferred to cell culture dishes. The cells were maintained in 37⁰C incubators.
∑ The differentiation and treatments of primary mouse bone cells
The primary mouse osteoblasts isolated from Rnf40Rosa-CreERT2 mice were maintained
in α-MEM supplemented with 10% (FBS) and 1% (P/S). For induction of Cre-
recombinase mediated deletion of Rnf40 gene the cells were treated for 7 days with
250nM of 4-hydroxy-tamoxifen (4OHT) or equal volume of 100% ethanol. Then the
cells were washed twice to remove the 4OHT and further maintained 2 additional
days in the plain media with no 4OHT. At this timepoint cells of the undifferentiated
(defined as day 0 in the study) state were harvested. For the differentiation, the rest
of the cells were treated with 5 mM β-glycerophosphate, 0.2 mM ascorbate and 10
nM dexamethasone (the last only the first 3 media changes). The media was
replaced every second day.
The osteoblast-osteoclast co-culture experiment
This experiment with prior osteoclast isolation and subsequent TRAP staining was
performed by Peng Liu from Jan Tuckerman’s group at Insitute of Comparative
Molecular Endocrinology (CME), University of Ulm as briefly described below.
∑ Osteoclast Isolation
The osteoclasts were isolated form 6-8 week old mice. The bones of the mice were
dissected and cleared off the muscle tissues. The epiphyses were cut and the bone
marrow was flushed off into 15 ml tubes with complete α-MEM (Gibco) medium with
10 % fetal calf serum (FCS from Gibco). After collecting the bone marrow flushes,
the tubes were centrifuged at 1000 rpm for 5 min. The cellular pellet was
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resuspended in 9 ml of cold water by pipetting up and down for 5 tiimes and one time
in 10x PBS to lyse the red blood cells. The remaining cells were pelleted by another
round of centrifugation and subsequently resuspended in 10 ml of α-MEM complete
medium with 30ng/ml macrophage colony-stimulating factor (M-CSF from R&D
Systems). The 5 ml of the resuspended cells was transferred into 100mmx20mm
Corning non-treated suspension culture dishes where the stromal cells and
lymphocytes can’t adhere. Following 2-3 days, the macrophages (the osteoclast
progenitors) were ready to use for co-culture experiment.
∑ The co-culture experiment
At day 0, 4000 calvarial osteoblast cells from mutant Rnf40Rosa-CreERT2 mice were
seeded into 96-well plates in α-MEM complete medium containing 10nM vitamin D
(Sigma). The next day, 200000 osteoclast progenitor cells from wild-type animals
were seeded into osteoblast containing wells. On day 4 and 7 the media was
refreshed with addition of vitamin D. On day 10, cells were fixed and subjected to
tartrate-resistant acid phosphatase (TRAP) staining.
∑ TRAP Staining
The cells of co-culture experiment were stained for TRAP activity with Acid
Phosphotase Leukocyte Kit (Sigma). Namely, the cells were fixed for 30 seconds
with fixative solution consisting of 25.51% (v/v) citrate solution, 66.32 % (v/v)
acetone and 8.17% (v/v) formaldehyde (37%). Following the fixation, cells were
washed with PBS and further maintained in PBS. Prior the fixation, the TRAP
staining solution was prepared.  For that 0.5 ml of Fast Garnet GBC Base Solution
and 0.5 ml of Sodium Nitrite Solution were mixed softly by inversion for 30 seconds
and incubated for 2 minutes. This mix  was then added to another consisting of 45 ml
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of prewarmed DI water (37° C), 0.5 ml Naphthol AS-Bl Phosphate Solution, Acetate
Solution 2.0 ml and 1.0 ml Tartrate Solution. Right after fixation, the fresh prepared
TRAP solution was added to the cells and cells were incubated for 1 hour in 37° C
incubator protected from light. Cells were washed with PBS and maintained in PBS
for visualization and counting performed under 40xmagnification with Leica
DMI6000B microscope. The number of TRAP positive multinucleated cells was
estimated in three replicates. Moreover, the expression of Opg and Rankl were




Isolation of RNA from cells was performed using the Trizol extraction protocol. In
brief, cells were washed once with PBS and treated with QIAzol reagent in a volume
of 500µl for a well of 6-well plate. Plates were incubated 3 min at RT on a shaker and
transferred onto ice. Cells were scraped and transferred to eppendorf tubes.  The
primary mouse osteoblasts rich in extracellular matrix were additionally subjected to
homogenization with the beads. Samples were subsequently twice extracted with
100µl of chloroform each time vortexed for 30 s and centrifuged at 4⁰ C for 20 min,
10000 rpm. After combining the aqueous supernatants, isopropanol (1:1) was added
and the RNA was precipitated overnight at -20⁰ C. Following the 30 min
centrifugation at 4⁰ C, 12000 rpm, the pellets were twice washed with 70% ethanol
and after last wash air-dried and diluted in 30 µl of DEPC treated nuclease free
water. The concentration of obtained RNA was evaluated on Nanodrop.
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Reverse Transcription (cDNA synthesis)
1µg of RNA in 10µl of nuclease free water was mixed with 2µl of 15µM 9mer random
primer and 4µl of 2.5nM dNTP bundle mix and subjected to 5 min of incubation at
70⁰ C.  Then, a master mix containing of 1.625 µl of nuclease free water, 2µl of 10x
reverse-transcription buffer, 0.125 μl of 25 U MMLV-reverse transcription enzyme
and 0.25 μl of 10 U Murine RNase-Inhibitor was added to the RNA mix from previous
step and the reaction mix was incubated for 1 hr at 42⁰ C and subsequently at 95⁰ C
for 5 min to inactivate the enzyme. After cooling, the sample volume was brought to
50µl with nuclease free water.
Quantitative Real-Time PCR (qRT-PCR)
The qRT-PCR was performed in 25µl reaction volume. Namely, 1 µl of cDNA or ChIP
isolated DNA were mixed with a 24 µl of master mix containing 14µl of qRT-PCR
mix, 8.5 µl DI H2O and 1.5 µl of 5µM forward and reverse primer mix. The PCR
reaction was performed using two-step protocol:
Temperature Time Cycles
95⁰ C 2 min 1
95⁰ C 15 sec
40-45 cycles
60⁰ C 1 min
The melting curve was recorded from 70 °C to 95 °C with the plate read every 0.5
°C. The relative DNA amount was quantified based on standard curve made from
serial (1:4) dilutions of control (Input in case of ChIP) samples. All qRT-PCR samples
were normalized to an internal reference gene and displayed relative to the control




∑ Fixation and nuclear extraction
Cells grown in 15cm cell culture plates were fixed at RT for 20 min with 12 ml of 1%
formaldehyde in PBS. The formaldehyde was quenched for 5 min at RT with 1.3 ml
of 1.25M Glycine. The cells were washed twice with ice-cold PBS and 1.5 ml Nelson
Buffer with the protease inhibitor cocktail was added.  Plates were placed onto ice
and after 5 min of incubation, the cells were scraped, resuspended well with pipetting
up-down and the cell extracts were transferred into 1.5ml eppendorf tubes. The
samples were centrifuged at 4⁰ C for 2 min at 2000g and the nuclear pellet was once
again resuspended in Nelson Buffer with inhibitors and the centrifugation was
repeated. The nuclear pellet was either snap-frozen at this point or subjected to
sonication.
∑ Sonication
The nuclear pellet was resuspended in 250-300µl of Gomes Lysis Buffer containing
either 0.1% SDS  - for BRD4, RNAPII, transcription factor ChIPs, or 0.5% SDS – for
histone modification ChIPs. Usually because of the bigger volume of nuclear pellet,
extracts from one plate were diluted in higher volume of Gomes Lysis Buffer and split
then into 2-3 parts for shearing (not more than 300µl of chromatin sample per tube).
After incubation of 15 min on a rotating wheel at 4⁰ C, the nuclear extracts from
hFOB cells were subjected to 18-25 cycles of sonication on Bioruptor Pico with 30
sec ON/OFF duty time. Before proceeding into IP 20-30 µl of extracts were taken for




After shearing 20-30 µl of chromatin extract was subjected to phenol-chloroform-
isoamyl DNA extraction procedure. Namely, the chromatin extracts were diluted with
100µl of Weinmann Buffer supplemented with 1µl of proteinase K (20µg/µl) and
incubated for at least 4 hr at 65 °C. 100µl of 10mM TRIS (pH 8) mixed with 10µl of
LiCl (8M) and 4 µl of linear polyacrylamide (2µg/µl) were added to the samples. The
samples then were mixed in 1:1 ratio with phenol-chloroform-isoamyl solution and
thoroughly vortexed for 30 s. Following the centrifugation for 2 min at full speed the
aqueous phase was transferred into new tubes whereas the rest was subjected for
back-extraction of remaining DNA by addition of 200µl buffer containing 10mM TRIS
(pH 8) and 0.4 M LiCl. The second aqueous phase was added to the first after the
second round of centrifugation.  The DNA was precipitated with 2.5 volumes of 100%
ethanol for at least 2hr at -80 °C and centrifuged at full speed for 30 min. The DNA
pellet was washed twice with 70% ethanol and the pellets were air-dried and
dissolved in 15 µl of DI H2O.  All the steps of DNA isolation were performed at RT.
The dissolved DNA samples were ran on 1-1.5% agarose gel. The size distribution
of sheared chromatin extracts were confirmed to be in a range of 1500-1000 bp
reaching up to 250 bp (optimal size range 500-300bp). In other case the shearing
was repeated.
∑ Preclearing and IP
After confirming the efficiency of sonication, the snap-frozen chromatin extracts were
thawed on ice and precleared with 50% slurry of sepharose beads prepared in
Gomes Lysis buffer with inhibitors. After one hour of incubation on rotating wheel at
4 °C the samples were centrifuged at 12000 g for 2 min. The supernatant was split
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into corresponding number of IP samples required including also the negative IgG
control. Specific ratio to IP samples was taken for input DNA (usually 1/5-1/10 to IP
amount). The IP samples were brought to a final volume of minimum 500µl by a
Gomes Lysis Buffer with inhibitors. At this point, if the SDS concentration in the
samples was higher than 0.1%, the samples were diluted with Gomes Lysis Buffer
without SDS.  1-2µg antibody was added to diluted chromatin extracts and the IP
samples were incubated overnight at 4⁰ C on a rotating wheel. Meanwhile, the
solution of blocked protein A sepharose beads was prepared. Namely, the Protein A
sepharose beads (≈ 0.5ml volume in 15ml tube) were mixed with 0.5g BSA in
Gomes Lysis Buffer, incubated overnight at 4°C to allow the swelling. The next day
the swollen sepharose was washed 3 times with Gomes Lysis Buffer (centrifugation
2min, 1000g) and finally the 50% slurry was made in Gomes Lysis Buffer with
protease inhibitors.  The blocked protein A beads were then added to the IP
samples, and the incubation was continued for another 2 hours. The IP complexes
then were subjected to a series of 7 washes: once with Gomes Lysis buffer, twice
with Gomes Wash buffer, twice  again with Gomes Lysis buffer and, finally, twice
with TE buffer. For washing the beads were always centrifuged at 4 °C for 2 min at
2000g.
∑ DNA Isolation and confirmation of IP-efficiency
The input samples and the beads after the last step of washes were resuspended in
50µl of 10mM TRIS (pH 8) with 0.2µg/µl RNAse and incubated for 30 min on a
shaker at 37 °C. Then, 50µl of 2x Weinmann Buffer with 1µl of proteinase K (20µg/µl)
was added to the beads, and the samples were incubated overnight on a shaker at
65 °C. The rest of the steps were repeated as described for shearing test. Namely,
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the DNA was isolated similarly with phenol-chloroform-isoamyl extraction procedure.
The DNA was diluted in 20µl of DI H2O and thoroughly mixed. Some of the sample
was taken and further diluted to confirm the efficiency of immunoprecipitation by
qRT-PCR on positive and negative sites. The PCR signals of the IP samples were
normalized to Input DNA (taking into account the ratio of IP chromatin extract to
Input), respectively and displayed as enrichment over Input in percent. The
background signal was estimated using DNA from IgG immunoprecipitated DNA. If
necessary, DNA was then subjected to library preparation for subsequent
sequencing.
Genotyping
The mouse tail or ear biopsies were subjected to overnight digestion with 60-
100mg/ml Proteinase K.  The DNA was isolated following isopropanol precipitation
with subsequent washes in 70% ethanol and final dilution of DNA in 50µl DI water.
The DNA concentration was verified and in amount of 50ng was used for the PCR




10x HotFire Buffer 2.5
2mM dNTP mix 2.5
25mM MgCl2 2
5µM Primer F 1





In case there were three primers used for genotyping (such as for Runx2-Cre or
Rosa-CreERT2), then the 1µl of the third primer was added to the reaction with
respective reduction in the volume of water used.  The PCR conditions used for
genotyping are indicated below:
Temperature Time Cycles
95°C 15 min 1x
95°C 30 sec
35xT °C (see below) 30-45 sec
72°C 1 min
72°C 10 min 1x
4°C ∞ O/N
Temperatures used for different targets were as follows: Rnf40/LoxP - 62⁰ C (45
sec); Usp22/LoxP  - 67⁰ C (30 sec); Runx2-Cre - 60⁰ C (30 sec); Bglap-Cre (generic
Cre) – 62 ⁰C (45 sec) and Rosa-CreERT2 - 55⁰C (45 sec).
Protein Analysis
∑ Protein Isolation
Following the PBS wash, the RIPA buffer with protease inhibitors was added to the
cells, and the plates were incubated on the ice on a shaker to allow the cell
detachment and lysis. The cells were scraped after 5 min of incubation. The cellular
lysate was then subjected to sonication on Bioruptor for 10 cycles with 30 sec
ON/OFF settings.  The protein samples from primary mouse osteoblasts were
additionally homogenized for 5 sec and also subjected to manual sonication for 10
cycles (5% power), 2 rounds on Bandelin Sonoplus Sonicator because of high
content of viscous extracellular matrix.
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∑ Western Blot Analysis
Protein samples were separated via sodium dodecylsulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Namely, the SDS gels with required percentage were
prepared and the sheared protein samples boiled with Laemmli buffer at 95⁰ C for 5-
10 min, were then loaded onto the gel. The gel was run with SDS Running Buffer at
10-15 mA. The separated proteins were transferred onto the PVDF Transfer
Membrane in Transfer Buffer at 100 V for 90 min. The membrane was blocked for
30-45 min in 5% milk solution in TBS-T. Following the blocking, the membrane was
incubated with primary antibody solutions at 4⁰ C. The next day, the membrane was
washed 3 times with TBS-T for 10 min and subjected for 1 hour incubation with HRP-
coupled secondary antibody solutions in 5 % milk in TBS-T at RT. After the second
incubation, the membranes were washed again 3 times. Subsequently, the
membranes were developed with Immobilon Western Chemiluminiscent HRP
substrate or SuperSignal West Femto Maximum (for weaker signals) and the
chemiluminescence was detected on gel imaging system.
Next Generation Sequencing
ChIP DNA Library Preparation
The ChIP DNA was subjected to 30-40 cycles of sonication on Bioruptor Pico with 30
sec ON/OFF settings. The DNA was then directly used for library preparation by
MicroPlex™ Library Preparation Kit following the manufacturer’s instructions based
on three basic steps of end repair, adaptor ligation and the last step of library
amplification. The ChIP libraries were mainly prepared in triplicates. After purifying
the amplified libraries with Ampure XP magnetic beads, the concentration of DNA
was measured on Qubit and 2-4ng of DNA in 1µl was loaded onto High Sensitivity
Material and methods
79
DNA microfluidic chips and the average size distribution of the libraries were
analyzed on Bioanalyzer.
RNA Library Preparation
∑ Verification of RNA Integrity on Gel
500-1000ng of whole cell RNA, mixed with RNA Loading Dye was ran in FA running
buffer on 1.2% agarose gel prepared in FA gel buffer with extra addition of 37%
formaldehyde to a final concentration of 0.66%.  The RNA integrity was evaluated
based on the sharpness and ratio of 28sRNA (≈5 kb size) and 18sRNA (≈2 kb size)
bands (28s should be twice intense than 18sRNA).
∑ mRNA Library Preparation
The whole cell RNA in amount of 1µg from hFOBs and 4 µg from mouse primary
cells were used for library preparation by using the NEXTflex Rapid Directional RNA-
Seq Kit according to manufacturer’s protocol. In brief, following the mRNA
enrichment by Poly(A) magnetic beads, the mRNA was fragmented and subjected to
first and then to second cDNA strand synthesis with addition of dUTPs. Consistently,
the ends of the DNA were repaired and adapters were ligated. The adapter ligated
DNA was subjected to amplification with simultaneous use of Uracil DNA
Glycosylase in reaction mix, to allow the degradation of second cDNA strand and
subsequent amplification of first strand. The concentration and size of amplified
libraries were estimated similarly as for ChIP DNA library.
Sequencing and Data Analysis
Pooled libraries were used for cluster generation on cBot following 51 bp single-end
sequencing on HiSeq 2000 from Illumina performed by the Transcriptome Analysis
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Laboratory (TAL) in Goettingen, Germany. The sequencing BaseCaller bcl output
files were further demultiplexed to FASTQ files using CASAVA 1.8.2 by TAL.
∑ ChIP-Sequencing Bioinformatic Analysis
After verification of the quality of FASTQ files by FastQC, the FASTQ files were
mapped to the human reference genome assembly hg19 using Bowtie2 (Langmead
and Salzberg, 2012) with very-sensitive presets in end-to-end mode. For
visualization the corresponding BAM files of the replicates were merged within each
condition. For visualization in the genome browser and to generate the heatmaps, all
the BAM files were filtered on MAPQ >=10 (MAPQ>=2 for TF ChIPs) with removal of
duplicates and normalized to fragments (reads) per kilobase per million (RPKM)
using the bamcoverage tool on deepTools (Ramírez et al., 2014) (Galaxy Version
1.1.4 and later for TF BAMs 1.5.9.1.0). The visualization was performed using the
Integrative Genomics Viewer (Thorvaldsdóttir et al., 2013). For the differential
binding analysis and chromatin segmentation, only the reads with MAPQ >=2
(Samtools 0.1.19) were retained for each BAM file and the BAM files were further
deduplicated with MarkDuplicates Picard Tools (version 1.140). Heatmaps were
generated using deepTools, the profile and correlation plots were made with
deepTools and Cistrome Galaxy. The annotation file containing the genomic
coordinates for all the human genes (assembly hg19) and CGI content within ± 1kb
TSS regions were downloaded from the UCSC Table Browser (Karolchik et al.,
2004). For correlations of ChIP-Seq signal with gene expression, duplicate TSS
(from different transcripts) were removed. Based on gene expression values from
hFOB RNA-Seq data, genes with DESeq “average baseMean” values < 20 and gene
length < 1000bp were further removed from the analysis. Moreover, for genes
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bearing more than one TSS, the TSS bearing the highest BRD4 signal was
considered.
The peak calling step was performed with Model-based Analysis of ChIP-Seq 2
(MACS2) (Zhang et al., 2008) on Galaxy Cistrome (version 2.1.0.20140616.0) using
default settings with q-cutoff <0.05. For BRD4, H3K27ac, H3K27me3, H2Bub1 and
RNAPII –broad option was used, whereas for TF ChIP the narrow peak option was
utilized. For each condition the corresponding input samples were used as control.
To determine osteoblast-specific BRD4 binding regions differential binding analysis
of all the BRD4 binding sites and regions among four different cell lines
(differentiated hFOB, MCF7, MCF10A and L3.6) was performed by using “DiffBind”
(Ross-Innes et al., 2012) R package version 3.2.2. To determine the regions bound
by BRD4 that are specific to differentiated hFOB the DiffBind thresholds were set to:
Fold Concentration Change (hFOB vs the rest of the cell lines) >1 and FDR<0.05.
These specific regions were further subdivided via Epigenome Count-based
Segmentation (EpiCSeg) (Mammana and Chung, 2015) software. The states were
determined based on the combination of five histone modifications H3K27ac,
H3K27me3, H3K79me2, H3K4me3, H3K4me1 from normal human osteoblasts
(NHOST) (Encode Consortium, 2012) as well as H3K27ac, H3K27me3 from
differentiated hFOBs. Segments 3 and 4 were used as potential enhancer sites
(marked by BRD4, H3K27ac and H3K4me1). Consecutive segments 3 and 4 were
joined and considered as one region using Bedtools (Quinlan and Hall, 2010) merge
(book end option). The resulting region file was analyzed using the Genomic
Regions Enrichment of Annotations Tool (GREAT) (McLean et al., 2010) to identify
genes associated with these putative enhancers and perform GO enrichment
analysis (biological processes) on these genes. The same file was used as input for
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ReMap (Regulatory Map of Transcription Factor Binding Sites) (Griffon et al., 2015)
to calculate the enrichment of TFs based on publically available ChIP-seq data.
Because of the larger size of some of the segments, we further intersected this file
with DNAse-seq bed file from NHOST (ENCODE) to obtain the center of the regions
(based on DNAse summits). We then performed de novo motif discovery using peak-
motifs from Regulatory Sequence Analysis Tool (RSAT) suite (Medina-Rivera et al.,
2015; Thomas-Chollier et al., 2012) on the regions flanking ±250 bp around the
identified centers of “Segment 3+4”. The differential mode was used between
“Segment 3+4” versus “Segment 1+2+5” using oligo-analysis 6nt and 7nt outputting
5 motifs.
The BRD4 RPKM values, identified using the “reference-point” mode of
computeMatrix tool on deepTools Galaxy (version 1.5.9.1.0), flanking ±500bp around
the TSS of genes in differentiated hFOBs were used to group the genes into “Very
Low” – log2BRD4 RPKM < 2.3; “Low” – 2.3 < log2BRD4 RPKM < 2.8; “Medium” – 2.8
< log2BRD4  RPKM  <  3.3;  “High”  –  log2BRD4 RPKM >3.3. The H3K27ac values
within the groups were similarly identified on the same regions as BRD4. For
RNAPII, regions ranging from TSS to +300 bp downstream were used. The H2Bub1
occupancy values were identified on the whole gene bodies (using the “scale-
regions” mode of computeMatrix tool on deepTools Galaxy).
∑ RNA-Sequencing Bioinformatic Analysis
For RNA-Seq the FASTQ files were mapped to the human genome (assembly hg19)
using TopHat Gapped-read mapper (Kim et al., 2013a) for RNA-seq data with very
sensitive Bowtie2 settings on Galaxy Platform (Version 0.9) (Goecks et al., 2010).
The read counting was performed via HTSeq (Anders et al., 2015) (version 0.6.0)
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with following parameters: -f bam -r pos -s reverse -a 10 -t exon -m union. The count
files were subsequently subjected for differential analysis using the DESeq2
Package (Love et al., 2014) on R (Bioconductor version 3.2.2). For hFOB RNA-Seq,
the Wald Test was utilized for a comparison of one-factor conditions (in case of
DIF_JQ1 or DIF_siBRD4 #3+#4 vs DIF_DMSO or DIF_siCNTR, respectively),
whereas for differential analysis of conditions differing by 2 factors (in case of
DIF_DMSO + DIF_siCNTR vs UND_DMSO + UND_siCNTR) Likelihood Ratio Test
reduced by “treatment” was used. The same model was implemented in case of
comparison across all conditions and samples for estimation of sample-to-sample
distances depicted in PCA plot. The similar settings were used for analysis of
mRNA-Seq data from mouse primary calvarial cells.
The differentiation induced changes in hFOBs showed the same tendency and
variance both in siCNTR as well as DMSO treated conditions between
undifferentiated and differentiated states on mRNA level (Figure 10), respectively.
Therefore, for the differential analysis, the siCNTR and DMSO conditions were
combined within the same state and treated as replicates of one state. The PCA
analysis also revealed a high level of similarity between both siRNAs used against
BRD4 (Figure 10). For that reason, gene expression counts of the both conditions
(siBRD4 #3 and 4) were combined and treated as replicates of one treatment. The
threshold values to determine the differentially expressed genes during
differentiation (DIF_siCNTR+DIF_DMSO vs UND_siCNTR+UND_DMSO) were as
follows: DESeq2 “average baseMean” > 20, abs(log2fold change) >=1 and FDR <
0.05. For differentiation-unregulated genes the thresholds were set to abs(log2 fold
change value) <=0.2 and FDR >0.8. For JQ1 regulated genes (DIF_JQ1 vs
DIF_DMSO) the thresholds were set to “average baseMean” >20, abs(log2 fold
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change) >=0.8, FDR < 0.05 and abs(log2 fold change) <=0.2 and FDR >0.85 in case
of unregulated genes. For siBRD4 regulated genes (DIF_siBRD4 #3 + #4 vs
DIF_siCNTR), following thresholds were used: “average baseMean” >20, abs(log2
fold change) >=0.7, FDR <0.05 and in case of siBRD4 unregulated genes the same
thresholds as for JQ1 unregulated genes were used. The overlap of the regulated
genes and subsequent venn diagrams were performed on R (3.2.2) by using the
VennDiagram package(Chen and Boutros, 2011).
For mouse mRNA-Seq analysis, the following thresholds of gene regulation were
used: for differentiation regulated genes (DIF_VEH vs UND_VEH) “average
baseMean” >20, abs(log2fold change) >=0.9 and FDR <0.05, for Rnf40 regulated
genes in differentiated state ( DIF_4OHT vs DIF_VEH) ) “average baseMean” >20,
abs(log2fold change) >=1 and FDR <0.05; for Rnf40 regulated genes in
undifferentiated state (UND_4OHT vs UND_VEH) “average baseMean” >20,
abs(log2fold change) >=1 and FDR <0.05.
The Gene Ontology (GO) analysis was performed using the “goseq” (Young et al.,
2010) Bioconductor package version 3.2.2. The significantly enriched GO categories
were identified based on the FDR values < 0.05 using the Benjamini and Hochberg
test. The resulting list of GO categories and the corresponding “bubble plots” were
further synthesized using REVIGO (Supek et al., 2011) which clusters the categories
based on semantics.
For the gene set enrichment analysis (GSEA) (Subramanian et al., 2005) the
variance stabilization transformed read counts obtained through DESeq2 analysis
were used. GSEA was performed with default settings (1000 permutations of gene
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sets, Signal2Noise ranking metric). For enrichment analysis gene ontology sets
(C5.all) were used.
The RNA-Seq heatmaps were performed with heatmap.2 from gplots R package
(Warnes et al., 2015).
Animal Studies
The mouse lines
All the animal studies were performed in accordance with the Institutional Animal
Care and Use Committee and the Institutional Guidelines for Humane Use of
Animals in Research. The initially designed RNF40 construct (with two loxP sites
flanking exons 3 and 4 of the Rnf40 gene and two short flippase recognition target
(FRT) sites around the neomycin (Neo) selection cassette) were electroporated in
129Sv/Pas-derived MPI II ES cells. The targeted clones were subsequently verified
by quantitative and long-range PCR. Germ line chimeras were obtained by morulae
aggregation (Kordowich et al., 2012). Following germ line transmission, the
neomycin cassette was removed by crossing the Rnf40loxPNeo mice to a mouse strain
expressing the FLP recombinase under the control of the Rosa26 promoter (Farley
et al., 2000). The resulting mutant Rnf40LoxP mice (Rnf40Tm1Saj) were crossed back
for nearly 5 generations with C57/BL6 mice.
The USP22LoxP mice were generated using a “knockout first” approach. The
embryonic stem cell line (Usp22tm1a(KOMP)Wtsi C57Bl6) were ordered from the
University of California-Davis Knockout Mouse Project (KOMP) Repository. In these
mice, the USP22 second is flanked by LoxP sites. Moreover, the first intron of the
USP22 gene carries LacZ and neomycin resistance cassettes flanked by FRT sites.
Since the lacZ and Neo cassetes are followed by polyadenylation sequences this
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results in subsequent truncation of Usp22 gene (USP22 KO). The KO construct was
originally put in C57/BL6-N which were later back-crossed to C57/BL6-J for at least
for 5 generations. The Usp22tm1a(KOMP)Wtsi mice were then crossed with Rosa26 FLP
recombinase mice to obtain the USP22LoxP mice.
The Rosa-CreERT2 and Bglap-Cre mice were obtained from JAX® Mice and
Services. The generation of the mouse lines is described by Ventura et al., 2007 and
Zhang et al., 2002, respectively. The Runx2-Cre mice were provided by Jan
Tuckerman from Institute of Comparative Molecular Endocrinology (CME), University
of Ulm (Rauch et al., 2010).
Mouse skeletal preparation
The mice were double injected with calcein solution (10µl/g of body weight) 9 and 2
day before the sacrification. Mice were euthanized with carbon dioxide. The skin and
inner organs of the animals were removed. The skeleton with muscles were fixed for
3 days in 4% PFA solution, after which the skeletons were washed with tap water
and transferred into 70% ethanol for long term storage.
The skeletons were sent to our collaborators Peng Liu from Jan Tuckerman’s group
at Institute of Comparative Molecular Endocrinology (CME), University of Ulm who
performed the rest of analysis with mouse bones.
µCT Analysis
This analysis was performed by Peng Liu from Jan Tuckerman’s group at Insitute of
Comparative Molecular Endocrinology (CME), University of Ulm.
The bones (femora and vertebrae) were analyzed using a Skyscan 1176 in vivo
micro CT (Bruker, Billerica, USA) equipped with an X-ray tube working at 50-80
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kV/100 µA. Resolution was 9 μm, rotation step was set at 1°, and a 0.5 mm
aluminum filter was used. For reconstruction of femora, region of interest was
defined 0.3 mm apart from the distal growth plate into the diaphysis spanning
1.8 mm. Trabecular bone volume/tissue volume (BV/TV), trabecular thickness
(Tb.Th.), trabecular separation (Tb.Sp.), trabecular number (Tb.N.) and cortical bone
perimeter (B.Pm) were determined according to guidelines by ASBMR
Histomorphometry Nomenclature Committee (Dempster et al., 2013). The size
parameters of the bones were identified as follows: for torso - the length from the
atlas to the sacrum; for femur - the length from the fovea capitis to the patella; for
vertebra - the length of L5 vertebral body. Student T-test was used for statistical
evaluation (comparison versus WT).
Bone Histomorphometry
The bone histomorphometric analysis including the paraffin and plastic embedding of
the bones, the estimation of bone formation rate and osteoclast numbers was
performed by Peng Liu from Jan Tuckerman’s group at Insitute of Comparative
Molecular Endocrinology (CME), University of Ulm
∑ Embedding of bones into plastic
The mouse bones were placed into histological cassette which were subjected to a
series of following treatments: 2-4 hours incubation at RT in 90% ethanol; 2 times 2-
4 hours each incubation at RT in 100% ethanol; 2 times 24 hours each incubation at
RT again in 100% ethanol; 3-4 days incubation at RT in infiltration solution I followed
by 7-10 days incubation in infiltration solution II consisting of 100ml destabilized
Methacrylate (MMA from Merck), 0.33 g Benzoylperoxid (BPO, Sigma) and
10ml Nonylphenyl (Merck); finally the cassettes with bones were incubated overnight
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at 4⁰ C in polymerization solution containing 100ml destabilized Methacrylate (MMA
from Merck), 0.66 g Benzoylperoxid (BPO, Sigma) and 10ml Nonylphenyl (Merck)
0.5ml N,N-Dimethyl-p-toluidin (Merck).
∑ Embedding of bones into paraffin
The PFA fixed bones were washed with DI water for 2 hours and subjected to
decalcification in duration of 10 days at 37⁰ C in EDTA (pH 7.2 set by NaOH and
HCl) in a shaking incubator (125 rpm). The EDTA was refreshed every 2-3 days. The
decalcified bones were washed for 2 hours in DI water and then embedded into
liquid paraffin.
∑ Bone formation rate
The dual calcein labeled bones embedded into plastic were utilized for measurement
of bone formation rate (BFR) and mineral apposition rate (MAR) based on the width
of the two  green lines which is indicative of bone growth between two injection time
points (7 days). The analysis and evaluation were performed by Osteomeasure
Software (Osteometrics, Decatur, USA). Student T-test was used for statistical
evaluation ( comparison versus WT).
∑ Osteoclast number estimation
The paraffin embedded bones were subjected to deparaffinization with xylol for 5 min
twice. Subsequently, the decalcified bones were rehydrated by series of incubation
in 100% ETOH - 5 min, 96% Ethanol - 2 min,  80% Ethanol - 2 min, 50% Ethanol - 2
min and DI H2O - 2 min. The rehydrated bones were incubated for 10 min in TRAP-
buffer consisting of 0.328% (w/v) Sodium-acetate (Sigma) and 0.23% (w/v) Di-
Sodium-tartrate (AppliChem) with pH 5 adjusted with HCl. Subsequently, the slides
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were incubated for 2-4 hours at 37° C in TRAP-staining solution consisting of 10%
(w/v) Naphthol-AS-BI-Phosphate (Sigma) and 1% (v/v) Dimethylformamid (DMF,
Sigma) mixed with subsequent addition of TRAP-buffer, 60% (w/v) Fast Red Violett
LB Salt (Sigma) and 0.5% (v/v) Triton X 100. The slides were washed with DI water
and stained with Hämalaun for 3 min at RT (diluted with DI H2O in 1:5 ratio). After
shortly rinsing in DI H2O, the slides were shortly immersed shortly for 2-3 times into
1.2% (v/v) water diluted HCl. The slides were immediately washed in tap water, and
incubated in lukewarm tap water for another 10 min. The slides were then covered
with Aquatex (Merck). The number of osteoclasts identified by red-pink color with
blue-violet nucleus and osteoclast surface was identified on Osteomeasure Software





Role of BRD4 in osteoblast differentiation
BRD4 is indispensable for osteoblast differentiation
Cellular differentiation is a complex process involving coordinated network of
transcription factors and epigenetic modifiers acting on cis- as well as trans-
regulatory elements to selectively regulate lineage-specific gene expression. In this
study we decided to elucidate role of epigenetic reader BRD4 in formation and
maintenance of osteoblastic phenotype. Functional relevance of BRD4 in the
regulation of bone formation was addressed in several in vitro models of osteoblast
differentiation, namely in human fetal osteoblasts (hFOB) and in mouse IDG-SW3
osteocyte cells. hFOBs immortalized with temperature-sensitive SV40 T-antigen
(Harris et al., 1995) are defined as early osteoblasts whereas similarly immortalized
IDG-SW3 cells can be characterized as late-stage osteoblasts/osteocytes with
mineralization potential (Woo et al., 2011).  To determine the involvement of BRD4
at earlier steps of osteoblast differentiation we used siRNA mediated depletion as
well as small molecule induced inhibition of BRD4 protein by JQ1 following 5 days of
differentiation in hFOBs. Two single siRNAs in addition to siRNA smartpool were
used for knockdowns to exclude the off-target effects (Figure 7A,B). Alkaline
phosphatase staining of the cells used to assess the differentiation efficiency of
osteoblastic lineage revealed decreased activity of the enzyme following the BRD4
inhibition or knockdown (Figure 7C).
In order to test our hypothesis we also looked at the global H2Bub1 protein levels






increase in H2Bub1 consistent with our previous finding (Karpiuk et al., 2012), loss of
BRD4 function did not impact the H2Bub1 levels on a global scale (Figure 7B).
Figure 7. Loss of BRD4 results in impaired hFOB differentiation A. Western Blot analysis of
BRD4 and H2Bub1 levels in whole cell protein extracts in hFOBs undifferentiated or osteoblast
differentiated for 5 days following treatment with DMSO or JQ1, or non-targeting control siRNA
(siCNTR) or BRD4 siRNA smartpool (siBRD4 SP) or two single siRNAs (siBRD4 #3 and #4). HSC70
and H2B were used as loading controls. B. Relative BRD4 gene expression assessed by qRT-PCR in
hFOBs treated similarly as in (A). Gene expression was normalized to RPLP0 levels in
undifferentiated controls, respectively. Mean±SD, n=3. Student t-test was performed for statistical
analysis where ***p<0.001, **p<0.01, *p<0.05. C. Alkaline Phosphatase staining of differentiated
hFOBs treated similarly as in A.
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Nonethelles, targeting BRD4 by JQ1 or siRNA reduced the differentiation-induced
expression of osteoblast-specific marker genes such as RUNX2, ALPL and Opg
(TNFRSF11B) (Figure 8).
Figure 8. BRD4 is required for the expression of osteoblast-specific genes. hFOBs were
differentiated for 5 days following DMSO or JQ1 (upper panels) or Control (siCNTR) or BRD4
(siBRD4) siRNA treatments (lower panels). The relative expression of osteoblast marker genes was
evaluated via qRT-PCR analysis and normalized to expression level of RPLP0 housekeeping gene in
undifferentiated state. Mean±SD, n=3. Student t-test was performed for statistical analysis where
***p<0.001, **p<0.01, *p<0.05.
Furthermore, we tested the effect of BRD4 inhibition on mineralization capacity of
mouse IDG-SW3 osteocytes. These cells completely failed to mineralize after 14
days of differentiation in presence of JQ1 and showed reduced mineralization after
26 days of differentiation (Figure 9A).  Similarly, the expression of marker genes
Mepe, Bglap and Dmp1 was also significantly reduced upon BRD4 inhibition




Figure 9. BRD4 is important for the mineralization of mouse osteocytes. The mouse IDG-SW3
osteocyte cells were differentiated for 14 and 26 days following DMSO or JQ1 treatment. A. The cells
were stained with Alizarin red for detection of mineralized nodules. B. The relative expression of
mouse osteocyte marker genes was evaluated via qRT-PCR and normalized to mouse Gapdh
housekeeping gene in undifferentiated state. Mean±SD, n=3. Student t-test was performed for
statistical analysis where ***p<0.001, **p<0.01, *p<0.05
Taken together, these results show that the BRD4 is indispensable for osteoblast
lineage commitment independent of differentiation stage. Moreover, these effects do
not seem to be mediated through the regulation of H2Bub1 levels.
Transcriptome wide effects of BRD4 perturbation
To determine the BRD4 mediated global control on gene expression and associated
pathways we performed transcriptome sequencing in hFOBs following differentiation
with subsequent BRD4 inhibition by JQ1 or depletion by two independent siRNAs







Figure 10. Quality diagnostics of RNA-Seq data from hFOBs. A. Heatmap of hierarchical
clustering of Elucidean sample distances and B. Principal Component Analysis (PCA) of the mRNA-
Seq data after variance stabilized transformation
The data quality was assessed by hierarchical sample clustering along with principal
component analysis on variance stabilized transformation of mRNA-Seq data.  As
revealed by the clustering analysis, replicates clustered together within each
condition verifying the similarity between these samples (Figure 10A). Interestingly,
the differences induced by differentiation were similar within each condition
(compare undifferentiated with the respective differentiated controls), whereas
DMSO or siCNTR treatment induced on their own clear differences (Figure 10B).
Moreover, two BRD4 siRNAs showed highest level of similarity in their actions, which





Figure 11. Gene Ontology on differentiation regulated genes. Functional Classification Summary
of GO terms associated with A. differentiation upregulated genes (log2fold change ≥1, FDR<0.05)
and B. differentiation downregulated genes (log2fold change ≤-1, FDR<0.05), created by GO
visualization tool REVGO. The color code depicts the log10 p-values of enriched GO term clusters.
As expected, the differential analysis of gene expression changes revealed that
differentiation upregulated genes are significantly enriched in gene ontology (GO)
terms involved in skeletal development (Figure 11A). Genes downregulated with
differentiation were mainly associated with cell division and cell cycle (Figure 11B)
pathways which is consistent with the notion that before differentiation cells undergo
cell cycle arrest (Funato et al., 2001).
Notably, BRD4 knockdown and inhibition blocked the differentiation induced changes
but to a different extend (Figure 12A, B). The overlap between JQ1 and siBRD4
regulated genes was not high and seemed different. Consistent with the positive role
of BET proteins in gene transcription, we observed higher number of downregulated





12). Interestingly, a large fraction of BRD4-regulated genes were also differentially
regulated during osteoblast differentiation, further supporting a lineage-specific
function of BRD4 in osteoblast differentiation.
Figure 12. Transcriptome wide effects of BRD4 perturbation. A. Heatmap depicting log2fold
change values of mRNA-Seq data from hFOBs: (left) of JQ1 versus DMSO treated hFOBs in
differentiated state; (middle) of control (siCNTR+DMSO) hFOBs in differentiated versus
undifferentiated state; (right) of siBRD4 (#3 & #4) versus siCNTR treated hFOBs in differentiated
state. Each row represents single gene. Genes up- (log2fold change value ≥0.8, padj≤0.05) and
downregulated (log2fold change value ≤-0.8, padj≤0.05) in JQ1 versus DMSO treated hFOBs in
differentiated state were selected for the heatmap. B-C. Venn Diagramms showing overlap of
significantly regulated genes with following thresholds: in DIF_UP – differentiation upregulated genes
(log2fold change value ≥1, padj≤0.05); in DIF_DN – differentiation downregulated genes (log2fold
change value ≤-1, padj≤0.05); in JQ1_UP – JQ1 upregulated genes (log2fold change value ≥0.8,
padj≤0.05); in JQ1_DN – JQ1 downregulated genes (log2fold change value ≤-0.8, padj≤0.05); in
siBRD4_UP – siBRD4 (#3 & #4) upregulated genes (log2fold change value ≥0.7, padj≤0.05); in
siBRD4_DN – siBRD4 downregulated genes (log2fold change value ≤-0.7, padj≤0.05).
Although BRD4 loss mediated effects extended beyond the list of differentiation
regulated genes, the gene set enrichment analysis (GSEA) on the downregulated by






pathways associated with extracellular matrix, collagen and skeletal development
(Table 1), In the case of JQ1 downregulated genes (log2fold change<-0.8,
padj<0.05) effects seemed broader involving different developmental pathways in
general including the skeletal system as well (Table 2).
NAME ES NES FDR q-val
EXTRACELLULAR_REGION 0.57 2.18 0.00000
EXTRACELLULAR_REGION_PART 0.57 2.15 0.00053
EXTRACELLULAR_MATRIX_PART 0.68 2.14 0.00035
VOLTAGE_GATED_CATION_CHANNEL_ACTIVITY 0.65 2.09 0.00026
EXTRACELLULAR_MATRIX 0.61 2.07 0.00021
COLLAGEN 0.79 2.07 0.00018
VOLTAGE_GATED_CHANNEL_ACTIVITY 0.63 2.07 0.00030
PROTEINACEOUS_EXTRACELLULAR_MATRIX 0.61 2.06 0.00026
GATED_CHANNEL_ACTIVITY 0.59 2.05 0.00046
CATION_CHANNEL_ACTIVITY 0.58 2.03 0.00042
REGULATION_OF_HEART_CONTRACTION 0.75 2.02 0.00057
SUBSTRATE_SPECIFIC_CHANNEL_ACTIVITY 0.56 2.01 0.00061
ION_CHANNEL_ACTIVITY 0.56 1.99 0.00073
SKELETAL_DEVELOPMENT 0.59 1.99 0.00068
Table 1. GSEA report on siBRD4 downregulated genes.
Table 2. GSEA report on JQ1 downregulated genes.
NAME ES NES FDR q-val
CYTOKINE_ACTIVITY 0.71 2.21 0.0000
CHEMOKINE_ACTIVITY 0.81 2.18 0.0000
CHEMOKINE_RECEPTOR_BINDING 0.80 2.17 0.0000
G_PROTEIN_COUPLED_RECEPTOR_BINDING 0.74 2.12 0.0000
LOCOMOTORY_BEHAVIOR 0.68 2.09 0.0000
REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS0.88 1.98 0.0013
EXTRACELLULAR_REGION_PART 0.55 1.90 0.0049
HEMATOPOIETIN_INTERFERON_CLASSD200_DOMAIN
_ CYTOKINE_RECEPTOR_BINDING 0.74 1.90 0.0053
BEHAVIOR 0.57 1.89 0.0064
EXTRACELLULAR_REGION 0.53 1.88 0.0068
EXTRACELLULAR_SPACE 0.55 1.87 0.0073
IMMUNE_RESPONSE 0.54 1.85 0.0102
RESPONSE_TO_EXTERNAL_STIMULUS 0.54 1.84 0.0109
HUMORAL_IMMUNE_RESPONSE 0.69 1.80 0.0231
LEUKOCYTE_MIGRATION 0.79 1.79 0.0268
COLLAGEN 0.73 1.79 0.0265
VASCULATURE_DEVELOPMENT 0.60 1.72 0.0409
MUSCLE_DEVELOPMENT 0.51 1.57 0.1346
ECTODERM_DEVELOPMENT 0.50 1.53 0.1555
SKELETAL_MUSCLE_DEVELOPMENT 0.59 1.52 0.1613
SKELETAL_DEVELOPMENT 0.46 1.46 0.2259
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Taken together, these results uncover role of BRD4 in directing and maintaining the
osteoblast-specific lineage determination by regulating the expression of genes
involved in skeletal development, ossification, extracellular matrix organization
Differentiation induced genes recruit more BRD4 at TSS
It has been shown previously, that CDK9 controls differentiation of human
mesenchymal stem cells (hMSC) into osteoblast linage through regulation of
phosphorylation of RNA Polymerase II (RNAPII) and the downstream
monoubiquitination of histone H2B (H2Bub1) which marks the lineage-specific gene
transcription (Karpiuk et al., 2012). In accordance with this notion we decided to look
for genome-wide localization of BRD4 along with H2Bub1 and RNAPII II to elucidate
BRD4 associated molecular signatures involved in osteoblast lineage determination.
Moreover, since very often BRD4 occupation correlates with histone H3 K27
acetylation (H3K27ac) (Nagarajan et al., 2014, 2015; Zhang et al., 2012), we also
sought to look for global changes in H3K27ac levels in the context of differentiation
regulation. Hence, chromatin immunoprecipitation followed by high-throughput
sequencing (ChIP-Seq) of BRD4, RNAP II, H3K27ac and H2Bub1 was performed on
undifferentiated and differentiated hFOBs. Additionally, to study the genome wide
consequences of BRD4 inhibition on transcriptional regulation, H3K27ac and
H2Bub1 ChIP-Seq, as marker of active transcription and elongation, respectively,
were performed following JQ1 treatment. The efficiency of ChIP was verified by qRT-
PCR on positive as well as negative genomic sites prior the sequencing (Figure 13).
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Figure 13.Confirmation of ChIP efficiency in hFOBs. Undiffirentiated or osteoblast differentiated
hFOBs with or without JQ1 treatment were subjected to BRD4, RNAPII, H2Bub1 and H3K27ac
chromatin immunoprecipitation (ChIP). qRT-PCR was used to verify the efficiency of
immunoprecipitation on the positive as well as negative sites (note : different sites were used for
different proteins). For background estimation IgG ChIPs were used. The ChIP efficiency is displayed
as enrichment over Input in percent. Mean±SD, n=3.
In general, BRD4 correlated with RNAPII and H3K27ac levels on all the genomic
regions (Figure 14).  As expected, the correlation with H2Bub1 was almost not
apparent since H2Bub1 is known to mainly localize to transcribed regions of the
genes (Minsky et al., 2008) and other genomic regions are devoid of H2Bub1.
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Figure 14. Genome wide correlation heatmap of BRD4, RNAPII, H3K27ac and H2Bub1 ChIP
Signals. Normalized ChIP-Seq coverage files (bigwig files) of BRD4, RNAPII in undifferentiated and
differentiated hFOBs, H3K27ac and H2Bub1 in undifferentiated, differentiated hFOBs treated with
DMSO or JQ1, respectively were used to compute average coverages over 10KB bins for each
condition and treatment. The Pearson correlations were evaluated for the given datasets on all the
genomic regions.
In order to elucidate how BRD4 regulates differentiation on transcriptional level we
sought to analyze the correlation of BRD4 occupancy around the transcription start
site (TSS) of differentiation regulated genes with the respective changes in gene
expression. Significantly upregulated during differentiation osteoblast-specific genes,
such as matrix proteoglycan Decorin (DCN) (Takeuchi et al., 1994) and  Odd-
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Skipped Related 2 (OSR2) (Kawai et al., 2007) showed increased binding of BRD4
around the TSS (Figure 15). Consistently, RNAPII and H2Bub1 occupancy raised on
the gene bodies indicating elevated transcriptional elongation (Figure 15).
Figure 15. Differentiation induced genes exhibit higher enrichment of BRD4 around the TSS
upon differentiation. IGV profiles for 2 genes (top-DCN, bottom-OSR2) picked from the RNA-Seq list
of differentiation upregulated genes (DIF_UP). Each lane represents normalized average occupancy
(in RPKM) for BRD4, RNAPII, H3K27ac, and H2Bub1 in undifferentiated (pink) and differentiated
(cyan) hFOBs, respectively. Grouped autoscale was used for each condition.
To get the overall picture of BRD4 involvement in transcriptional control of osteoblast
phenotype, we grouped the genes into three groups based on the regulation as
follows: differentiation induced genes (DIF_UP, log2fold change ≥1, padj<0.05),
downregulated genes (DIF_DN, log2fold change ≤ -1, padj<0.05) and unregulated
genes (abs(log2fold change) < 0.2, padj>0.8) and mapped BRD4 around the
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promoter regions of these genes. In general, the BRD4 binding increased upon
differentiation around the TSS of all the indicated groups, however, the genes of
DIF_UP group exhibited highest increase (Figure 16 and 17).
Figure 16. BRD4, RNAPII, H3K27ac and H2Bub1 show highest increase on osteoblast-specific
genes upon differentiation. Heatmaps depicting occupancy (RPKM values) of BRD4, RNAPII,
H3K27ac and H2Bub1 in undifferentiated and differentiated hFOBs, respectively around the TSS
(±3KB) of genes upregulated (DIF_UP), unregulated (DIF_UN) and downregulated (DIF_DN) during
differentiation. Each row in the heatmaps represents one gene. The gene order in heatmaps was
sorted from high to low based on BRD4 levels in differentiated state. The ordering was maintained the
same for RNAPII, H3K27ac and H2Bub1, respectively. “0” defines the transcription start site of each
gene.
Similarly, differentiation induced genes accumulated more RNAPII, H3K27ac and
H2Bub1 around the TSS. However, almost no difference in occupancy was observed
in the case of differentiation unregulated or downregulated genes (Figure16 and 17).
In general, differentiation induced gene expression changes correlated well with the
change in BRD4, RNAPII, H3K27ac and H2bub1 levels, especially in the case of
differentiation upregulated genes (Figure 18).
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Figure 17. Osteoblast-specific genes are the least marked genes in undifferentiated hFOBs.
Average enrichment profiles (in RPKM values) of RNAPII, H3K27ac, BRD4 and H2Bub1 in
undifferentiated and differentiated hFOBs, respectively on the same genomic regions used for
heatmaps in (Figure 16). The profiles are depicted for differentiation upregulated (DIF_UP),
unregulated (DIF_UN) and downregulated (DIF_DN) genes separately for undifferentiated (UND) and
differentiated (DIF) state. “0” defines the transcription start site.
Interestingly, while upregulated genes exhibited relatively low levels of BRD4 along
with RNAPII, H3K27ac and H2Bub1 in undifferentiated state, differentiation
unregulated genes were initially highly marked by all of the four indicated marks
(compare DIF_UP with DIF_UN group, Figure 16 and 17). Since higher occupancy of
“positive” histone modifications at the promoters correlates with higher gene
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expression (Su et al., 2016), we decided to see whether the same could be observed
in the case of differentiation unregulated genes.
Figure 18. Correlation of differentiation induced gene expression change with BRD4, RNAPII,
H3K27ac and H2Bub1 change. Density scatter plots depict on the y-axis log2 fold change values of
normalized ChIP-Seq signal occupancy in RPKM in differentiated hFOBs versus undifferentiated
hFOBs at ± 500bp around the TSS for BRD4 and H3K27ac; 300 bp downstream of TSS – for RNAPII
and on the gene body (TSS to TTS)– for H2Bub1. The x-axis represents log2fold change values of
baseMean counts (differentiated hFOB vs undifferentiated) altogether of genes from all the three
groups abovementioned. The R stands for Pearson Correlation coefficient.
Indeed, when we compared the baseMean counts of the genes from each group it
turned out that the unregulated genes are highly expressed in undifferentiated
hFOBs (Figure 19). Consistently, the upregulated genes were initially the least
expressed genes when compared to downregulated or unregulated group of genes.
Upon differentiation, the baseMean counts of upregulated genes reached the same
level as for unchanged genes, while downregulated genes became less expressed




GO:0044260 cellular macromolecule metabolic process 2.31E-05
GO:0044237 cellular metabolic process 1.65E-04
GO:0010467 gene expression 1.65E-04
GO:0043170 macromolecule metabolic process 5.79E-04
GO:0044238 primary metabolic process 6.64E-04
GO:0008152 metabolic process 6.95E-04
GO:0016070 RNA metabolic process 2.53E-03
GO:0010468 regulation of gene expression 7.07E-03
GO:0071704 organic substance metabolic process 7.89E-03
GO:0006139 nucleobase-containing compound metabolic process 8.51E-03
GO:0046483 heterocycle metabolic process 1.15E-02
GO:0006807 nitrogen compound metabolic process 1.23E-02
GO:0006725 cellular aromatic compound metabolic process 1.92E-02
GO:0090304 nucleic acid metabolic process 2.30E-02
GO:0034641 cellular nitrogen compound metabolic process 4.25E-02
Table 3. Gene Ontology Analysis on differentiation unregulated (DIF_UN) genes
Figure 19. Differentiation unregulated genes are highly expressed genes. Boxplots showing
log2fold gene expression counts (baseMean values) for genes upregulated (DIF_UP), unregulated
(DIF_UN) and downregulated (DIF_DN) with differentiation in undifferentiated and differentiated
hFOBs, respectively. The gene expression counts were obtained from differential gene expression
analysis of RNA-Seq data with DESeq2 package. For statistical analysis Wilcoxon Rank Sum test was
performed where ***p<0.001, **p<0.01, *p<0.05
Interestingly, the gene ontology analysis on the differentiation unregulated genes
revealed enrichment for cellular metabolic processes which suggests
“housekeeping” functions of these genes (Table 3)
Results
107
Figure 20. Promoter CGI content doesn’t define the outcome of transcriptional regulation
during differentiation. Pie charts represent the CGI (CpG Island) content within the promoter region
(±1KB TSS) of differentiation upregulated (DIFF_UP), unregulated (DIF_UN) and downregulated
genes. “CGI_HIGH” promoters are considered those with the sequences length at least 200 bp and
with a G + C content of 50% and a CpG frequency (observed/expected; [o/e]) of 0.6 (Larsen et al.,
1992).
Given the positive correlation between the highly expressed housekeeping genes
with promoter CpG island (CGI) content (Larsen et al., 1992; Zhu et al., 2008), we
questioned whether differentiation dependent genes would exhibit difference in
promoter CGI content that would define the outcome of BRD4 dependent
transcriptional regulation. Although, most of the differentiation unregulated genes
were high CGI genes ( ≈87%), the distribution of differentiation upregulated or
downregulated genes within CGI “HIGH” or “LOW” was not much different ( ≈80%
and 72%, respectively) suggesting CGI content independent regulation of gene
expression by BRD4 during differentiation (Figure 20).
Altogether, these findings indicate that increased transcription of osteoblast lineage
defining genes correlates with elevated recruitment of BRD4 around the TSS of
these genes. Moreover, the promoter CGI content most likely does not define the
outcome of the differentiation dependent differential regulation of gene expression.
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BRD4 marked genes differently respond to JQ1 treatment
JQ1 inhibition of BRD4 is mediated through its direct interaction with acetyl-lysine
binding pockets of bromodomains disabling these from binding to acetylated
chromatin. This means the observed effects of JQ1 treatment on transcriptional
regulation involves genes that are or should be initially BRD4 marked. Indeed,
osteoblast-specific genes – DCN and elastin (ELN) (Twine et al., 2014)
downregulated with JQ1 treatment show substantial enrichment of BRD4 at the
promoter regions (Figure 21). These genes are similarly marked by H3K27ac,
RNAPII and H2Bub1 in differentiated state. Consistently, H2Bub1 levels as a readout
of transcriptional elongation dropped with JQ1 treatment.
Figure 21. JQ1 dependent genes are BRD4 marked genes. IGV profiles for 2 genes (top – DCN,
bottom – ELN) picked from the RNA-Seq list of JQ1 downregulated genes. Each lane represents
normalized average occupancy (in RPKM) for BRD4, RNAPII, H3K27ac and H2Bub1 in differentiated
hFOBs treated with DMSO (cyan) or  JQ1 (yellow), respectively. Group autoscale option was used for
DMSO and JQ1 treated H2Bub1 and H3K27ac profiles.
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Interestingly, a reduction was also observed in H3K27ac levels upon JQ1 treatment.
We therefore tested whether this effect was due to overall changes in protein levels
of H3K27ac. Indeed, JQ1 induced decrease in differentiated hFOBs in H3K27ac
levels, whereas siRNA mediated knockdown of BRD4 did not exhibit similar effect
(Figure 22).
Figure 22. JQ1 affects global H3K27ac protein levels. Western Blot analysis of H3K27ac levels in
whole cell protein extracts in differentiated  for 5 days hFOBs following treatment with DMSO or JQ1,
or non-targeting control siRNA (siCNTR) or BRD4 siRNA smartpool (siBRD4 SP) or two single
siRNAs ( siBRD4 #3 and #4). H3 were used as loading control.
To elucidate how promoter associated BRD4 occupancy accounts to transcriptional
regulation of target genes, we grouped genes into three groups based on the effect
of JQ1 treatment in differentiated hFOBs: up- (log2fold change >0.8, padj<0.05), un-
(abs(log2fold change) <|0.2|, padj>0.85) and downregulated (log2fold change <-0.8,
padj<0.05) and identified occupancy of BRD4 as well as RNAPII, H3K27ac and
H2Bub1 around the TSS (± 3 KB) of these genes.
As expected JQ1 downregulated genes were highly BRD4 enriched which also
correlated with high H3K27ac levels around the promoter regions (Figure 23).
However, this was not consistent with RNAP II and H2Bub1 levels around the TSS of
these genes. On contrary, JQ1 downregulated genes exhibited least amount of
RNAPII and H2Bub1 occupancy when compared to the other two groups of genes
(Figure 23 and 24).  Consistently, H2Bub1 levels dropped across the JQ1
downregulated genes and JQ1 upregulated genes gained more H2Bub1. Given the
global reduction of H3K27ac protein levels upon JQ1 treatment (Figure 22), the
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genes of all three groups showed decreased levels of H3K27ac around the
promoters.
Figure 23. JQ1 downregulated genes are highly BRD4 bound. Heatmaps depicting occupancy (in
RPKM) of BRD4, RNAPII in differentiated hFOBs and H3K27ac and H2Bub1 in differentiated hFOBs
with DMSO or JQ1 treatment, respectively. Each row represents ±3KB region around the TSS of
genes upregulated (JQ1_UP, log2fold change ≥0.8, FDR<0.05), unregulated (JQ1_UN, abs(log2fold
change) ≤0.2, FDR>0.85) and downregulated (JQ1_DN, log2fold change ≤-0.8, FDR<0.05) upon JQ1
versus DMSO treatment in differentiated hFOBs. The gene order in heatmaps was sorted from high to
low based on BRD4 levels in differentiated state. The ordering was maintained the same for RNAPII,
H3K27ac and H2Bub1 heatmaps, respectively. “0” defines the transcription start site of each gene.
As in the case with differentiation unregulated genes JQ1 unaffected genes were
highly BRD4, RNAPII, H3K27ac and H2Bub1 enriched suggesting higher gene
expression (Figure 23 and Fugure 24). Indeed, the estimated gene expression
counts were the highest for JQ1 unregulated genes in differentiated control hFOBs.
Interestingly, JQ1 upregulated genes were the least expressed genes (Figure 25)
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although harbored relatively higher levels of RNAPII (Figure 24) compared to other
two groups indicating to perhaps “poised” state of polymerase on these genes
.
Figure 24. H2Bub1 Levels Change Consistently with Gene Expression Change induced by JQ1.
Average enrichment profiles (in RPKM) of BRD4, RNAPII in differentiated hFOBs and H3K27ac and
H2Bub1 in differentiated hFOBs with DMSO or JQ1 treatment, respectively, on the same genomic
regions used for heatmaps in (Figure 23). The profiles are depicted for JQ1 upregulated (JQ1_UP),
unregulated (JQ1_UN) and downregulated (JQ1_DN) genes, separately for DMSO or JQ1 treated
state. “0” defines the transcription start site.
In this case BRD4 levels were more predictive of gene expression status. Therefore
we sorted all the genes into four groups based on BRD4 levels, namely we defined 4
groups depending on the log2 BRD4 RPKM values around the TSS(±500) of the
genes in differentiated control state: “Very Low” (<2.3), “Low”(2.3-2.8), “Medium”
(2.8-3.3) and “High” (>3.3) (Figure 26) and looked for gene expression pattern within
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each group. Similarly, RNAPII, H3K27ac and H2Bub1 signals showed the same
tendency gradually increasing from “Very Low” to “High” group.
.
Figure 25. BRD4 dependent genes are highly expressed genes. Boxplots showing log2fold gene
expression counts (baseMean values) for genes upregulated (JQ1_UP), unregulated (JQ1_UN) and
downregulated (JQ1_DN) with JQ1 treatment in DMSO or JQ1 treated differentiated hFOBs,
respectively. The gene expression counts were obtained from differential gene expression analysis of
RNA-Seq data with DESeq2 package. For statistical analysis Wilcoxon Rank Sum test was performed
where ***p<0.001, **p<0.01, *p<0.05
The quantified gene expression counts estimated in baseMean values also







Figure 26. RNAPII, H3K27ac and H2Bub1 levels correlate with BRD4 levels. A. Boxplots showing
log2 RPKM values of BRD4 ±500bp around the TSS of genes in differentiated hFOBs treated with
DMSO. Based on the BRD4 values genes were grouped in 4 classes: “Very Low” – log2 BRD4
RPKM< 2.3; “Low” – 2.3 < log2 BRD4 RPKM < 2.8; “Medium” – 2.8 < log2 BRD4 RPKM < 3.3; “High”
– log2 BRD4 RPKM >3.3. B-D. Boxplots showing log2 RPKM values of RNAPII (300 bp downstream
of TSS), H3K27ac (±500bp around the TSS) and H2Bub1 (on the gene body from TSS to TTS)
occupancy, respectively in differentiated hFOBs  within “Very Low”, “Low”, “Medium” and “High” BRD4
groups identified in (A). For statistical analysis Wilcoxon Rank Sum test was performed where
***p<0.001, **p<0.01, *p<0.05
Surprisingly, the absolute gene expression change induced by JQ1 treatment in
differentiated hFOBs was the highest in the “Very Low” group (Figure 27). This
indicated that lowly expressed and low BRD4 marked genes appeared to be more
sensitive to JQ1 inhibition.
Figure 27. Gene expression correlates with BRD4 occupancy at TSS. Boxplots showing log2
values of gene expression counts (baseMean values) in (UP left) differentiated hFOBs treated with
DMSO, (UP right) in differentiated hFOBs treated with JQ1 and (DOWN) log2fold gene expression
change induced by JQ1 versus DMSO in differentiated hFOBs within “Very Low”, “Low”, “Medium”
and “High” BRD4 groups. For statistical analysis Wilcoxon Rank Sum test was performed where
***p<0.001, **p<0.01, *p<0.05.
Nonetheless, not all of the JQ1 regulated genes, as mentioned before, were low




GO:0044237 cellular metabolic process 2.25E-18
GO:0044260 cellular macromolecule metabolic process 1.40E-17
GO:0006139 nucleobase-containing compound metabolic process 4.10E-16
GO:0034641 cellular nitrogen compound metabolic process 9.78E-16
GO:0046483 heterocycle metabolic process 1.11E-15
GO:0010467 gene expression 1.70E-15
GO:0090304 nucleic acid metabolic process 3.48E-15
GO:0006725 cellular aromatic compound metabolic process 6.28E-15
GO:0044238 primary metabolic process 7.17E-15
GO:0006807 nitrogen compound metabolic process 1.37E-14
GO:0071704 organic substance metabolic process 3.93E-14
GO:0043170 macromolecule metabolic process 3.93E-14
GO:0008152 metabolic process 4.78E-14
GO:1901360 organic cyclic compound metabolic process 1.40E-13
GO:0016070 RNA metabolic process 4.78E-13
Table 5. Gene Ontology Analysis on JQ1 unregulated (JQ1_UN) genes (top 15 hits)
genes belonged to the BRD4 “High” group whereas 32 % of these genes were found
within the “Very Low” group (Table 4). In case of JQ1 upregulated genes almost half
was comprised of BRD4 “Very Low” group genes, speaking for indirect mechanisms
of gene expression regulation in this case. The distribution of JQ1 unchanged genes
within the groups was more or less even among all of them.
As in case with differentiation unregulated genes, JQ1 unaffected genes were
similarly enriched for GO terms associated with metabolic pathways (Table 5).
Table 4. Distribution of JQ1 group genes within the BRD4 groups
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However, also here the promoter CGI content of the genes in all the three JQ1
groups was not much different between the groups (Figure 28) indicating CGI
independent responsiveness to JQ1 inhibition of BRD4.
Figure 28. JQ1 Sensitivity Doesn’t Depend on Promoter CGI Content. Pie charts represent the
CGI (CpG Island) content within the promoter region (±1KB TSS) of JQ1 upregulated (JQ1_UP),
unregulated (JQ1_UN) and downregulated genes (JQ1_DN). “CGI_HIGH” promoters are considered
those with the sequences length at least 200 bp and with a G + C content of 50% and a CpG
frequency (observed/expected; [o/e]) of 0.6 (Larsen et al., 1992)
Altogether, these results indicate that TSS-associated BRD4 occupancy generally
correlates with gene expression levels but only partially explains the extent of its
requirement for gene expression, suggesting that additional mechanisms of
transcriptional control may determine the effects of BRD4 inhibition or loss.
Moreover, promoter CGI content does not define the outcome of promoter mediated
transcriptional regulation by BRD4.
Identification of osteoblast-specific BRD4 bound putative
enhancers
The transcriptional regulation of a gene is achieved by a cooperation of promoter-
and enhancer-mediated events. BRD4 is known to occupy enhancers and facilitate
enhancer RNA production (Di Micco et al., 2014; Kanno et al., 2014; Nagarajan et
al., 2014; Zhang et al., 2012). Consistent with a proposed function at both enhancers
and promoter proximal regions, nearly half of BRD4-enriched regions (45.3%) were
localized to distal intergenic regions (Figure 29). Moreover, BRD4 occupancy
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markedly correlated with RNAPII and H3K27ac on all the genomic regions (Figure
24). These findings support the notion that distal BRD4-bound regions might serve
as transcribed enhancers responsible for the establishment and maintenance of an
osteoblast-specific transcriptional program
Figure 29. Genome wide distribution statistics of BRD4 in differentiated hFOBs. CEAS (Cis-
regulatory Element Annotation System) statistics in differentiated hFOBs at important genomic
regions (left) showing the distribution of the given genomic features for the genomic input DNA and
(right) for BRD4 ChIP.
We therefore sought to determine whether “promoter unrelated” BRD4 could be
linked with the enhancers involved in osteoblast fate determination and
maintenance. To find exclusively osteoblast-specific BRD4 bound regions we sought
to identify and exclude BRD4 occupied sites that could be common between different
tissues. Although there is considerable amount of ChIP-Seq data available online on
BRD4, we decided to use for comparative analysis the datasets produced in our lab
with the same conditions and antibody to avoid the variations that could be due to
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choice of antibody and protocols used. Namely, we used datasets generated from 4
different cell lines: MCF10A, MCF7 treated with Estradiol (+E2), L3.6 and
differentiated hFOBs. As shown (Figure 30), all 4 of these cell lines used had more
distinct clusters of BRD4 bound regions than number of commonly shared sites.
Figure 30. Cell type specific distribution of BRD4. Venn Diagramm showing the overlap of BRD4
peaks between the four cell lines: differentiated hFOBs (DIF_FOB), MCF10A, MCF7 treated with
Estradiol (+E2) and L3.6 cells.
To find osteoblast-specific BRD4 regions we performed differential binding analysis
between these cell lines and obtained 7822 differentially occupied regions which
showed at least 2 fold higher BRD4 binding with FDR<0.05 in hFOBs. Since active
enhancers can be identified based on the combination of active histone marks we
performed chromatin segmentation analysis using Epigenome Count-based
Segmentation (EpiCSeq) (Mammana and Chung, 2015) to further characterize
osteoblast-specific BRD4-enriched regions. Based on high degree of epigenetic
similarity of hFOB cells and Normal Human Osteoblast (NHOST) cells as identified
through the high correlation of H3K27ac and H3K27me3 profiles between these two
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Figure 31. Correlation of H3K27ac and H3K27me3 profiles between hFOBs and NHOST cells.
Heatmaps depict Pearson correlation coefficients of A. H3K27ac in differentiated hFOBs with
H3K27ac in NHOST and B. H3K27me3 in differentiated hFOBs with H3k27me3 in NHOST. BAM files
were used to compute average coverages over 10KB bins for each condition. The correlations were
evaluated on all the genomic regions.
Based on the segmentation analysis, 5 chromatin states were identified on these
regions (Figure 32). States 1 and 2 were most likely associated with actively
transcribed promoter regions as revealed by the combination of H3K27ac, H3K4me3
and H3K79me2 occupancy, where H3K4me3 is particularly associated with TSS-
proximal regions and H3K79me2 with the proximal transcribed region of active
genes. States 3 and 4 appear to represent putative enhancers based on the
presence of both H3K27ac and H3K4me1 marks, both known to be associated with
active enhancer regions. State 5 was only positive for H3K27ac, and specific for
hFOBs, possibly indicating that these regions may be specific for the hFOB system
and therefore less informative about general mechanisms related to osteoblast
lineage-specification.
Figure 32. Chromatin segmentation of differentially BRD4 bound osteoblast-specific sites. A.
hFOB-specific differentially BRD4 bound regions (log2fold change>1 versus the other cell lines,
FDR>0.05) were subjected to EpiCSeg segmentation analysis. 5 histone modifications from NHOST
cells – H3K27ac, H3K4me1, H3K79me2, H3K4me3 and H3K27me3 and 2 from hFOBs – H3K27ac
and H3K27me3 were used to identify chromatin states associated with selected BRD4 sites. The
heatmap shows 5 chromatin states which were identified based on the combination and enrichment
intensity (normalized counts) of used histone modifications. B. Bar chart showing the fraction of bins
within each state identified from EpiCSeg analysis on differentially bound differentiated hFOB-specific
BRD4 regions. The values next to the bars depict the number of regions (peaks) within each state.
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Therefore we focused subsequent analysis on states 3 and 4. Consistently, the
majority of “Segment 3+4” constituted distal intergenic regions or introns (Figure 33).
Figure 33. Genomic Distribution statistics on BRD4 bound sites within “Segment 3+4”. CEAS
(Cis-regulatory Element Annotation System) statistics in differentiated hFOBs at important genomic
regions (left) showing the distribution of the given genomic features for the genomic DNA and (right)
for BRD4 signal on Segment 3+4.
Indeed, the IGV visualization of all the data for hFOB, NHOST, MCF7, MCF10A and
L3.6 in this case shown for the osteoblast-specific genes - tumor necrosis factor
receptor superfamily member 11b, or osteoprotegerin (TNFRSF11B) (Simonet et al.,
1997) and collagen type I alpha 1 (COL1a1) (Komori, 2009), confirms the distal
localization and osteoblast specificity of identified segments 3 and 4 (Figure 34). We
also aligned all the available hFOB and NHOST ChIP-Seq data on the regions of
“Segment 3+4”. Interestingly, upon differentiation the BRD4 signal substantially
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increased on these regions implying involvement of these putative enhancers in the
osteoblast fate determination (Figure 35).
Figure 34. Segments 3 and 4 possess “putative” enhancer marks and are in close proximity to
osteoblast-specific genes. IGV profile showing the distribution of segments around the osteoblast-
specific TNFRSF11B (up) and COL1A1 (down) gene. Each lane represents normalized occupancy of
BRD4 in MCF7+E2 (darkblue), in MCF10A (purple), in L3.6 (magenta); BRD4, H3K27ac and
H3K27me3 in differentiated hFOBs (cyan); H3K27ac, H3K4me1,DNAse-Seq, H3K4me3, H3K79me2
and H3K27me3 in NHOST (coral). The profiles were autoscaled on IGV.
Moreover, H3K27ac and RNAPII levels slightly increased on these regions during
differentiation suggesting the possibility of transcription from these enhancers
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(Figure 35). Certainly, all of these regions were enriched with H3K27ac and
H3K4me1 in NHOST cells.
Figure 35. Segment 3+4 gain more BRD4, RNAPII and H3K27ac upon differentiation.  A.
Heatmaps and B. Average enrichment profiles (in RPKM)  showing BRD4, RNAPII, H3K27ac in
undifferentiated and differentiated hFOBs, respectively and H3K27ac, H3K4me1 signal in NHOST  ±
3KB around the center of identified from EpiCSeg  “Segment3+4” (defined by “0” here). The segments





We also aligned the DNAse-seq data from NHOST on these sites. Notably,
“Segment 3+4” demonstrated also high DNAse hypersensitivity (Figure 36) which is
supporting the activity (“openness”) of the given regions. Thus, with the help of
differential binding and chromatin segmentation analysis, we were able to identify
putative osteoblast-specific enhancers potentially involved in lineage determination
Figure 36. “Segment 3+4” display high DNAse signal in the related NHOST cells. DNAse A.
heatmap and B. average enrichment profile (in RPKM)  in NHOST  ± 3KB around the center (defined
by “0” here) of  “Segment 3+4”.   The segments in heatmaps are ordered from high to low based on
BRD4 levels in differentiated hFOBs.
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Osteoblast-specific BRD4 bound putative enhancers show
selective enrichment for distinct TFs.
Enhancers can regulate target gene expression in distance independent manner. To
find out which possible genes are associated with the enhancers from “Segment
3+4” we used “Genomic Regions Enrichment of Annotations Tool” (GREAT).
Figure 37. “Segment 3+4” associated BRD4 putative enhancers are mainly distally localized to
any given gene TSS. Bar chart from GREAT analysis depicting the distance and orientation of
“Segement 3+4” regions from the nearest TSS.
Interestingly, the majority of these enhancers were found to be 50 to 500 kb away
from known gene-specific TSS regions (Figure 37). Consistent with their specific
enrichment in hFOB cells, these genes were enriched for pathways associated with
skeletal development and extracellular matrix organization (Figure 38). However, not
all of these genes were regulated with differentiation and not all were responsive to
JQ1 (Figure 38B-D). Nonetheless, some of osteoblast essential genes were also






Figure 38. Genes associated with putative enhancers from Segment 3+4 are enriched with
bone related pathways. A.Biological Process gene ontology analysis output of genes associated
with putative enhancers from „Segment 3+4“ identified by GREAT. The bars represent the –log10
Binominal Bonferoni p value of the indicated pathways. B-D. Venn diagrams depicting the overlap of
differentiation up- (DIF_UP, log2fold change ≥1, FDR<0.05) and downregulated (DIF_DN, log2fold
change ≤-1, FDR<0.05) genes (B), JQ1 up- - (JQ1_UP, log2fold change ≥0.8, FDR<0.05) and
downregulated (JQ1_DN, log2fold change ≤-0.8, FDR<0.05) genes (C), and differentiation
upregulated with JQ1 downregulated genes (D), respectively with the genes associated with
“Segment 3+4”   obtained by GREAT analysis. E. Some of the osteoblast related genes were selected
from the GREAT list and verified by qRT-PCR on the dependence to JQ1 regulation in differentiated
hFOBs. The relative expression of the genes was normalized to the expression level of RPLP0
housekeeping gene in differentiated state. Mean±SD, n=3. Student t-test was performed for statistical
analysis where ***p<0.001, **p<0.01, *p<0.05.
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The functional activity of an enhancer is dependent on the transcription factors
bound to it at a given time. The high DNAse hypersensitivity within the putative
enhancers from “Segment 3+4” in NHOST cells (Figure 36) suggested the presence
of nucleosome free regions that could serve as potential binding sites for tissue-
specific transcription factors (TF). One of the main transcription factors involved in
the osteoblast differentiation is the Runt-related transcription factor 2 (RUNX2) (Otto
et al., 1997). Strikingly, “Segment 3+4” was found to be enriched with RUNX2 in
NHOST (Figure 39).
Figure 39. RUNX2 is enriched at putative enhancers of “Segment 3+4”. RUNX2  A.  heatmap
and  B. average enrichment profiles (in RPKM)  in NHOST  ± 3KB around the center of “Segment3+4”
(defined by “0” here).The segments in heatmaps are ordered from high to low based on BRD4 levels
in differentiated hFOB cells.
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To identify additional transcription factor binding motifs enriched in these regions, we
performed differential motif analysis of “Segment 3+4” versus the “Segments 1+2+5”.
We observed an enrichment of consensus sequences for the Activator protein-1
(AP1) transcription factor family as well as the Hippo/YAP-regulated Transcriptional
enhancer factor TEF-1 (TEAD1) within the osteoblast-specific BRD4-bound regions
of “Segment3+4” (Table 6).
Table 6. RSAT short summary on "Segment 3+4" vs "Segment 1+2+5"
Results
128
 Moreover, an enrichment analysis within “Segment 3+4” of a large number of
publically available datasets for the occupancy of various transcription factors and
cofactors was performed using Regulatory Map of Transcription Factor Binding Sites
(ReMap)(Griffon et al., 2015).These analyses confirmed the significant enrichment of
AP1-bound regions on “Segment 3+4” (Figure 40) and further identified a significant
overlap with additional transcription factors including Signal Transducer and
Activator of Transcription 3 (STAT3) and CCAAT/Enhancer-Binding Protein-beta
(C/EBPb).
Figure 40. Overlap of BRD4 bound “Segment 3+4” with the transcription factor binding sites
from different cell systems. Top 10 hits according to ReMap results performed on „Segment
3+4“.The bar charts depict the –log10 E-value (significance) of the overlap of BRD4 sites within the
Segment 3+4 with the indicated transcription factor binding sites.
In addition, according to ReMap, peroxisome proliferator-activated receptor gamma
(PPARG), nuclear receptor subfamily 3 group C member 3 (NR3C3) – progesterone
receptor and nuclear receptor subfamily 3 group C member 1 (NR3C1) –
glucocorticoid receptor and  myc-associated factor X (MAX) transcription factor
binding sites were similarly enriched within the “Segment 3+4”.
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Based on previously discovered functions in osteoblasts (Gutierrez et al., 2002;
Mahoney et al., 2005; Nicolaidou et al., 2012; Sabatakos et al., 2000; Stein et al.,
2015; Zhou et al., 2011), out of the computationally predicted transcription factors we
sought to characterize the potential involvement of AP-1 factors (FOSL2 and JUND),
C/EBPb, STAT3 and TEAD1 on the  osteoblast-specific “putative” enhancers of
“Segment 3+4.  Notably, based on RNA-seq data, all the identified transcription
factors were highly expressed in hFOBs and only RUNX2 and FOSL2 expression
were dependent on BRD4 (Figure 41), suggesting that these factors may serve as
central mediators to facilitate BRD4 recruitment to osteoblast-specific enhancer
regions.
Figure 41. The expression profile and regulation of TF genes in hFOBs. The differentiation and
siBRD4(#3 + #4) or JQ1 treatment  induced relative gene expression change of the transcription
factors associated with “Segment 3+4”  identified from RSAT and REMAP tools, were evaluated from
the RNA-Seq analysis  of the hFOBs as described in Figure 12. Each column represents log2fold
change values for the indicated conditions with padj = ***p<0.001; **p<0.01; *p<0.05.
After obtaining the regions of intersection of BRD4 with transcription factors from
ReMap we performed ChIP-qPCR for C/EBPb, TEAD1, STAT3, JUND and FOSL2.
Strikingly, almost all of the picked regions were enriched to some degree for the
mentioned transcription factor signals (Figure 42). H3K27me3 marked OLIG2 gene




Thus, we performed additional genome-wide occupancy studies of all five
transcription factors in hFOB cells to examine their overlap with osteoblast-specific
BRD4-enriched regions. Interestingly, these transcription factors displayed
differential binding patterns in hFOBs, where a significant number of C/EBPb-bound
regions were largely devoid of other factors (Figure 43A). A number of sites
displayed similar TEAD1, JUND and FOSL2 occupancy, while strongly enriched
STAT3-bound regions lacked binding of the other factors.
Figure 42. The qPCR verification of C/EBPb, TEAD1, FOSL2, JUND and STAT3 ChIP on
“Segment 3+4”. The efficiency of TF ChIPs was confirmed on 3 “potential” positive regions (A-C)
obtained from REMAP intersection bed file and (D) on a HK27me3 marked OLIG2 gene which was
used as a negative site. For background estimation IgG ChIPs were used. The ChIP efficiency is
displayed as enrichment over Input in percent. Mean±SD, n=3. The IGV profiles show the “Segment
3+4” and BRD4 enrichment on these regions with the red segments indicating the localization of the
qPCR primers designed for the given regions. For the negative OLIG2 genes H3K27me3 binding





Notably, BRD4 exhibited differential binding profiles at the transcription factor bound
regions, where C/EBPb-, JUND- and FOSL2-enriched sites displayed higher binding
of BRD4, compared to TEAD1- and STAT3-enriched regions, which showed
moderate and low levels of BRD4 occupancy, respectively (Figure 43B).
Figure 43. C/EBPb, TEAD1, FOSL, JUND and STAT3 display distinct biding pattern in hFOBs.
A.The heatmaps depict linear k-means clustering of normalized coverage signals (RPKM) of C/EBPb,
TEAD1, FOSL, JUND and STAT3 binding ±1.5KB around the center (defined here as “0”) of the
merged transcription factor peaks. B. Average binding profile of BRD4 (in RPKM) in differentiated





Remarkably, “Segment 3+4” displayed substantial binding of C/EBPb, TEAD1,
FOSL2 and JUND whereas almost no STAT3 signal was detected on these regions
(Figure 44).
Figure 44. Occupancy of C/EBPb, TEAD1, FOSL2, JUND and STAT3 on the “Segment 3+4”. A.
Average signal profiles and B. heatmaps depicting occupancy (in RPKM) of C/EBPb, TEAD1, FOSL2,
JUND and STAT3 ±3KB around the center (defined as “0” here) of „Segment 3+4“, respectively. In the
heatmaps each row represents one segment and is ordered from high to low based on signal intensity





Interestingly, some “Segment 3+4” regions showed co-occupancy of all TFs (Figure
45) while many osteoblast-specific genes such as ELN and DCN showed distinct
occupancy of the identified transcription factors at putative enhancer sites located
within 50 kb of the genes.
As a result, by using genomic methods and a set of bioinformatic tools we identified
osteoblast-specific BRD4 bound putative enhancers and transcription factors that
could associate with BRD4 on these regions to induce and maintain the lineage-
specific gene expression. Namely, 5 candidate transcription factors were found to be
enriched at these enhancer segments: C/EBPb, AP1 factors JUND and FOSL2,
TEAD1 and STAT3. Moreover, according to GREAT analysis these potential
enhancers were associated with genes enriched for bone related GO terms. Notably,
some of these genes were also dependent on functional activity of BRD4 which







Figure 45. Localization of different TF peaks at “Segment 3+4” around the osteoblast-specific
genes. IGV profiles depicting binding of C/EBPb, TEAD1, FOSL2, JUND and STAT3 in differentiated
hFOBs (cyan) and RUNX2 in NHOST (coral) on the BRD4 occupied sites along with DNAse signal
within “Segment 3+4”: A – one common site with co-locolization of all the TFs; B-C – on the putative
“enhancers” proximal to osteoblast-specific genes ELN and COL1A1, respectively.
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Role of H2Bub1 in osteogenesis
Conditional Rnf40Runx2-Cre mice show complex bone phenotype
In order to understand the biological significance of H2Bub1 during the skeletal
development in vivo, we decided to use conditional knockout approach in mouse
models since the complete knockout of RNF20 were shown to be embryonically
lethal (Tarcic et al., 2016). Namely, we decided to elucidate what impact would the
bone-specific deletion of RNF40 protein have in the developing mice.  For that, we
crossed the Runx2-Cre-recombinase expressing mice (Rauch et al., 2010) with Rnf40
floxed mice (Figure 46).
Figure 46. Generation of conditional bone-specific Rnf40 knockout mouse line. The expression of
Cre is under the control of an osteoblast-specific (Runx2) promoter. The floxed Rnf40 mouse line
contains loxP sites flanking the exon 3 and 4 of RNF40 gene. When the two mouse lines are bred
together, the Cre enzyme recognizes the loxP sites and deletes the intervening DNA sequence only in
the Cre expressing tissues.
The criteria for selecting Runx2 as the driver of Rnf40 deletion was its crucial role as a
master regulator of bone formation (Komori, 2009; Otto et al., 1997). Runx2 is a
transcription factor involved in skeletal development and is important at earlier stages of
osteoblastic commitment of mesenchymal stem cells. Moreover, it plays as essential




The effect of Runx2-mediated deletion of Rnf40 in mice was, indeed, very striking.
The knockout (KO) mice were much smaller in size (shorter bones) and hence lighter
in weight compared to their wild-type (WT) and heterozygous (HZ) littermates (Figure
47) suggesting Rnf40 loss induced defects in bone formation/growth that could be
due to functional impairment of osteoblasts. Moreover, given the significant role of
chondrocytes during bone lengthening one could assume the shorter bones size
may be similarly the result of defective chondrocyte hypertrophy and osteoblasts.
Consistently, the phenotypic observation was not gender specific.
Figure 47. Runx2 mediated deletion of Rnf40 in mouse skeleton leads to “dwarf”-like
phenotype. A. Representative X-ray scan images of conditional Rnf40Runx2-Cre KO and WT male mice
at age of 7 weeks. B. Average weight of conditional Rnf40Runx2-Cre WT, HET and KO mice in both
genders (female=F, male=M) at 3.5-4 weeks of age.
In order to evaluate the morphometric parameters of the bones from Rnf40
conditional mice (Table 7) the whole body skeleton of mice were subjected to µCT




Mouse # Gender Runx2-Cre Rnf40/LoxP Genotype
Age
(weeks) Weight
1 F - +/+ WT 3.5 8.9
2 F - +/+ WT 4 16.1
3 F + +/- HET 3.5 10.6
4 F + +/- HET 4 13.1
5 F + +/+ KO 3.5 4.6
6 F + +/+ KO 3.5 3.87
7 F + +/+ KO 4
8 F + +/+ KO 4 5.6
9 F + +/+ KO 4 4.3
10 M - +/+ WT 3.5 11.2
11 M - +/+ WT 3.5 11
12 M - +/+ WT 3.5 10.3
13 M + +/- HET 4 13.8
14 M + +/+ KO 3.5 4.31
15 M + +/+ KO 4 6.1
Table 7. Conditional Rnf40Runx2-Cre mice used in the study for µCT analysis
.
To our surprise, although the bones of conditional Rnf40Runx2-Cre knockout mice were
much shorter in size, the bones of these mice showed increased mineral density
which implied increased bone matrix formation (Figure 48).  Consistently, the
morphometric parameters of trabecular bone quantified in femurs and vertebrae,
such as number of trabeculae (Tb.N) as well as thickness were significantly higher in
the knockouts in both genders (Figure 49).  These findings, however, were not
consistent with our expectations based on in vitro studies were loss of H2Bub1
impaired the differentiation of human mesenchymal stem cells into osteoblasts
(Karpiuk et al., 2012).
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WT (n=2F) HET(n=2F) KO(n=5F)
Torso length 4.2 cm 4.1 cm 3.0±0.2 cm
Femur length 9.14 mm 9.13 mm 6.18±0.33 mm
Vertebra (L5) length 2.010 mm 1.971 mm 1.334±0.161 mm
WT (n=3M) HET (n=1M) KO (n=2M)
Torso length 4.0±0.1 cm 5.0 cm 3.25 cm




Figure 48. Conditional Rnf40Runx2-Cre KO mice show increased bone matrix formation. A. Bone
size parameters of bones from Rnf40Runx2-Cre mice used in the study, shown separately for females
(up) and males (below). B-C. Representative µ-CT scan pictures of the femur (B) and L5 vertebrae
(C) of female mice at age of 3.5-4 weeks. The bones were analyzed using a SkyScan 1176 micro CT
(Bruker, Billerica, USA) equipped with an X-ray tube working at 50 kV/100 µA. Resolution was 9 μm,
rotation step was fixed at 1°, and a 0.5 mm aluminum filter was used. For reconstruction of femora,






Interestingly, the KO mice also lacked the teeth which implies either defects in the
function of osteoblasts or perhaps incomplete functional activity of osteoclasts
(through possible perturbation of osteoblast-osteoclast communication) which are
important regulators of tooth eruption through alveolar resorption (Wise et al., 2002).
Figure 49. Bone histormorphometric parameters in conditional Rnf40Runx2-Cre mice indicate
increased bone mass in knockout animals. Trabecular bone volume/tissue volume (BV/TV),
trabecular thickness (Tb.Th.), trabecular separation (Tb. Sp.), trabecular number (Tb.N.),) of femora
(A) and vertabrae (B) in female conditional Rnf40Runx2-Cre mice and in femora of male mice (C),
respectievely were determined according to guidelines by ASBMR Histomorphometry Nomenclature
Committee (Dempster et al., 2013).
Altogether, the Runx2-mediated deletion of Rnf40 in mice resulted in a complex
phenotype with signs of osteopetrosis, i.e. increased bone mass and inconsistently
shorter bone size characteristic for achdonroplastic mice.
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USP22 has no role in bone development in vivo
Since Runx2 mediated loss of Rnf40 in mice showed clear defects in skeletal system
leading to shorter bone size and increased bone density we questioned whether we
could achieve reversed phenotype by deleting  Ubiquitin Specific Peptidase 22
(USP22), the enzyme responsible for removal of  ubiquitin moieties from H2BK120
(Johnsen, 2012). For that, we crossed the Runx2-Cre with USP22 floxed mouse line
(Figure 50). The generated progeny of transgenic mice did not show any phenotypic
differences between the genotypes.
Figure 50. The floxed allele of USP22.  The floxed USP22 mouse line contains loxP sites flanking
the exon 2 of USP22 gene.
Moreover, the evaluation of bone histomorphometric parameters through µCT
analysis confirmed the absence of differences among the genotypes (Figure 51).
This suggested that although the removal of H2Bub1 accounts for defects in skeletal
development, the opposite did not have major impact on bone formation.
Mouse# Gender Runx2-Cre USP22/LoxP Genotype
Age
(weeks) Weight
1 M - +/- WT 6w 17.5
2 M - +/+ WT 6w 21.9
3 M - +/+ WT 6w 20.5
4 M - +/- WT 6w 19.8
5 M - +/+ WT 6w 19.4
6 M + +/- HET 6w 18.5
7 M + +/+ KO 6w 22.6
8 M + +/+ KO 6w 16.5
9 M + +/+ KO 6w 16.2







WT (n=5) HET(n=1) KO(n=3)
Torso length 5.2±0.1 cm 4.9 cm 5.1±0.2 cm
Femur length 10.65±0.53 mm 10.05 mm 10.20±1.22 mm
Vertebra (L5) length 2.598±0.023 mm 2.575 mm 2.567±0.096 mm
B
Figure 51. Conditional USP22Runx2-Cre KO mice show no differences in bone parameters.  A.
Bone size parameters of bones from USP22Runx2-Cre mice used in the study. B. Average weight of
conditional WT, HET and KO mice at 6 weeks of age C-D. Representative µ-CT scan pictures of the
femur (C) and L5 vertebrae (D). The bones were analyzed using a SkyScan 1176 micro CT (Bruker,
Billerica, USA) equipped with an X-ray tube working at 50 kV/100 µA. Resolution was 9 μm, rotation
step was fixed at 1°, and a 0.5 mm aluminum filter was used. For reconstruction of femora, region of
interest was defined 0.3 mm apart from the distal growth plate into the diaphysis spanning 1.8 mm. E-
F. Trabecular bone volume/tissue volume (BV/TV), trabecular thickness (Tb.Th.), trabecular
separation (Tb. Sp.), trabecular number (Tb.N.),) of femora (E) and vertabrae (F), respectievely were
determined according to guidelines by ASBMR Histomorphometry Nomenclature Committee
(Dempster et al., 2013).
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Bone-specific deletion of Rnf40 leads to osteopetrosis-like
phenotype
Since conditional Runx2-specific Rnf40 knockout mice displayed complex phenotype
involving both the osteoblasts and most likely the chondrocytes, we decided to
further analyze solely osteoblast-specific role of Rnf40 driven H2B
monoubiquitination in the context of bone formation. Therefore we used another
mouse line bearing Cre-recombinase expression under the control of osteocalcin
Bglap promoter (Zhang et al., 2002). Bglap is an extracellular matrix protein
expressed by osteoblasts involved in mineralization (Hauschka et al., 1989; Lee et
al., 2007). According to Zhang et al., Bglap-Cre was exclusively expressed in
osteoblasts and osteocytes. Similarly, Bglap-Cre mouse line was crossed with Rnf40
floxed mice to achieve conditional deletion of  Rnf40 in the bones from the initial
steps of bone formation. Interestingly, unlike the Runx2-specific Rnf40 knockout
mice, the conditional osteocalcin-specific Rnf40 knockout mice did not display any
visual differences in the appearance or weight when compared to wild-type or
heterozygous littermates (Figure 52,Table 9) suggesting absence of achondroplasia-
like phenotype.
Figure 52. Conditional Rnf40Bglap-Cre KO mice don’t show any phenotypic changes. Average
weight of conditional WT, HET and KO mice for both genders (F=female, M=male) at 6 weeks of age.
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Mouse# Gender Bglap-Cre USP22/LoxP Genotype
Age
(weeks) Weight
1 F + -/- WT 6 w 15.2
2 F + -/- WT 6 w 16.5
3 F - +/- WT 6 w 14
4 F - +/+ WT 6 w 16.5
5 F + +/+ KO 6 w 16
6 F + +/+ KO 6 w 17.5
7 F + +/+ KO 6 w 17.5
8 F + +/+ KO 6 w 13.4
9 F + +/- HET 6 w 16.2
10 F + +/- HET 6 w 16.3
11 F + +/- HET 6 w 18.4
12 F + +/- HET 6 w 15.4
13 M + -/- WT 6 w 18
14 M + -/- WT 6 w 21
15 M + -/- WT 6 w 22.4
16 M + -/- WT 6 w 18.5
17 M - +/- WT 6 w 21.8
18 M + +/+ KO 6 w 20.8
19 M + +/+ KO 6 w 21.3
20 M + +/+ KO 6 w 21.3
21 M + +/+ KO 6 w 17
22 M + +/+ KO 6 w 19.5
23 M + +/- HET 6 w 18.7
24 M + +/- HET 6 w 20.8
25 M + +/- HET 6 w 20.6
26 M + +/- HET 6 w 19.5
27 M + +/- HET 6 w 19.3
Table 9. Conditional Rnf40Bglap-Cre mice used in the study for µCT analysis
However, despite the fact that Rnf40 is required for the differentiation of hMSCs into
osteoblastic lineage (Karpiuk et al., 2012) , the µCT analysis of the mice skeletons
revealed increased bone mass similar to Rnf40Runx2-Cre conditional mice (Figure 53)











Figure 53. Conditional Rnf40Bglap-Cre KO mice show increased bone mineral density. A. Bone
size parameters of femora (left) and L5 vertabrae (right) from male mice at 6 weeks of age used in the
study. B-C. Representative µ-CT scan pictures of the femur (B) and L5 vertebrae (C) of male mice.
The bones were analyzed using a SkyScan 1176 micro CT (Bruker, Billerica, USA) equipped with an
X-ray tube working at 50 kV/100 µA. Resolution was 9 μm, rotation step was fixed at 1°, and a 0.5 mm
aluminum filter was used. For reconstruction of femora, region of interest was defined 0.3 mm apart
from the distal growth plate into the diaphysis spanning 1.8 mm. D-E. Trabecular bone volume/tissue
volume (BV/TV), trabecular thickness (Tb.Th.), trabecular separation (Tb. Sp.), trabecular number
(Tb.N.),) of femora (D) and vertabrae (E), respectievely were determined according to guidelines by
ASBMR Histomorphometry Nomenclature Committee (Dempster et al., 2013). Student’s T-test was
used for statistical analysis.
Bone is a very dynamic tissue undergoing lifelong process of remodeling comprising
two opposite processes of osteoblast mediated bone formation and osteoclast
dependent bone resorption. Coupling of both is essential for bone formation, growth
and healthy metabolism of bone tissue.  To evaluate how bone development could
be affected in conditional Rnf40 deficient mice we assessed the bone formation rate
in these mice via fluorometric double labeling of newly synthesized mineralizing
tissue by calcein (Suzuki and Mathews, 1966)
Figure 54. Bone formation rate is not affected in conditional Rnf40Oc-Cre mice. Conditional
Rnf40Bglap-Cre mice were double injected with calcein with a gap of 1 week 2 days prior sacrificing. The
femurs were subjected to dynamic bone histomorphometry analysis. A. Fluorescent micrographs of
femur cortical bone of 6 weeks old male mice showing double calcein labeling. B. Bone formation
rate per bone surface (BFR/BS) and mineral apposition rate (MAR) were quantified for 4 wildtype





Interestingly, the bone formation rate (BFR) which is indicative of the actively
mineralizing bone surface amount that depends on the number of active osteoblasts,
as well as the mineral apposition rate (MAR) that demonstrates the average activity
of osteoblasts and the rate at which these cells produce calcifying matrix for a given
period of time was not different between the genotypes suggesting absence of
functional defects in osteoblasts (Figure 54).
However, the most striking finding was to discover that the number of osteoclasts
was significantly decreased in the Rnf40 knockout animals (Figure 55).  This, in fact,
explains why the conditional Rnf40 knockout mice displayed higher bone matrix




Figure 55. Conditional Rnf40Bglap-Cre mice display decreased osteoclast numbers. The plastic
embeded femoral sections were subjected to A. TRAP stainings shown for growth plate and
trabeculae separately. B The number of osteoclasts and the osteoclast surface was definied on
“osteomeasure” software and  depicted as number of osteoclasts per bone perimeter ( N.OC/B.PM)
and osteoclast surface per bone surface ( Oc.S/BS, %). Student T-test was used for statistics.
The in vivo data in mice, altogether, highlighted the importance of Rnf40 mediated
H2B monoubiquitination in skeletal development. Although at first sight it seemed
that the mice developed morphologically healthy bones in Rnf40 deficient conditions,
the increased bone mass due to decreased number of osteoclasts suggested that
the osteoblast-osteoclast “communication” in these mice were more likely affected in
a negative way.  Since Bglap is a solely osteoblast-specific protein and hence the
expression of Cre-recombinase was restricted only to osteoblastic lineage, despite
unaffected mineral tissue deposition amount and rate the Rnf40 deficient osteoblasts
were most likely functionally unable to induce osteoclast differentiation and/or
activity.
Rnf40 deficient primary osteoblasts exhibit reduced
differentiation capacity
In order to understand how Rnf40 deficiency in osteoblasts contributed to a bone
mass change in osteoclast dependent manner we sought to analyze primary
molecular effects of Rnf40 loss in osteoblasts ex vivo.
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Figure 56. Time course 4OHT treatment in primary osteoblasts ex vivo.  A. Schematic
representation of 4-hydroxy-tamoxifen (4OHT) induced Rnf40 gene deletion. The Cre-recombinase
fused with mutated estrogen binding domain (ERT2) is placed under the control of ubiquitously
expressed Rosa26 promoter.  The fused Cre protein can be translocated into the nucleus once
binding with 4OHT ligand where it leads to the deletion of LoxP intervening DNA sequence flanking
the exon 3 and 4 of Rnf40 gene. B. Time course 4OHT treatments were used to test the efficiency of
Rnf40 gene deletion. Agarose gel pictures of Rnf40 wildtype or Rnf40 floxed PCR products performed
on DNA from primary long bone cells isolated from Rnf40Rosa-CreERT2 mouse homozygous for
Rnf40/LoxP sites after 2-7 days of 4OHT treatment, respectively. The arrow indicates 1000bp.
The primary long or calvarial bone cells were isolated from Rnf40Rosa-CreERT2 mice at
age of six weeks or the first three days after birth, respectively. 7 days of 4-hydroxy-
tamoxifen (4OHT) treatment was sufficient for almost complete recombination and
loss of Rnf40 gene in primary osteoblasts (Figure 56).
We then checked the differentiation potential of the primary osteoblasts ex vivo
(Figure 57A).  Interestingly, Rnf40 deficient cells with significant loss of H2Bub1
(Figure 57B) didn’t differentiate well into alkaline phosphatase (ALP) positive cells.
Moreover, they failed to mineralize after 21 days of differentiation (Figure 57C).
Since the differentiation potential of the cells was significantly impaired upon Rnf40
knockout, we also analyzed the expression of lineage-specific genes in both the
calvarial as well as long bone cells. Loss of Rnf40 lead to reduced expression of the
marker genes in both cell types (Figure 58) consistent with the previously reported in





Figure 57. Rnf40 knockout primary osteoblasts failed to differentiate.  A. Schematic
representation of experimental design. Primary osteoblasts were treated 7 days with 250nM 4OHT or
equivalent volume of 100% ethanol (VEH), after which the treatments were removed and cells were
cultured 2 more days in complete media. Cells were stained for Alkaline phopshotase activity (0d) and
protein extracts for undifferentiated state (UND) were harvested at this time point. Then cells were
induced do differentiate for 7, 17 and 21 days. At 7 days of differentiation cells were used for alkaline
phosphatase staining and protein, RNA and ChIP extracts were harvested. At 17 days following
differentiation cells were stained for alkaline phosphatase activity and at 21 days – with alizarin red
staining. B. Western Blot analysis of Rnf40 and H2Bub1 in whole cell protein lysates harvested at 0
and 7 days of differentiation from primary calvarial osteoblasts. HSC70 and H2B were used as loading
controls. C. Scanned images of wells with primary calvarial osteoblasts stained for alkaline
phosphatase activity at 0d, 7d and 17d and Alizarin Red – at 21 days of differentiation.
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Figure 58. Expression of osteoblast-specific genes is reduced in Rnf40 deficient cells, The
primary cells were differentiated as stated in (Figure 57). The relative expression of osteoblast marker
genes in calvarial osteoblasts (upper panel) and long bone cells (lower panel) was evaluated via qRT-
PCR analysis and normalized to expression level of  Gapdh housekeeping gene in undifferentiated
vehicle treated state. Mean±SD, n=4. Student t-test was performed for statistical analysis where
***p<0.001, **p<0.01, *p<0.05.
To look for transcriptome wide effects caused by Rnf40 loss in primary osteoblasts
the mRNA of these cells was subjected to high-throughput sequencing. The





conditions (Figure 59A). Interestingly, the differences induced by Rnf40 loss in
differentiated state were higher than in undifferentiated state (Figure 59B).
Figure 59. Quality diagnostics of RNA-Seq data from primary calvarial osteoblasts. A.Heatmap
of hierarchical clustering of Elucidean sample distances and B. Principal Component Analysis (PCA)
of the mRNA-Seq data after variance stabilized transformation.
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Notably, knockout of Rnf40 gene in calvarial osteoblasts almost reverted the
differentiation induced gene expression program (Figure 60). Interestingly, already in
undifferentiated state Rnf40 loss affected the same set of genes as in differentiated
cells where in the latter the effects were further enhanced.
Figure 60. Transcriptome wide effects of Rnf40 deficiency in primary osteoblasts. Heatmap
depicting log2fold change values of mRNA-Seq data from primary calvarial osteoblasts: (left) of 4OHT
versus VEH treated cells in undifferentiated state; (middle) of control VEH treated cells in
differentiated versus undifferentiated state; (right) of 4OHT treated cells versus VEH in differentiated
state. Each row represents single gene. Genes up- (log2fold change value ≥1, padj≤0.05) and
downregulated (log2fold change value ≤-1, padj≤0.05) in 4OHT versus VEH treated condition in





The list of Rnf40 dependent genes in undifferentiated state included several hits
involved in extracellular matrix organization and endochondral ossification (Figure
61A).  In the differentiated state the list was broader involving in general skeletal





Figure 61. Gene Ontology on Rnf40 dependent genes in primary calvarial osteoblasts.
Functional Classification Summary of GO terms associated with genes downregulated (log2fold
change ≤-1, padj≤0.05) with Rnf40 knockout in A. undifferentiated and B. differentiated calvarial
osteoblasts. The bubble plots were created by GO visualization tool REVGO. The color code depicts
the log10 p-values of enriched GO term clusters.
As previously mentioned the coupling of osteoblast mediated bone formation and
osteoclast driven bone resorption is the leading mechanism of bone mass
maintenance. We therefore sought to test whether the Rnf40 deficient osteoblasts
would exhibit defects in triggering the activation of osteoclasts that would explain the
increased bone mass observed in condtional Rnf40Bglap-Cre knockout mice.  Number
of factors produced by osteoblasts and osteocytes are known to coordinate the
activation of osteoclasts (Boyce and Xing, 2007). Interestingly, the receptor activator
of nuclear factor kappa-B ligand gene (Rankl) expression was significantly reduced
in Rnf40 knockout primary osteoblasts whereas the osteoprotegerin (Opg, or
Tnfrsf11b) level was not affected much (Figure 62A).
Figure 62. Primary Rnf40 deficient calvarial osteoblasts fail to trigger osteoclast formation.
Primary Calvarial Osteoblasts from Rosa26-CreERT2 x Rnf40/flox mouse following 7 days of vehicle
or 4OHT treatment were co-cultured with primary bone marrow derived macrophages  and subjected
to 9 days of 10nM vitamin D treatment. A. Relative expression of Rankl and Tnfrsf11B gene in control
(VEH) or KO (4OHT) osteoblasts used for co-culture experiment. B. TRAP staining was used to
visualize the osteoclasts. C. Quantification of TRAP positive multinucleated osteoclasts in co-culture
with control (VEH) or KO (4OHT) calvarial osteoblasts.
Results
155
Moreover, the co-culture of Rnf40 deficient primary calvarial osteoblasts with
wildtype macrophages revealed decreased formation of multinucleated osteoclasts
from the latter (Figure 62B).
Altogether these findings revealed the indispensable function of Rnf40 mediated
H2Bub1 during the differentiation of osteoblasts. The cells devoid of Rnf40 failed to
mineralize ex vivo, however these observations were not consistent with the
previously mentioned in vivo data where the conditional bone-specific Rnf40
knockout mice developed functionally normal bones. Consistently, the Rnf40
deficient osteoblasts also failed to trigger osteoclast formation ex vivo due  to
reduced RANKL gene expression which more likely explains the increased bone





Bone development is a complex process that is coordinated by a sophisticated
network of extra- and intracellular signaling cascades. Growing evidence suggests
importance of epigenetic regulators during development and in determination of cell
fate. A combination of epigenetic mechanisms allows proper activation of molecular
events that control specific cell identity and its maintenance. Perturbation of these
epigenetic mechanisms can be the leading cause of development - and
differentiation defects, on one side, and can be targeted for therapeutic use, on the
other side. In the present study we aimed to elucidate the molecular epigenetic
mechanisms governing bone formation which could possibly provide a basis for
better understanding and hence development of effective therapies for bone-related
diseases.
BRD4 acts independent of H2Bub1 to regulate gene expression
In general, bone formation is achieved through two processes known as
intramembranous and endochondral ossification both of which involve the
transformation of progenitor mesenchymal stem cells. Indeed, the differentiation of
mesenchymal stem cells into bone forming osteoblasts and cartilage forming
chondrocytes is the key determining event underlying healthy skeletal development
(Bruder et al., 1994; Gilbert, 2000).
Given the positive correlation of H2Bub1 with differentiation induced gene
expression in MSCs (Karpiuk et al., 2012) our initial hypothesis suggested BRD4 as
upstream component of CDK9-WAC-RNF20/40 axis to regulate osteoblast-specific
gene expression program. Although we observed an increase in H2Bub1 levels in
hFOBs upon differentiation, consistent with previous finding, the global protein
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H2Bub1 levels were not affected by loss or inhibition of BRD4  suggesting H2Bub1
independent function of BRD4 in regulating osteoblast differentiation.
Association of H2Bub1 exclusively with transcribed regions of protein coding genes
as revealed by genome wide enrichment analysis, correlation with the transcribing
RNAPII implies H2Bub1 as “readout” of transcriptional elongation (this study and
Fuchs et al., 2014). Moreover, the bulky structure of H2Bub1 makes it into an
important regulator of nucleosome stability and dynamics (Chandrasekharan et al.,
2009; Fierz et al., 2011; Jung et al., 2012) and thereby, more likely, hints to “rate
limiting” function of  H2Bub1 in controlling the “speed” of RNA Polymerase passage
and perhaps the proximal RNAPII pause release.
The role of BRD4 in regulation of gene expression is broader. It is involved at several
levels of transcriptional regulation, namely facilitating transcription initiation and
elongation by promoter- and more importantly, by enhancer-coupled events (Kanno
et al., 2014; Liu et al., 2013; Nagarajan et al., 2014; Patel et al., 2013). Functional
activity of BRD4 largely relies on the presence of activating histone acetylation
marks (Dey et al., 2003; Filippakopoulos et al., 2012; Roe et al., 2015; Zhang et al.,
2012). In addition, several reports uncovered the ability of BRD4 to bind also
acetylated transcription factors (Brown et al., 2014; Huang et al., 2009; Roe et al.,
2015; Shi et al., 2014). However, there is also an increasing amount of evidence
pointing to bromodomain-independent functions of BRD4 in regulating gene
expression (Rahman et al., 2011; Wu et al., 2013). Furthermore, implication of
histone chaperone and acetyltransferase “abilities” of BET proteins (Devaiah et al.,
2016; Kanno et al., 2014) also brings in another level of complexity into the
understanding of BRD4 dependent transcriptional regulation. Altogether, these facts
imply that BRD4 promotes gene expression in a “hierarchical” and context-
Discussion
158
dependent manner where action through H2Bub1 pathway would only partially
explain the broad effects of BRD4 loss on gene regulation. This can be also
supported by the finding that despite the inhibition of BRD4 by JQ1 where JQ1
downregulated genes consistently lost H2Bub1 on the transcribed region, the JQ1
upregulated genes gained it which speaks for dependence of H2Bub1 levels on the
outcome of gene expression change rather than BRD4 itself.
BRD4 is indispensable for development and maintenance of
osteoblast phenotype
The first hint about the possible relevance of BRD4 for skeletal development came
from the study by Houzelstein et al., 2002. Here the authors for the first time
discovered that heterozygosity for BRD4 in mice leads to developmental defects
including abnormalities in skull bones. Our study further strengthened the role of
BRD4 in bone formation. Namely, we uncovered indispensability of BRD4 at earlier
as well as later stages of osteoblast differentiation.  Although global mRNA or protein
levels of BRD4 did not change upon differentiation there was a considerable
increase of BRD4 occupancy around the TSS of genes and the change was
markedly higher on genes upregulated during differentiation. More importantly, the
increase in BRD4 occupancy was observed on the identified osteoblast-specific
putative enhancers implying a potential function of BRD4 in controlling osteoblast-
specific gene expression
Both JQ1 and siRNA mediated knockdown of BRD4 elicited similar pattern in
regulation of osteoblast-specific genes. However, the overlap between these two
treatments was not high. Consistent with the fact that JQ1 targets all BET proteins
including BRD2, -3 and -4 (Filippakopoulos et al., 2010) and the potential differences
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induced by inhibition of bromodomain-mediated protein-protein interactions versus
effects observed following a complete loss of BRD4 protein expression, the
differences observed between effects of JQ1 and BRD4 knockdown were not
surprising. According to RNA-Seq data out of the BET family proteins only BRD4 and
BRD3 were expressed in hFOBs. Unlike BRD4 protein, BRD3 lacks the C-terminal
P-TEFb interaction domain and there is little evidence about the role of BRD3 in
transcriptional regulation (Wang and Filippakopoulos, 2015). BRD3 was shown to
interact with acetylated GATA1 to regulate erythroid differentiation (Gamsjaeger et
al., 2011; Lamonica et al., 2011). Interestingly, Lamourex et al. recently highlighted
antiproliferative effects of JQ1 in osteosarcoma cell lines to be mainly mediated
through BRD4 but not BRD3 or BRD2 (Lamoureux et al., 2014).
Moreover, the differences in transcriptome-wide effects of BRD4 loss or inhibition by
JQ1 might be also explained by the fact that the latter would only expose the
bromodomain dependent functions of BRD4. In this case some additional
experiments such as JQ1 Chem-Seq or BRD4 ChIP-Seq following the JQ1 treatment
would help to address the significance of bromodomain dependent function of BRD4
in regulation of osteoblast-specific gene expression. Nonetheless, the overall
increased occupancy of BRD4 around the TSS of genes and putative enhancers
during differentiation, enrichment of BRD4 and JQ1 dependent genes with skeletal
system associated GO terms clearly support the specific function of BRD4 in
regulating osteoblast dependent transcriptional program.
BRD4 and gene expression control
In general, BRD4 was found to positively correlate with gene expression, i.e. more
expressed genes were highly marked by BRD4. Surprisingly, however, the intuitive
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assumption that highly BRD4 marked genes would be the most sensitive to BRD4
inhibition or loss did not happen to be completely true.  In contrast, only a subset of
BRD4 dependent genes was highly marked by this protein. Notably, lowly expressed
and lowly marked BRD4 genes showed the highest change in expression upon JQ1
treatment. The association of JQ1 unregulated genes with metabolic pathways
indicated life maintaining – housekeeping biological functions of these genes where
a minor change could potentially have drastic effects on the cellular wellbeing. In
general, housekeeping genes are known to show high CGI (CpG island) content at
the promoter regions (Larsen et al., 1992; Lercher et al., 2003).  Although, most of
the highly expressed JQ1 unregulated genes were indeed high CGI genes, the CGI
content of JQ1 regulated genes was not significantly lower. The similar pattern was
observed with differentiation dependent and unregulated genes suggesting hierarchy
of more complex mechanisms involved in the regulation of gene expression control.
On the other side, the stability of the nucleosomes flanking the TSS, the DNA
sequence of -1 and +1 nucleosomes that defines the specificity of the binding for
chromatin remodelers might be the other characteristic factor for differentiating the
highly and lowly expressed genes (Kubik et al., 2015). Whether highly expressed
BRD4 marked genes also possess “fragile” promoters remains a matter of further
investigation.  Based on the findings of the current study one could assume that the
key factor in controlling gene expression level would be not the “amount” of loss
induced by the treatment but rather the “amount” of remaining activating
factors/marks left following the treatment. Therefore low marked and hence low




BRD4 on osteoblast-specific enhancers
The fact that TSS associated BRD4 levels were not predictive of JQ1 sensitivity in
the subgroup of JQ1 dependent genes hinted to possible involvement of other
mechanisms of gene expression regulation mediated by BRD4. Broad intergenic
localization of BRD4 in hFOBs and correlation with RNAPII on these regions
suggested involvement of BRD4 in additional regulation of gene expression through
enhancer-coupled events. Enhancers can be defined as transcription factor bound
regulatory DNA elements distally controlling target gene expression in a
spatiotemporal manner. Chromatin interaction analysis revealed partitioning of
mammalian genome into topologically associated domains (TAD) where enhancers
were shown to form long-range interactions with target promoters within the
insulated regions (Dixon et al., 2012; Dowen et al., 2014). In such manner, due to
the chromatin “looping” enhancers can be brought to closer proximity to the target
promoters. Therefore, the integrity of “looped” structures within the TADs is certainly
important for proper gene expression control. On the other hand, increasing amount
of evidence suggests transcription of noncoding RNAs from enhancers which
similarly can influence target gene expression (De Santa et al., 2010; Hah et al.,
2013; Kim et al., 2010) . Characterization of hFOB-specific BRD4 sites uncovered
cell-type-specific localization pattern of BRD4 on potential enhancer regions. This
suggests that although BRD4 acts as general transcriptional regulator it does so in
cell-type-specific manner.
Interestingly, most osteoblast-specific BRD4 bound enhancer regions revealed
elevated enrichment of BRD4 along with H3K27ac and RNAPII upon differentiation.
More importantly, most of these regions were also associated with osteoblast-
specific genes. However, chromatin conformation capture techniques followed by
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next-generation sequencing would be required to identify the direct target promoters
of each enhancer. Moreover, loss-of-function experiments involving deletion of
enhancer containing DNA regions could address the functional relevance and
enhancer redundancy in regulating target gene expression.
Context-specific function of BRD4
The tissue-specific function of an enhancer is dictated by the panel of transcription
factors bound to it at a given time. The transcription factors define the composition
and hence the outcome of enhancer-promoter interactions on gene regulation (van
Arensbergen et al., 2014; Matharu and Ahituv, 2015; Nolis et al., 2009). The
identification of osteoblast-specific BRD4-bound putative enhancers and
transcription factors associated with these regions further strengthens the role of
BRD4 in lineage determination. Five candidate transcription factors were
computationally predicted to be potentially enriched at BRD4 bound enhancer
segments: C/EBPb, AP1 factors JUND and FOSL2, TEAD1 and STAT3. Previous
studies already established important functions of C/EBPb, AP1 and STAT3
transcription factors in regulating osteoblast differentiation (Gutierrez et al., 2002;
Nicolaidou et al., 2012; Sabatakos et al., 2000; Zhou et al., 2011). Although the
specific role of TEAD1 in the context of bone formation has not yet been studied, its
importance can be implied based on its interaction and dependence on the TAZ
transcriptional co-activators (Stein et al., 2015). Specifically, TAZ was shown to
regulate osteoblast differentiation and mediate the effects of canonical Wnt signaling,
a central regulator of osteoblast differentiation (Byun et al., 2014; Hong et al., 2005).
One of the main transcription factors involved in the osteoblast differentiation is the
Runt-related transcription factor 2 (RUNX2) (Otto et al., 1997). Although the RUNX2
motifs were not specifically identified by motif discovery tool, analysis of RUNX2 in
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NHOST cells suggested its co-localization on osteoblast-specific BRD4-enriched
regions. Consistently, RUNX2 was previously reported to interact with both AP1
factors as well as C/EBPb (D’Alonzo et al., 2002; Gutierrez et al., 2002; Meyer et al.,
2014a) to regulate osteoblast differentiation. Moreover, C/EBPb along with RUNX2
were shown to localize to epigentically active enhancers during differentiation of
osteoblasts (Meyer et al., 2014b) .Thus, it is very likely that BRD4 localization to
“Segment 3+4” is mediated by functional cooperation between RUNX2 and other
DNA binding transcription factors . In general, the distinct binding pattern of the
identified TFs suggests that each plays a specific role in coordinating BRD4 function
during the establishment of osteoblast-specific transcriptional programs. Whether
these TFs directly interact with BRD4 in bromodomain-dependent manner or
indirectly by means of additional co-factors needs further analysis. The strong
association of p300 with BRD4 specifically on enhancers as well as with C/EBPb,
AP1, TEAD1 and STAT proteins suggests a possible model where the identified
transcription factors could utilize p300 to recruit BRD4 onto tissue-specific enhancers
(Arias et al., 1994; Mink et al., 1997; Paulson et al., 1999; Schwartz et al., 2003;
Stein et al., 2015). Moreover, some of the transcription factors may themselves
serve as acetylation targets for p300 (Ni et al., 2014; Roe et al., 2015), offering an
additional, more direct mode of mediating BRD4 recruitment to enhancers.
Although BRD4 is a ubiquitously expressed protein that serves as a general
facilitator of transcriptional activation, an increasing body of evidence indicates that it
regulates gene expression in a context-specific manner where the specificity is
defined by the repertoire of transcription factors and co-factors expressed. Together,
our findings support the role of BRD4 as a central intermediary of the induction of
gene expression in response to external signaling via its recruitment to both the
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promoter and enhancer regions bound by a subset of transcription factors. Thus,
these findings begin to provide an explanation of the intricacies and diversity of
BETi-mediated transcriptional effects elicited in different tissues and cell lines. A
further understanding of the context-dependent functions of BET proteins will be
essential for the efficient and correct clinical application of BET inhibitors in various
diseases.
The complex phenotype of Rnf40Runx2-Cre conditional knockout
mouse
The early knowledge about importance of histone H2B monoubiquitination (H2Bub1)
in developmental regulation came initially from yeast studies (Fleming et al., 2008;
Hwang et al., 2003; Tanny et al., 2007; Wood et al., 2005). In addition, several
reports had indicated the crucial role of H2Bub1 for the maintenance of germ line
stem cells in Drosophila (Buszczak et al., 2009; Wright et al., 2011). However, many
questions remain unanswered regarding the functional relevance of this modification
for the mammalian development.
To confirm the biological significance of H2Bub1 signaling in vivo we sought to
determine how modulating RNF40 expression would affect normal bone
development in mice. By using the conditional knockout approach we generated
mouse line bearing osteoblast-specific loss of Rnf40 under the control of Runx2
promoter.
RUNX2 is the initial transcription factor required for osteoblastic commitment of
mesenchymal stem cells. RUNX2 deficient mice display complete absence of bone
formation and die shortly after birth (Komori et al., 1997). RUNX2 is similarly
essential for maturation of chondrocytes which implies its role in endochondral
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ossification in addition to intramembranous bone formation (Chen et al., 2014).
RUNX2 expressing cells are therefore referred as bipotential with ability to
differentiate into osteoblasts or chondrocytes. And only the expression of
downstream transcription factor Osterix (SP7) that negatively regulates SOX9, the
determinant of chondrocyte phenotype,  further directs the fate of the mesenchymal
cells into functional osteoblasts (Nakashima and de Crombrugghe, 2003).
The Runx2-Cre mouse line used in this study was reported to show efficient
recombination in long bones and calvaria, and consistently some partial
recombination events were observed in the cartilage (Rauch et al., 2010). This most
likely explains the “dwarfism” of conditional Rnf40Runx2-Cre knockout mice suggesting
the defects in both osteoblast as well as chondrocytes lacking functional Rnf40 gene.
However, this assumption needs further validation and use of cartilage-specific
Rnf40 mutant mouse would enlighten the specific function of this protein in
chondrocytes.
Moreover, the defects in intramembranous ossification most likely contributed to
smaller skull size in the knockout mice. Perhaps, this was the main reason why mice
were developing hydrocephalus. Hydrocephalus is known to be very common also
aduring achondroplastic abnormalities observed in humans (Steinbok et al., 1989).
Therefore, early termination of the experiment was required to reduce the suffering
of animals mainly shortly after weaning.
Furthermore, the mice also lacked the teeth. RUNX2 is equally important for the
differentiation of odontoblasts, the cells responsible for dentin formation (Chen et al.,
2009). Additionally, osteoclasts are similarly relevant during tooth eruption (Wang
and McCauley, 2011) and whether the absence of teeth were due to direct defects in
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osteoblasts and/or odontoblasts, or due indirect functional insufficiency of
osteoclasts needs further investigation.
Altogether, the combination of phenotypic changes observed in conditional
Rnf40Runx2-Cre suggested both osteopetrotic- as well as achondroplastic-like
phenotypes. Further analysis, involving estimation of bone formation rate to address
the defects in bone remodeling and osteoblast-osteoclast coupling, quantification of
osteoblast and osteoclast numbers, histological assessment of the growth plates to
address the defects in chondrocytes and, in general, in endochondral ossification are
required to delineate the functional significance of RNF40 in different cellular
compartments involved in bone formation.
USP22 in developing bone
To date most of the knowledge about biological function of USP22 come from tumor
based studies. In fact, USP22 has been reported to be one of 11 genes associated
with cancer stem-cell signature and essentially leads to poor outcome and
decreased survival rate in patients with different types of cancer (Glinsky et al., 2005;
He et al., 2015; Zhang et al., 2011b).
USP22 is a ubiquitously expressed protein and has been implicated in regulation of
stem cell differentiation (Sussman et al., 2013). Loss of USP22 leads to embryonic
lethality (Lin et al., 2012) whereas significant reduction of USP22 was associated
with growth retardation and differentiation defects especially in highly proliferating
tissues like intestine (Kosinsky et al., 2015). As a member of the deubiquitination
module (DUB) of the SAGA complex, USP22 is considered one of the important
regulators of H2B K120 monoubiquitination (Henry et al., 2003; Lang et al., 2011).
Furthermore, USP22 was reported to have additional target proteins such as SIRT1,
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COX-2 and RCAN1 (Ao et al., 2014; Hong et al., 2015; Xiao et al., 2015). However,
in contrast to our expectations, the conditional deletion of Usp22 in mouse
osteoblasts did not reveal any significant phenotypic or morphological changes in the
skeletal system of the mice.
It has been shown before that association of USP22 with ATXN7L3 and ENY2 and
additionally with ATXN7 that anchors DUB module within the SAGA complex is in
fact important for the enzymatic activity of the complex as a whole (Lan et al., 2015;
Lang et al., 2011; Samara et al., 2010). Moreover, several reports had indicated that
USP22 loss alone was not sufficient to affect H2B monoubiquitination and
interestingly, depletion of ATXN7L3 or ENY2 greatly increased H2Bub1 levels
(Atanassov et al., 2016; Lang et al., 2011). Characterization of two additional
deubiquitinating enzymes USP27X and USP51 based on high homology to USP22
protein, could explain the redundant function of H2Bub1 specific DUBs (Atanassov et
al., 2016). Moreover, USP44, was demonstrated to show enzymatic activity towards
monoubiquitinated at K120 H2B (Fuchs et al., 2012). Consistently, differentiation
defects observed in the intestines of Usp22LacZ were also shown to be not associated
with changes in H2Bub1 levels (Kosinsky et al., 2015).
Altogether, in the view of all the above mentioned facts, the absence of bone-specific
function of USP22 was in fact not surprising. However, one could assume that
USP22 deficient bones would show impaired regenerative potential and fracture-
healing experiments would be additionally required to test this hypothesis. Moreover,
given the fact that USP22 acts as a co-activator during estrogen- and glucocorticoid-
receptor mediated transactivation (Zhao et al., 2008), one could analyze the role of
USP22 during menopause- and steroid-induced osteoporosis, respectively.
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The osteopetrotic-like phenotype of Rnf40 deficient mice
Use of Rnf40Runx2-Cre conditional mouse line with the complex phenotype restricted
our understanding of the osteoblast-specific function of Rnf40. Therefore we utilized
another bone-specific mouse line bearing Cre expression under the Bglap
(osteocalcin) promoter.  Osteocalcin is a secreted protein involved in matrix
mineralization produced mainly by osteoblasts and osteocytes (Hauschka et al.,
1989; Lee et al., 2007). The expression of Bglap is regulated by Runx2 and Sp7
transcription factors (Lee et al., 2007; Nakashima and de Crombrugghe, 2003).
Interestingly, the conditional Rnf40Bglap-Cre knockout mice displayed mainly
osteopetrotic-like phenotype with no signs of growth retardation confirming the
previously observed “dwarfism” in Rnf40Runx2-Cre to be mainly associated with
potential defects in chondrocytes. However, the absence of changes in bone
formation rate and fully developed skeleton in these mice suggested intact function
of osteoblasts. Interestingly, this was not consistent with the observed reduction in
differentiation capacity of Rnf40 deficient primary osteoblasts. Since BGLAP is a
relatively late expressed gene, one could assume that function of RNF40 is more
relevant at earlier stages of osteoblast commitment. In that case, the smaller skull,
absence of the teeth and shorter bone size observed in conditional Runx2-specific
Rnf40 knockout mice, could in fact support the stage-specific function of RNF40 in
regulation of osteoblast differentiation. Positive regulation of RUNX2 and SP7 master
transcription factors by RNF40 further strengthens the relatively earlier contribution
of RNF40 in regulating the osteoblast lineage commitment. However, further
confirmation of changes in osteoblast number and bone formation rate in Rnf40Runx2-
Cre mice would be required to support this statement. Furthermore, additional ex vivo
studies with subsequent knockout of Rnf40 in primary mouse osteoblasts at different
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time points following differentiation induction would uncover the requirement of more
committed osteoblasts in Rnf40. Additionally, a similar approach could be performed
in the another inducible Rnf40Sp7-CreERT2 mouse model with postnatal 4-
hydroxytamoxifen injections to confirm the stage specificity of H2Bub1 signaling in
developing bone.
The reduction in osteoclast number was most likely the main reason leading to
increased bone density in Rnf40Bglap-Cre knockout mice. Further ex vivo analysis of
Rnf40 deficient osteoblasts with significant reduction in Rankl expression supported
the potential contribution of perturbed osteoblast-osteoclast “interaction” as
underlying mechanism of osteopetrotic-like phenotype observed in Rnf40 knockout
mouse. Moreover, several reports had outlined the role of osteocalcin in recruitment
and differentiation of osteoclasts (Glowacki and Lian, 1987; Hauschka et al., 1989)
and given the fact that Bglap is positively regulated by Rnf40 could additionally
explain the decrease in osteoclasts numbers in Rnf40 deficient mice.
Consistent with the role of osteocalcin in energy metabolism (Lee et al., 2007)  one
could also expect differences in the glucose tolerance and fat deposition of
conditional Rnf40Bglap-Cre knockout mice. However, another experimental setup
involving high-fat diet and glucose tolerance test would be required to address this
assumption.
Implications of Rnf40 in lineage-specific gene expression
regulation
Altogether, the conditional knockout approach with bone-specific deletion of Rnf40
gene in mice strengthened the functional relevance of H2Bub1 signaling for bone
formation and development. However, further investigation and follow-up studies are
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required to fully uncover the RNF40-H2Bub1 dependent molecular mechanisms
involved in the regulation of osteoblast-specific gene expression pattern.
Despite the universal feature of H2Bub1 association with actively transcribed genes,
the overall decrease in the levels of this modification upon RNF20/40 loss results in
selective regulation of genes (this study, Fuchs et al., 2012; Karpiuk et al., 2012;
Prenzel et al., 2011; Shema et al., 2008). A number of factors may define the
specificity of H2Bub1 in gene regulation. However, noteworthy is to mention the
transcription factor circuits that are the key determinants of specific cellular
phenotype. In fact, the osteoblastic differentiation is tightly controlled by the nuclear-
hormone receptor signaling.  Of specific importance is the vitamin D for the healthy
bone development and functioning. Following the ligand induction, vitamin D
receptor (VDR) dimerizes with the retinoid X receptor (RXR) and binds to regulatory
DNA elements this way facilitating target gene expression (Imai et al., 2013).
Interestingly, BGLAP was identified as a first gene to be regulated by VDR and more
importantly it harbors vitamin D response element (VDRE) in its promoter region
(Ozono et al., 1990). Moreover, several line of evidence suggests interaction of
RUNX2 with VDR to promote osteoblast-specific gene expression (Marcellini et al.,
2010; Paredes et al., 2004). Importantly, RANKL has been reported to be one of the
vitamin D most responsive genes. Consistently, several VDR binding sites were
identified upstream of RANKL promoter (Pike et al., 2014).
Despite the adverse effects of clinically used glucocorticoids on bone, glucocorticoid
receptor (GR) signaling was shown to be equally important for triggering osteoblast
differentiation and matrix mineralization (Eijken et al., 2006). Glucocorticoid response
elements (GRE) were found within the promoter regions of BGLAP and COL1A1
genes (Heinrichs et al., 1993; Peterkofsky et al., 1999).
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It is also noteworthy to mention the positive role of sex hormones estrogen and
androgen receptor signaling in bone physiology (Almeida et al., 2013; Määttä et al.,
2013; Russell et al., 2015). Notably, both estrogen and androgen receptor mediated
signaling were shown to be dependent on RNF20 and RNF40 for target gene
expression in breast and prostate cancer cell lines, respectively (Jääskeläinen et al.,
2012; Prenzel et al., 2011). Moreover, AR mediated transactivation involved direct
interaction with USP22 (Zhao et al., 2008).
The fact that RANKL expression can be regulated both by VDR and RNF40
suggests relevance of H2Bub1 signaling in mediating VDR dependent transcriptional
regulation. However, further validation by ChIP-Seq of VDR and RNF40 to find the
co-localization pattern on the target genes would be required. Additionally, the
overall contribution of RNF40 to hormonal regulation of osteoblast differentiation can
be identified by Co-IP and ChIP studies of RNF40 with the nuclear hormone
receptors implicated in the bone physiology.
Concluding remarks
Over past years development and characterization of small molecule inhibitors
targeting specific groups of epigenetic enzymes has been shown efficient in the
treatment of several disorders. An important breakthrough was the discovery of
highly specific BET protein inhibitors that efficiently blocked the oncogene dependent
transcriptional programs responsible for cancer development and progression
(Cheng et al., 2013; Coudé et al., 2015; Filippakopoulos et al., 2010; Lamoureux et
al., 2014; Lockwood et al., 2012; Roe et al., 2015). Importantly, pharmacological
inhibition of BET proteins exhibited positive role in osteosarcoma as well (Lamoureux
et al., 2014). The authors identified BRD4 inhibition as an important mechanism in
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controlling bone cancer growth and proliferation, and remarkably by blocking the
differentiation of both the osteoblasts and osteoclasts. BETi hampered the
osteosarcoma associated vicious cycle involved in the development of osteolytic
lesions and metastasis.  Interestingly, the BET inhibition displayed more prominent
effects in the osteoclasts than in the osteoblasts leading to reduced bone resorption
in mice (Park-Min et al., 2014). This most likely explains the absence of phenotypic
changes in healthy mice upon BETi injections and only the induced challenge on the
bones such as cancer, inflammation or osteoporosis would reveal the effects of BET
inhibition in osteoblasts. Interestingly, our study also revealed the anti-resorptive
function of RNF40 loss through modulation of RANKL expression. This suggests
inhibition of H2Bub1 signaling as a potential strategy to be used in osteoporosis or
cancer associated osteolysis as well. However, so far no inhibitors targeting the
RNF20 and RNF40 protein complex have been developed. Given the crosstalk
between H2B monoubiquitination and H3K4 and H3K79 methylations (Nakanishi et
al., 2009; Vlaming et al., 2014), the use of histone methyltransferase inhibitors could
potentially exhibit the same effects as RNF40 loss. However, this assumption
requires further careful investigation. Given the positive role of HDAC inhibitors in the
bone formation (Bradley et al., 2011) and their synergistic effects to BET inhibition
(Bhadury et al., 2014; Heinemann et al., 2015; Mazur et al., 2015) combined therapy




In the current study we identified two epigenetic regulators to be involved in the
osteoblast lineage determination. The initial role of RNF40 mediated H2Bub1 in
osteoblast specialization of mesenchymal progenitors was already reported (Karpiuk
et al., 2012).  We further confirmed the biological significance of this finding in vivo.
Despite its H2Bub1 independent function, BRD4 similarly regulated the osteoblast-
specific gene expression involving different mechanisms of gene expression control.
In summary, our work provides deeper insights into the regulatory mechanisms
controlling cell fate determination. Our findings support the notion that epigenetic
changes and regulators may carry a universal feature in transcriptional control
however the specificity to this control is dictated by the transcription factor circuits.
This is of great importance especially when considering the outcomes of specific
therapies targeting the epigenetic networks.
Altogether, based on the previous and obtained knowledge, the following model of
transcriptional regulation of osteoblast lineage determination can be suggested
(Figure 63).
In the undifferentiated precursor cells, upon differentiation-inducing signal, the extra-
and intracellular cascades activate the recruitment of early (pioneer) transcriptional
factors that facilitate the early events of chromatin de-condensation through
recruitment of chromatin remodeling and modifying enzymes such as histonemethyl-



















Figure 63. Model for transcriptional regulation of osteoblast-specific gene expression. The
explanation is given within the text.
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These transcription factors, hence, prime the chromatin for subsequent binding of
tissue-specific transcription factors (TTF) to target osteoblast-specific genes and
enhancers. The histone modifiers, in turn, catalyze subsequent methylation (for
instance H3K4me3 at promoter regions, and H3K4me1 at enhancer) and acetylation
of histone tails within the nucleosomes flanking the promoter and enhancer regions.
At the same time transcription factors along with looping proteins facilitate the
“bridging” of enhancers with target promoters through chromatin looping. The histone
modifications serve as a recruitment signal for various proteins involved in the
assembly of general transcriptional machinery followed by recruitment or RNA
Polymerase II to promoter and/or enhancers. The epigenetic reader BRD4 by
binding to acetylated histones and/or to acetylated TFs on promoter and enhancer
regions facilitates activation and release of P-TEFb (CDK9). Presumably, non-coding
enhancer RNAs (eRNA) stabilize the enhancer-promoter looping and assist in P-
TEFb activation. CDK9 mediated phosphorylation of Ser2 residues within
heptapeptide repeats of C-terminal tail of promoter-associated RNA Polymerase II
(RNAPII) are recognized by WAC adaptor protein which then enables recruitment of
E3 ligase complex RNF20/40 to transcribed region of the given gene.
Monoubiquitination of histone H2B at K120 (H2Bub1) facilitates further
decompaction of the chromatin. Moreover, histone chaperones such as Facilitates
Chromatin Transcription (FACT) complex trigger destabilization of H2Bub1 marked
nucleosomes through histone dimer exchange. Altogether, the sequential
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